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ABSTRACT  
Cholera is a persistent threat to public health and is endemic in many countries. Of 
late, there is an emergence of antibiotic resistance in Vibrio cholerae and treatment is 
effective only if given early, thus there is a need for rapid and more effective 
treatment of cholera. One such treatment could be the use of bacteriophages. During 
infection, V. cholerae adheres to the surface of enterocytes but does not invade the 
host. They are therefore not protected from bacteriophage infection. The study 
presented in this dissertation evaluates the potential of bacteriophage being used as a 
biocontrol for V. cholerae. The aim of this project was isolation and in vitro 
characterisation of bacteriophages, selection of a candidate bacteriophage for 
biocontrol and its use in an infant rabbit model to assess its therapeutic efficacy.  
 
Seven phages were isolated in China, attempts to isolate in the UK environments were 
unsuccessful and five more phages were obtained from various sources. In total 
twelve phages were characterised for the one step growth curves following their host 
strain growth curves, their lytic spectra, electron microscopy, PFGE, restriction 
analysis and annotation of sequenced genomes. These in vitro characterisations could 
help in selecting the candidate bacteriophage for in vivo phage therapy trials. Amongst 
WKHSKDJHVVWXGLHGWKHSKDJHĭPRVWQHDUO\ILWWHGWKHVHOHFWLRQFULWHULD,WVEXUVWVL]H
was 43 ± 5.5; while the latent period was 12 ± 0.0 and it had broad host range as it 
could lyse 67 % of the total 91 strains; while its genome did not show any undesirable 
genes associated with lysogeny/antibacterial resistance or any cholera toxin genes 
upon genome annotation. ,Q WKHUDSHXWLF WULDOV XVLQJ DQ LQIDQW UDEELW PRGHO ĭ
reduced the bacterial numbers significantly (4.7 log10 reduction with P < 0.001) and 
treated animals showed no symptoms of disease. 
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1. INTRODUCTION 
1.1  Cholera the disease 
Cholera is a historically important disease causing many deaths globally and remains a 
very significant public health concern in several developing countries. Along with 
other old world bacterial diseases such as tuberculosis, typhoid, plague etc that have 
costed millions of lives cholera is even today a considerable risk to public health. 
There were 1.5 million deaths for tuberculosis, 161 thousand deaths for typhoid and 
126 deaths for plague in the year 2013 (WHO 2013). Though the number of deaths for 
tuberculosis seems higher they were coupled with HIV (Human Immunodeficiency 
Virus) disease, while typhoid shows similar deaths and impact as like cholera but 
GRHVQ¶WWDNHSDQGHPLFSURSRUWLRQ7KXVFKROHUDVWLOOUHPDLQVWREHDEDFWHULDOGLVHDVH
with pandemic potential. The world has witnessed several cholera pandemics with the 
major focus being the Indian subcontinent and with the current pandemic affecting 
Central and South America with rapid epidemic spread (Roy, Zinck et al. 2014). The 
disease is endemic in Africa, Asia and South America, with the occurrence of 
outbreaks usually coinciding with and/or resulting from conflict and natural disasters 
(Martinez, Megli et al. 2010). The disease shows seasonality in South Asia with most 
outbreaks being reported just before and after the monsoon i.e. April and September to 
December, respectively, with case numbers peaking during the summer season i.e. 
from January to February. In South America and in the African countries the 
outbreaks occur following summer rains or floods (Emch, Feldacker et al. 2008). The 
incidence of cholera cases and deaths in recent years is shown in the Figure 1. The 
sudden surge of cases in the year 2011 is attributed to the Haiti epidemic following a 
devastating earthquake. Haiti still continues to contribute most of the cholera cases 
reported globally and it was estimated that 45,000 cases to be reported for the year 
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2014 (UNO 2014). The most recent epidemic outbreak occurred in South Sudan with 
1,812 cholera cases reported and 38 deaths (WHO 2014). Thus, in spite of extensive 
efforts by Governmental and non-Governmental agencies over the decades, cholera 
has not been eradicated as a major cause of epidemic disease and death. 
 
 
Figure 1: The cholera cases and deaths globally (2005-2013) 
(Source: WHO statistics data base, http://apps.who.int/ghodata/# accessed on 
18/03/2015) 
 
The CFR (Crude Fatality Rate i.e. percentage of people who die after being diagnosed 
positive for cholera) can be as high as 50% without treatment (Sack, Sack et al. 2004). 
Moreover, many cholera deaths remain unreported, owing to the remoteness of the 
communities in developing countries and a lack of communication and reporting 
infrastructure. Developed countries in Europe and North America usually have 
imported cases (Fig. 2), reported from travellers visiting disease-prone areas and 
returning back with the disease (Morger, Steffen et al. 1983). With appropriate 
sanitation measures in place, the developed countries are able to prevent cholera but 
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there is a real need to address the possible measures for prevention and effective 
cholera treatment in developing countries. 
 
 
Figure 2: Reports of imported cholera cases in the UK (2004±2012) 
(Source:http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/TravelHealth/
EpidemiologicalData/GastrointestinalInfections/travCholera/ accessed on 18/03/2015) 
  
1.2  Pathogenesis of cholera 
V. cholerae is an aetiological agent of cholera which is contracted through 
consumption of water or food contaminated with the organism mainly arising directly 
or indirectly from human faeces. V. cholerae produces an enterotoxin (CTX) which 
leads to acute, copious, watery diarrhoea with as much as 20 litres of fluid loss per day 
and death due to circulatory failure owing to dehydration, if not treated in time. V. 
cholerae is a curved and motile Gram negative rod shaped organism with a single 
polar flagellum. The strains of disease-causing V. cholerae are grouped into two 
serogroups O1 and O139, based on their lipopolysachharide (LPS) O antigens. 
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Serogroup O1 has three serotypes viz. Inaba, Ogawa and Hikojima; while two 
biotypes viz. classical and El Tor (Salyers and Whitt 2002). The earlier pandemics 
were caused by members of the O1 serogroup, but the eighth pandemic was reported 
to be caused by O139 which originated from the Bay of Bengal (Swerdlow and Ries 
1993).  
 
The major virulence genes needed for pathogenesis are clustered as two genetic 
elements viz. the genes encoded by the lysogenic filamentous phage CTXphi for 
cholera toxin (Levin and Tauxe 1996, Waldor and Mekalanos 1996, Davis and Waldor 
2003) and the genes encoded for the Toxin Co-regulated Pilus (TCP), a colonisation 
factor situated next to the Vibrio Pathogenicity Island (VPI) (Faruque, Albert et al. 
1998, Faruque and Mekalanos 2003). Cholera toxin (CT) and TCP are controlled by a 
regulatory protein, ToxR which co-regulates their expression. Intestinal colonisation 
by V. cholerae is mediated by fimbriae, which are filamentous protein structures e.g. 
TCP, Type B and Type C fimbriae (Hall, Vial et al. 1988). TCP is essential for the 
colonisation process. TCP attaches to receptors present on the mucosa of upper small 
intestine and helps in colonisation (Attridge, Voss et al. 1993). Other fimbriae (i.e. 
Type B and Type C) are non-adhesive and do not play a role in colonisation of V. 
cholerae (Nakasone, Yamashiro et al. 1994). After attachment the organism produces 
CT which causes secretory diarrhoea. The CT causes increased chloride ion secretion 
and net water flow in to the gut lumen and decreased sodium ion absorption into the 
tissues via the blood stream (Fig 3). As a result there is rapid loss of water into the 
lumen along with chloride ions causing massive diarrhoea and electrolyte imbalance 
(Salyers and Whitt 2002).  
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Figure 3: Movement of ions and water across the normal and affected gut 
 
The sodium and chloride ion channels are altered by high levels of cAMP (cyclic 
AMP) which is a mediator in intracellular signalling pathways and cAMP synthesis is 
catalysed by an enzyme adenyl cyclase. Activity of adenyl cyclase is regulated by G 
proteins which are intracellular signalling proteins (Ghose 2011). The cholera toxin 
keeps adenyl cyclase activated continuously through active G proteins. In normal gut 
the G proteins are in an active form when they are GTP bound and when GTP is 
hydrolysed by GTPase they become inactive (Alberts, Johnson et al. 2008). In the gut 
affected with CT, a toxin stops GTP hydrolysis and thus the G protein remains in an 
active state all the time (Salyers and Whitt 2002). Eventually, it increases the levels of 
cAMP which alter ion channels causing a huge efflux of chloride ions as well as water 
into the gut producing severe diarrhoea.  
 
In early stages of the disease, symptoms include muscle as well as stomach cramps 
accompanied by vomiting and fever. The disease later progresses into the severe 
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washing rice. The skin turns black and blue while the eyes and cheeks become sunken 
due to rapid dehydration (Anonymous 2015). 
 
1.3  Treatment/prophylaxis of cholera 
1.3.1 Rehydration therapy 
Rehydration therapy is effective if replacement of fluids lost due to severe diarrhoea 
are compensated as quckly as they are lost (Sack, Sack et al. 2004). WHO 
recommends that oral rehydration salts (ORS) (WHO 2002) which come in the 
standard sachets are useful but for severely dehydrated patients intravenous fluid 
replacements are needed. 
1.3.2 Antibiotic therapy 
Though rehydration therapy is the mainstay of treatment for cholera, oral antibiotics 
are given to dehydrated patients as soon as possible after vomiting stops (Sack, Sack 
et al. 2004). They are given to shorten the duration of illness and also to reduce the 
diarrhoeal fluid output (Lindenbaum, Greenough et al. 1967). The combination of 
antibiotics gives a synergistic effect in treatment of cholera (Mandal, Pal et al. 2009). 
The different types of antibiotics used and antibiotic resistance in V. cholerae are 
discussed further in the next section (§ 1.4). 
1.3.3 Vaccination 
Soon after discovery of V. cholerae as an aetiology of cholera, injectable parenteral 
vaccines (killed whole cell) were developed but these provided short lived immunity 
of just 6 months and frequently involved painful local inflammatory reactions 
(Mosley, Aziz et al. 1972). Later oral whole-cell/recombinant-B-subunit cholera 
vaccines (e.g. Dukoral) were developed which provide protection for up to 2 years 
(WHO 2010) for cholera and they also provide cross protection for enterotoxigenic E. 
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coli (ETEC) for up to 6 months (Peltola, Siitonen et al. 1991) and are recommended 
by WHO. Though recent oral cholera vaccines are better than earlier parenteral 
vaccines they do not confer 100 % protection but they reduce the risk by 80 % and the 
immunity can be overcome by a high inoculum of infective organisms (Sack, Sack et 
al. 2004). The oral cholera vaccines should not be taken as sole preventive measures 
in control of cholera disease in isolation from other measures (Lopez, Gonzales et al. 
2014).    
 
1.4  Antibiotic resistance in V. cholerae 
As with many other bacterial pathogens, V. cholerae is rapidly developing resistance 
to several antibiotics used for treatment of cholera (Kitaoka, Miyata et al. 2011). A 
UHSRUWRQµ*OREDOVXUYHLOODQFHRIDQWLELRWLFVHQVLWLYLW\RIVibrio cholerae¶LQWKH\HDU
1976 revealed that out of 1156 strains (single colony isolates from pure culture) 
examined, 27 were resistant to ampicillin, chloramphenicol, tetracycline, furazolidone 
and three different sulphonamides; while 2 were resistant to chloramphenicol only 
(O'Grady, Lewis et al. 1976). Recently, the reports of multiple drug resistant V. 
cholerae strains from different countries around the world have increased substantially 
viz. Bangladesh (Rashed, Mannan et al. 2012), Cameroon (Akoachere, Masalla et al. 
2013), China (Li, Tan et al. 2011), Ethiopia (Abera, Bezabih et al. 2010), Haiti 
(Sjolund-Karlsson, Reimer et al. 2011), India (Panda, Patra et al. 2012), Indonesia 
(Tjaniadi, Lesmana et al. 2003), Iran (Ranjbar, Rahmani et al. 2010), Madagascar 
(Rakoto Alson, Dromigny et al. 2001), Mozambique (Mandomando, Espasa et al. 
2007), Namibia (Smith, Keddy et al. 2008), Nepal (Karki, Bhatta et al. 2010), Pakistan 
(Jabeen, Zafar et al. 2008), Thailand (Chomvarin, Jumroenjit et al. 2012), Vietnam 
(Tran, Alam et al. 2012), Zimbawe (Islam, Midzi et al. 2009) etc.  
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The antibiotics for which resistance has been reported in the last decade are 
amoxicillin, ampicillin, chloramphenicol, cotrimoxazole, ciprofloxacin, doxycycline, 
erythromycin, fluoroquinolone, furazolidone, gentamicin, kanamycin, nalidixic acid, 
neomycin, norfloxacin, polymyxin B, quinolone, streptomycin, spectinomycin, SXT 
(sulfamethoxazole±trimethoprim), sulphonamides, tetracycline, trimethoprim and 
vancomycin (Kitaoka, Miyata et al. 2011). In the 1980s, the first antibiotics to which 
V. cholerae showed resistance were tetracycline, ampicillin and sulphonamides 
followed by nalidixic acid, cotrimoxazole and recently fluoroquinolones which led to 
emergence of multiple antibiotic-resistant V. cholerae (MARV) (Mandal, Dinoop et 
al. 2012). There are varied mechanisms whereby V. cholerae become resistant 
including efflux pumps, spontaneous mutations, conjugative exchange of extra 
chromosomal elements such as plasmids, transposons/SXT elements and integrons. V. 
cholerae is able to export the tetracycline, chloramphenicol, norfloxacin, ciprofloxacin 
or nalidixic acid molecules out of the cell using multidrug efflux pumps as they are 
chemically and structurally unrelated (Paulsen, Brown et al. 1996).  Spontaneous 
chromosomal muWDWLRQV FRQIHU UHVLVWDQFH WR WKH DQWLELRWLFV OLNH DODIRVIDOLQ DQG ȕ
lactam antibiotics (amoxicillin, ampicillin, cephalexin) which act by inhibiting cell 
wall biosynthesis (Allen, Atherton et al. 1979) and to quinolones which act by 
inhibiting DNA replication (Baranwal, Dey et al. 2002). Resistance is also conferred 
by horizontal gene transfer via extra chromosomal elements like plasmids 
(tetracycline, ampicillin, kanamycin, streptomycin, gentamicin and trimethoprim) 
(Kitaoka, Miyata et al. 2011), integrating transposable conjugative elements i.e. SXT 
elements (sulfamethoxazole, trimethoprim, streptomycin and furazolidone) (Waldor, 
Tschape et al. 1996) and integrons (trimethoprim) (Mazel 2006) by conjugation.  
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Antibiotic resistance is a major problem in V. cholerae with no new antibiotic classes 
being developed (Braine 2011) and thus there is a growing need for an alternative 
therapy. One such alternative treatment is the biological control of V. cholerae using 
host-specific bacteriophage (Barrow 2001, Matsuzaki, Uchiyama et al. 2014). Unlike 
broad-spectrum antibiotics which also kill beneficial intestinal bacteria, phages are 
species and strain specific and kill only the targeted bacteria. Lytic phages are 
responsible for limiting bacterial numbers in an aquatic environment with up to 80 % 
of mortality evidenced in the bacterial population (Weinbauer 2004). There is 
evidence for V. cholerae in the environment being controlled by lytic phages 
(Faruque, Islam et al. 2005, Jensen, Faruque et al. 2006, Nelson, Chowdhury et al. 
2008). Earlier reports on the use of phage therapy for cholera indicated partial success 
(Asheshov, Saranjam et al. 1930, Morison 1932, Monsur, Rahman et al. 1970, 
Marcuk, Nikiforov et al. 1971). There were no reports based on animal studies at that 
time. Thus, a systematic study based on in vivo animal experiments may give positive 
outcomes for disease control using this alternative approach. 
 
1.5  Bacteriophage 
Bacteriophages are viruses that infect bacteria. They are obligate intracellular 
parasites which rely on the host bacterium in order to replicate. Bacteriophages 
enclose their nucleic acid in a protein coat (capsid), which may be further surrounded 
by a lipid layer  (Nicklin, Graeme-Cook et al. 1999). In addition to the capsid (head), 
tailed bacteriophage (members of the Caudovirales order), possess a tail which may 
either be contractile (e.g. T4 phage) or non-FRQWUDFWLOHHJSKDJHȜ7KH\PD\DOVR
possess additional structures such as a collar, basal plate, spikes and tail fibres, which 
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are involved in attachment to the bacterium and injection of the nucleic acid into the 
cell (Fig. 4).  
 
Figure 4: Schematic representation of bacteriophage 
Phages are ubiquitous on earth and are found in large numbers in the environment (i.e. 
water, soil, sewage etc.), wherever their hosts are present (Guttman, Raya et al. 2003). 
Phages can remain viable under adverse conditions (Jonczyk, Klak et al. 2011). 
Phages exhibit three different lifestyles based on their survival strategies viz. lytic, 
lysogenic and pseudolysogenic (Miller and Day 2008). In a lytic life cycle, the phage 
infects the cell, multiplies and progeny phages burst from the cell killing the 
bacterium. In a lysogenic life cycle, the phage does not replicate but its genome goes 
into a quiescent condition where it is called prophage and where it is usually 
integrated into the host genome or alternatively it may be maintained as an 
extrachromosomal plasmid (Guttman, Raya et al. 2003). There are some phages which 
can enter either the lytic cycle or the lysogenic cycle and they are called the temperate 
phages, while some phages are strictly lytic. In a pseudolysogenic life cycle, the phage 
does not undergo lysogeny nor does it show a lytic response but it remains in a non-
active state (Ripp and Miller 1997). Pseudolysogeny occurs during starvation 
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conditions and when nutrient supplies are available again the phage can either enter 
the lysogenic or lytic life cycle. Apart from these three generally described life cycles, 
a carrier state life cycle (CSLC) is reported (Siringan, Connerton et al. 2014) as an 
alternative phage life cycle in which bacteria and phages are in an equilibrium state 
with some bacteria resistant to phage but some of them sensitive to phage and thus 
allowing both of them to sustain. 
 
For phage therapy purposes, lytic phages are utilised and thus only the lytic life cycle 
of phage is explained further. In the lytic life cycle (Fig. 5), the phage adsorbs on the 
surface of the bacterium at receptor structures such as lipopolysaccharides or 
membrane proteins in the outer membrane of the bacterium (Kutter, Raya et al. 2003) 
or pili (Roncero, Darzins et al. 1990). For adsorption in T4 like phages the first step is 
a reversible binding of long tail fibres to their specific receptors as mentioned above. 
The initial energy for this process is provided by the baseplate. Once three or more 
long tail fibres position the baseplate parallel to the host surface, the six short tail 
fibres or spikes bind irreversibly to a secondary receptor i.e. heptose residue of the 
LPS inner core (Crawford and Goldberg 1980, Montag, Hashemolhosseini et al. 
1990). In order to cross the peptidoglycan layer, the baseplate protein utilises a 
lysozyme enzyme which is located in the gp5 protein at its tip (Kanamaru, Leiman et 
al. 2002). When gp5 protein comes in contact with with phosphatidyl glycerol of the 
inner membrane, the signal for release of DNA is given and DNA is transported by 
electrochemical potential (Goldberg, Grinius et al. 1994). After injection of genetic 
material, the replication of phage DNA occurs. Later, synthesis of various phage 
components is carried out and further to it the assembly of all phage particles in to 
new progeny phages is done. The new virions burst out of the cell by the action of 
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holin and endolysin proteins. Holins form a pore in the inner membrane through 
which a peptidoglycan degrading enzyme (endolysin) accesses the cell wall, 
eventually causing it to rupture and release the bacteriophage progeny (Wang, Smith 
et al. 2000).  
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Figure 5: Schematic representation of lytic life cycle of bacteriophage 
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The different stages of the lytic life cycle are studied by the one step growth curve 
which was originally performed by Ellis and Delbrück (Ellis and Delbruck 1939). The 
one step growth curve was designed to determine the kinetics of phage multiplication 
and the number of phage particles that result from infection of a cell by a single 
phage. As depicted in Figure 6, after adsorption, the phage particles can not be 
isolated for some time (Doermann 1953) due to uncoating of phage and thus only 
naked phage DNA is present during this period of time which is called the eclipse 
phase. Chloroform-induced lysis and subsequent plating allows us to identify the 
eclipse period by enumerating intracellular phages which will be lower than the intial 
phage numbers until the time they start increasing again. The latent period is the 
minimum length of time from adsorption until release of newly formed phages 
extracellularly. The replication of nucleic acid and proteins formation occurs during 
the latent period. Later the phage particles undergo maturation i.e. the nucleic acid and 
proteins are assembled into mature phages. After maturation the phages are released 
by enzymatic lysis of the host bacterium. Burst size is defined as the average yield of 
phage particles per cell (§ 2.4.12). The latent period as well as burst size are 
characteristic of different phage strains but may vary according to the propagating 
host, media and temperature used (Guttman, Raya et al. 2003). With most phages a 
single round of multiplication is completed within 30-60 m (Madigan, Martinko et al. 
2003). 
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Figure 6: Schematic representation of phage one-step growth curve 
 
1.6  Phage therapy 
1.6.1 History of phage therapy 
The first antibacterial activity of phage was noticed against V. cholerae by a British 
bacteriologist Hankin in the year 1896 (Hankin 1896), when he filtered water from the 
rivers (Ganga and Yamuna) in India (Summers 2001) to find that a substance which 
was heat labile could cause lysis of V. cholerae and he thought that it could have 
limited the cholera epidemic. Later, bacteriophages were discovered independently by 
Twort (Twort 1915) DQGG¶+HUHOOH(d'Herelle 1917). The term bacteriophage meaning 
EDFWHULD HDWHUZDV FRLQHGE\ G¶+HUHOOH$V UHYLHZHGE\6XPPHUV (Summers 2005), 
the therapeutic potential of phages to treat bacterial infections was particularly 
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conducted experiments with claims of effectiveness against Salmonella pullorum and 
Pasteurella LQIHFWLRQV RI DQLPDOV ,Q  G¶+HUHOOH VHOI DGPLQLVWHUHG SKDJH
preparations and gave them to his colleagues and family members to ascertain their 
safety before administering them to human patients in treating bacillary dysentery. 
After he treated four patients of bubonic plague in Egypt, the British Government 
invited him to the Haffkine Institute, Bombay, India for Asiatic cholera treatment 
studies (these studies are discussed later in this chapter). Later, phages were 
commercially expoited by pharmaceutical companies for some time with exaggerated 
claims and marketing e.g. the Enterophagos preparation was marketed for treatment 
of herpes infections, urticaria and eczema (Barrow and Soothill 1997) which was 
FOHDUO\QRWSRVVLEOH%\WKHHQGRIWKH¶VWKHDGYHQWRIDQWLELRWLFVDFFRPSDQLHG
by the poor quality of some of the scientific studies arising from an inadequate 
understanding of the phage-host interactions led to phage therapy being discontinued 
in the western world. Nevertheless, phage therapy continued to be used in Russia and 
Eastern European countries (Chanishvili, Chanishvili et al. 2001, Ryan, Gorman et al. 
2011). 
  
1.6.2 Reappraisal of phage therapy in the west 
3KDJH WKHUDS\ ZDV DJDLQ UHYLYHG GXULQJ WKH ¶V DIWHU ULJRURXV FOLQLFDO SKDJH
therapy experiments were carried out by H. Williams Smith and his colleagues on oral 
infections of enterotoxigenic Escherichia coli (ETEC) diseases of neonatal animals 
and on systemic infection caused by E. coli in mice (Smith and Huggins 1982, Smith 
and Huggins 1983, Smith, Huggins et al. 1987). They successfully treated 
experimental systemic E. coli infection in mice using bacteriophage comparing the 
effect with antibiotics (Smith and Huggins 1982). They tested 15 phages isolated from 
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sewage, out of which 9 were anti-K1 (K1 is an antigen which is an important surface 
virulence factor of E. coli strain O18ac:K1:H7ColV+). Administered intramuscularly, 
the most effective phage was also the one found to be most rapidly lytic in vitro. 
Phage prevented death and illness in mice inoculated intramuscularly (in a different 
muscle) or intracranially with the bacterium. There was evidence of phage 
multiplication in vivo and a single dose of phage was more effective than 8 doses of 
streptomycin. Some resistant mutants arose but these were largely K1-negative 
mutants and thus of reduced virulence. Similar studies have been performed with E. 
coli septicaemia and meningitis in chickens and colostrum-deprived calves (Barrow, 
Lovell et al. 1998). As evidenced to be effective for treatement of meningitis, the 
phage therapy can be used in central nervous system diseases as phages can cross the 
blood brain barrier (Ritchie, Wagner et al. 2003). 6PLWK¶Vstudies on enteritis involved 
enterotoxigenic E. coli infection in neonatal calves, pigs and sheep. The pathogenesis 
of ETEC is virtually identical to that of cholera with adhesion to the small intestinal 
mucosa and production of a toxin affecting cAMP levels. In these cases, phages were 
sought which would attach to the surface virulence determinants K88 and K99, but 
without success, and phages attaching to LPS were used. Phages were used singly and 
in combination, the latter to ensure ability to control phage resistant mutants that arose 
against single phage use. Phages were used successfully prophylactically and also 
therapeutically such that administration could be delayed until the onset of diarrhoea. 
They could also be used to spray bedding which was also effective in preventing 
clinical disease after administration of the pathogen. Although, the interest in phage 
therapy in the West was reinvigorated by these very rigorous experiments, this 
approach had not taken hold as might have been expected given its experimental 
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success but there is now a resurgent interest owing to the emergence of antibiotic 
resistance in recent years (Chopra, Hodgson et al. 1997, Sack 2001)  
 
In recent years phage therapy was attempted for several other bacterial species viz. 
Salmonella spp. (Berchieri, Lovell et al. 1991, Goode, Allen et al. 2003, Atterbury, 
Van Bergen et al. 2007), Campylobacter spp. (Atterbury, Connerton et al. 2003, Loc 
Carrillo, Atterbury et al. 2005, Wagenaar, Van Bergen et al. 2005, Carvalho, Susano 
et al. 2010, Carvalho, Gannon et al. 2010, Connerton, Timms et al. 2011), Listeria 
monocytogenes (Leverentz, Conway et al. 2003, Leverentz, Conway et al. 2004), P. 
aeruginosa (McVay, Velasquez et al. 2007, Vinodkumar, Kalsurmath et al. 2008, 
Harper and Enright 2011, Morello, Saussereau et al. 2011, Krylov 2014), 
Staphylococcus aureus (Wills, Kerrigan et al. 2005, Gill, Pacan et al. 2006, 
Capparelli, Parlato et al. 2007, Sunagar, Patil et al. 2010, VinodKumar, Srinivasa et al. 
2011), Klebsiella pneumonia (Vinodkumar, Neelagund et al. 2005, Kumari, Harjai et 
al. 2009), Clostridium difficile (Ramesh, Fralick et al. 1999), Enterococcus faecalis 
(Biswas, Adhya et al. 2002, Yoong, Schuch et al. 2004, Uchiyama, Rashel et al. 2008) 
etc. There are increasing reports on the therapeutic utility of phages leading to 
development of a substantial knowledge bank for harnessing the true potential of 
phages in curing bacterial diseases. 
 
1.6.3 Phage therapy of cholera 
Fluid replacement therapy is often effective for cholera, if given in the earlier stages 
(§ 1.2). However, due to poor infrastructure and facilities in many countries where 
cholera is endemic, many patients during cholera outbreaks present with advanced 
stages of the disease (§ 1.2). In these cases the case fatality rate is usually high and 
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also there are limitations on the use of vaccines for cholera (§ 1.3.3) to prevent such 
situations. In addition, fluid replacement therapy results in extensive shedding of the 
pathogens during treatment and simultaneous use of antibiotics such as tetracycline 
can increase the risk of development of resistance. Thus, there is a need for a rapid 
and more effective alternative treatment for cholera and that could be the use of phage 
therapy. 
 
1.6.3.1 Phage therapy of cholera in humans 
The first study for phage therapy against cholera disease was reported by Felix 
G¶+HUHOOH'XULQJWKLVVWXG\ZKHQWKHFKROHUDSDWLHQWVZHUHWUHDWHGZLWKRUDOGRVHVRI
bacteriophage the mortality rate was 8.1 %, while in the controls i.e. patients treated 
with other medicines it was 62.9 %. The mortality rate in the phage treated group was 
zero if treatment occurred within 6 hours of appearance of the first symptoms 
(d'Herelle, Malone et al. 1930). It was also reported that between 1928 and 1931 
phage was used successfully to treat cholera cases in the North Eastern region of India 
viz. Shillong, Goalpara, Jakrem, Naogaon and Habibganj (Morison 1932). During the 
same period of time Asheshov and colleagues (Asheshov, Saranjam et al. 1930) 
reported successful treatment of patients in one location although their treatment with 
phage was unsuccessful in another location. The authors mentioned that although the 
phage was able to arrest the progress of disease it was more effective used as a 
prophylactic rather than a therapeutic. In the years 1958 and 1960, animal passaged 
phage preparations (§ 1.6.3.3) were successfully used in treating cholera patients in 
Afghanistan (Sayamov 1963). An initial intravenous or intramuscular phage 
administration with saline followed by oral administration for three days gave 
satisfactory results. 
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The WHO reported the studies which assessed the effectiveness of phage therapy for 
cholera (Monsur, Rahman et al. 1970, Marcuk, Nikiforov et al. 1971). Monsur and 
coworkers (Monsur, Rahman et al. 1970) treated eight patients of cholera with large 
doses of bacteriophage with high titre phage (1012 PFU/ml). They compared their 
results with 50 patients as control group treated with intravenous fluid alone and also 
with 18 patients treated with tetracycline. Four out of eight phage treated patients 
showed a rapid decline of V. cholerae numbers in stool samples as observed by means 
of dark field microscopy. The same four patients also showed appreciable reduction in 
the stool output and duration of diarrhoea compared to the control group. In another 
four patients treated with phage, V. cholerae numbers declined more slowly and the 
volume of the stool as well as the duration of diarrhoea was greater than the control 
group. Overall, the treatment with bacteriophage was partly (50%) effective based on 
the rate of decline of bacterial numbers, the stool output and duration of diarrhoea but 
was not as effective as the treatment with tetracycline.  
 
Marcuk and colleagues (Marcuk, Nikiforov et al. 1971) performed studies using phage 
preparations of between 108 and 109 PFU/ml given both orally and intramuscularly to 
adult as well as paediatric patients. They also compared their results with tetracycline 
treatment and with a placebo control. The post-treatment stool output (9.3 & 2.4 litres 
in phage treated; while 1.7 & 1.2 litres in tetracycline treated for adults and children, 
respectively), the duration of diarrhoea (76 & 52 h in phage treated; while 34 & 39 h 
in tetracycline treated for adults and children, respectively) and the duration of 
positive culture from stool samples (4.3 & 3.2 days in phage treated; while 0.7 & 0.8 
days in tetracycline treated for adults and children, respectively) were all significantly 
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less in the tetracycline treated group as compared to the phage treated and placebo 
groups. The authors mentioned that although phage therapy was promising, it did not 
work in their clinical trial. They reasoned that this might be due to relatively low 
dosage used in their trial compared to the earlier work of Monsur et al. (1970). 
 
8QWLO6PLWK¶VJURXSFDUULHGRXWKLVDQLPDOVWXGLHVWKHUHZDVYHU\OLWWOHNQRZQDERXW
the phage host interactions. Smith suggested that the phages of highest virulence in 
vitro should be used for in vivo studies. Previously, phage therapy experiments were 
poorly designed and in some cases phages were poured in to drinking water wells for 
control of cholera (Morison 1932). Also, the use of phage prophylaxis led to neglect 
of basic hygiene measures and thus, when antibiotics were successful in treating 
cholera, phage investigations were discontinued (Pollitzer, Swaroop et al. 1959). To 
understand better the nature of phage host interactions in vivo as suggested by Smith, 
a good animal model of cholera phage therapy is required. 
 
1.6.3.2 Animal models for cholera phage therapy 
Several animal models may be utilised for the study of pathogenesis of the V. cholerae 
and also for biological assays of their toxins. The first animal model developed was 
the adult rabbit (De and Chatterje 1953, Richardson 1968, Finkelstein and LoSpalluto 
1969, Nelson, Clements et al. 1976, Spira, Sack et al. 1981, Spira and Sack 1982, 
Pierce, Kaper et al. 1985, Russell, Tall et al. 1992), followed soon afterwards by the 
infant rabbit  (Dutta and Habbu 1955, Dutta, Panse et al. 1959, Jenkin and Rowley 
1959, Oza and Dutta 1963, Finkelstein, Norris et al. 1964, Kasai and Burrows 1966, 
Smith 1972, Madden, Nematollahi et al. 1981, Ritchie, Rui et al. 2010); mice (Ujiiye 
and Kobari 1970, Chaicumpa and Rowley 1972, Baselski, Briggs et al. 1977, 
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Angelichio, Spector et al. 1999, Krebs and Taylor 2011); rat (Aziz, Mohsin et al. 
1968); gnotobiotic/germfree mice (Sack and Miller 1969); sealed adult mice [SAM] 
(Richardson, Giles et al. 1984); dog (Sack, Carpenter et al. 1966, Carpenter, Sack et 
al. 1968) and non-human primates (Northrup and Chisari 1972). 
 
It was in the early 1950s that the use of animal models for cholera came to be assessed 
to improve understanding of the mechanism of pathogenesis of V. cholerae. Since 
then many animal models have been used but until today no animal model replicates 
completely all the essential features of the cholera as exhibited in humans (Richardson 
1994). The earliest animal model developed for cholera was adult rabbit model (De 
and Chatterje 1953) for investigation of the permeability changes in the capillaries due 
to V. cholerae after introducing them into ligated intestinal (ileal) loops of the small 
intestine. Further, Richardson (Richardson 1968) studied an ion translocase system of 
the rabbit intestinal mucosa which is inhibited by V. cholerae culture filtrates, while 
Finkelstein and Lospalluto (Finkelstein and LoSpalluto 1969) studied the biological 
activity of choleragen i.e. cholera toxin administered into ligated intestinal loops of 
adult rabbits. In 1981, Spira and colleagues (Spira, Sack et al. 1981) developed an 
adult rabbit model for enteric infection by V. cholerae and enterotoxigenic E. coli 
using a slip knot tie of the small intestine for challenge by vibrios which was removed 
after 2 hours and they designated this model as RITARD (removable intestinal tie-
adult rabbit diarrhoea) model. With this improvisation, they were able to produce 
massive and usually fatal cholera-like diarrhoea in adult animals. They further (Spira 
and Sack 1982) studied the kinetics of cholera infection in their RITARD model with 
production of overt diarrhea after 11 hours postchallenge. The RITARD model had 
also been used for investigating the pathogenesis of non-O1 V. cholerae (Russell, Tall 
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et al. 1992). Pierce et al (Pierce, Kaper et al. 1985) investigated the role of cholera 
toxin in enteric colonisation by vibrios in rabbits ileal loop (RIL) model. They noticed 
that fully toxigenic strains varied appreciably in their ability to colonise rabbit 
intestinal mucosa and colonisation was dose dependent.  
 
Dutta and Habbu (Dutta and Habbu 1955) were the first researchers to use the infant 
rabbit cholera model. They used ten day old rabbits weighing 100-200 g inoculated 
orally. Susceptibility to the disease was dependent on the age of the animals and all 
animals showed clinical signs and mortality up to 16 days of age. Despite the 
similarities with the human disease the signs differed in several aspects viz. absence of 
vomiting, minimal pathological picture, marked congestion of small intestine and 
distension of the large intestine with fluid. The signs of cholera could also be 
reproduced in infant rabbits by oral administration of the cell free products (Dutta, 
Panse et al. 1959, Oza and Dutta 1963) confirming the role of cholera toxin in the 
pathogenesis of cholera. Finkelstein and colleagues (Finkelstein, Norris et al. 1964) 
also confirmed the usefulness of the infant rabbits as experimental cholera models. 
They suggested that in spite of the drawback that immaturity of animals makes 
immunological studies difficult, there are certain advantages in that their intestinal 
tract remains unobstructed and even oral administration of cell free material produces 
cholera symptoms. They found that an atraumatic preparatory gastric lavage was 
necessary to avoid gastric acidity and they used catheter-mediated per os introduction 
of organisms into stomach but also used laparotomy for intraintestinal introduction of 
organisms. They observed the inhibition of gastric emptying due to a potential role of 
cholera toxin in the intraintestinally infected animals. It was noted that some strains of 
cholera or El Tor vibrios were unable to cause cholera in infant rabbits. Smith 
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demonstrated the production of diarrhoea in infant rabbits of 6-9 days old by oral 
administration of cholera toxin (Smith 1972). Madden and coworkers (Madden, 
Nematollahi et al. 1981) studied virulence of non O1 V. cholerae in infant rabbit 
assays. In this case, for pathogenicity assays, infant rabbits were inoculated 
intraintestinally by unspecified method and all animals showed a positive reaction. 
Fluid accumulated in the intestines and the animals either died or became sick with 
diarrhoea. Recently, a nonsurgical model of cholera gravis in infant rabbits was 
reported (Ritchie, Rui et al. 2010). Three-day-old rabbits pre-treated with cimetidine 
as antacid were inoculated with V. cholerae orogastrically and all the animals 
developed lethal watery diarrhoea. Non-toxigenic V. cholerae which do not produce 
cholera toxin (CT) and toxin-coregulated pilus (TCP) did not induce cholera-like 
disease in the infant rabbits. They also highlighted the association of V. cholerae with 
the host intestine for their attachment and exit from the intestinal tract is significantly 
influenced by CT-dependent mucin secretion. 
 
If we compare the adult rabbit model with the infant rabbit, the former are resistant to 
experimental cholera infection and for adult rabbit cholera model to be effective the 
prevention of peristalsis through intestinal ligation is required (Finkelstein 1996). 
Adult animals, especially rabbits, need surgical modification of their intestinal tract in 
order to create intestinal loops RIL or RITARD. Thus except by surgical modification 
adult animals do not produce cholera symptoms as susceptibility to the disease is also 
dependent on the age of the animals as animals showed mortality only up to the 
sixteenth day of life (Dutta and Habbu 1955). There may also be an inhibition of the 
V. cholerae in the adult animals by the gut flora which may therefore require 
clearance by using antibiotics prior to infection (Rhine and Taylor 1994). In the infant 
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rabbits the intestinal tract remains open and clear and thus oral administration of cell 
free material is also able to produce cholera signs (Finkelstein, Norris et al. 1964). The 
colonisation of intestinal villi was observed at a faster rate in the infant rabbits than in 
the adult rabbits and V. cholerae evenly covered the intestinal surface of infant rabbits 
while they occurred in patches in the adults (Nelson, Clements et al. 1976). This might 
be the reason that infant rabbits are more susceptible to experimental infection in the 
patent gut than the adult rabbits.  
 
Infant mice also show fatal infection after oral administration of vibrios (Chaicumpa 
and Rowley 1972). Ujiiye and colleagues (Ujiiye and Kobari 1970) first developed 
this model for cholera in which they demonstrated that infant mice responded well to 
oral infection by V. cholerae with diarrhoea and death. They observed that 
experimental cholera was produced only in the infant mice less than 10 days of age.  
Mice were isolated from their mothers after 5 or 6 days of suckling and were starved 
for 1 day before infecting them. Diarrhoea and deaths were recorded during the 5 days 
following challenge. Chaicumpa and Rowley (Chaicumpa and Rowley 1972) 
confirmed these findings With diarrhoea developing by 18 h while and occurring 
between 24 and 48 h of infection. Infection resembled human cholera as up to 10-fold 
more vibrios were recovered from the gastrointestinal tract after initial challenge. 
Baselski and coworkers (Baselski, Briggs et al. 1977) used infant mice to study 
intestinal fluid accumulation induced by oral challenge with V. cholerae and delivered 
the challenge dose into the stomach per os using a tuberculin syringe. Evans blue dye 
was also introduced in the stomach which was seen through the abdominal wall 
indicating the proper delivery of the inoculum. The Fluid accumulation (FA) ratio, 
which is the gut weight/remaining body weight, was quantified to see the diarrhoeal 
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response of mice to oral challenge with live vibrios or enterotoxin. The FA ratio was 
both time and dose dependent. The onset of FA occurred by 8 h post-challenge and 
was at its peak by 10 h.  
  
There are two obvious choices of animal models for phage therapy of V. cholerae viz. 
infant rabbits and infant mice. Amongst them, the infant rabbits produce the signs 
resembling human cholera more closely than do infant mice. V. cholerae colonizes 
rabbits and humans by mechanisms that are similar, though rabbits are not the natural 
hosts for V. cholerae (Pierce, Kaper et al. 1985).  Though the infant mice produce 
signs of cholera as in infant rabbits, inhibition of gastric emptying was noticed in 
infant mice challenged orally or subcutaneously with cholera toxin (Ujiiye and Kobari 
1970). Infant rabbits do not require starving as is the case with infant mice. One other 
practical advantage of infant rabbits over the mice is that they are larger and their 
handling is easier during in vivo studies. 
 
1.6.3.3 Phage therapy of cholera using animal models 
As discussed earlier (§ 1.6.3.2), the choice of animal model for phage therapy of V. 
cholerae is very critical owing to many factors which play a crucial role in making 
phage therapy either successful or not. Some of the studies on phage therapy of V. 
cholerae showed a lack of success possibly either due to the inability of V. cholerae to 
produce disease in the animal models or due to inappropriate selection of phage which 
were not capable of lysing the bacteria. Though Koch discovered V. cholerae (comma 
bacillus at his time) as the causative organism of cholera in the year 1883, later he 
failed to prove his third postulate (i.e. pure culture of micro-organism will produce 
disease in susceptible animal when injected) as he could not get suitable animal model 
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to prove this (Salyers and Whitt 2002). Much later on some animal models were 
developed to study pathogenesis of cholera as described in preceding section but none 
of the model could produce complete array of symptoms typical to cholera disease. 
Very few studies were done for phage therapy of cholera using animal models as 
discussed further in this section and they indicate that phage therapy did not work or 
was not as effective as antibiotics and thus it is possible that inspite of proper selection 
of animal model and appropriate phage selection the phage therapy may not work. 
 
Sayamov (Sayamov 1963) devised a method of passaging phages into the small 
intestine of guinea pigs for enhancing the lytic abilities of phages. After animal 
passaging of the phages, they successfully used them in human patients (§ 1.6.3.1). 
During this animal passaging the segments of small intestine of guinea pigs were 
isolated by ligatures. These intestinal loops were inoculated with V. cholerae (107 
CFU/ml) and simultaneously introducted with 0.1 ml of unknown titre phages. They 
used nine animals in control group and nine in the treatment group. After 24hrs it was 
observed that phages had completely lysed the bacteria and no bacteria were 
recovered or were present in very small numbers. In this study, though guinea pigs 
were used for phage passaging and phages effectively reduced the bacterial numbers 
during passaging, there are no further reports of guinea pigs being used either for 
cholera pathogenesis or for phage therapy.  
 
Sarkar and colleagues (Sarkar, Chakrabarti et al. 1996) used the adult rabbit ileal loop 
(RIL) model (§ 1.6.3.2) for examining the potential of V. cholerae typing phages to 
reduce in vivo numbers of organisms and fluid accumulation. Ten typing phages 
(ATCC 51352 B1-B10) were utilised for this study with the phage (1011 PFU/ml) 
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inoculated into the segments of ileal loop either alone or in combination with 108 
CFU/ml V. cholerae O1 biotype ElTor Ogawa MAK 757. They have not provided the 
number of control and treatment animals used in this study. These phages did not 
reduce the number of challenge bacteria nor the fluid accumulation ratios. The 
production of cholera toxin was not inhibited by the challenge of phages and 
additional factors in the intestinal milieu may have inhibited phage activity. However, 
Sulakvelidze and Barrow (Sulakvelidze and Barrow 2005) pointed out that the lytic 
ability of these phages was not specifically examined in vitro but it was likely that at 
least some phages could have had in vitro lytic ability against the challenge strain. 
Also they suggested that the negative outcome of the above study could be due to the 
use of the RIL model, which is not an optimal model for evaluating the efficacy of 
phages for therapy against naturally occurring cholera  The negative outcome of the 
RIL model prompted Bhowmick and coworkers (Bhowmick, Koley et al. 2009) to 
perform this study in the RITARD model (§ 1.6.3.2). They challenged with 109 
CFU/ml of V. cholerae MAK 757 (animal passaged earlier in adult mice to increase 
its virulence) in each of the six control and phage treated rabbits. The diarrhoea of 
variable severity was developed. In the phage-treated rabbits they gave 109 CFU/ml V. 
cholerae MAK 757 with 108 PFU/ml cocktail of phages which developed mild 
diarrhoea. Fewer pathological changes in the intestine were observed after phage 
treatment. The authors claimed that their study is the first direct evidence of phage 
multiplication in an open system such as the intestine infected by a V. cholerae O1 
serogroup strain. Further to this, their group (Jaiswal, Koley et al. 2013) performed 
oral cocktail phage therapy with five lytic V. cholerae specific phages to combat 
orally inoculated V. cholerae O1 in adult rabbits. They administered 1×108 PFU of 
phage cocktail, 6 h and 12 h prior as well as post-infection. For administration of 
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phages 6 h prior and after infection they used two rabbits, while one rabbit was used 
as a bacterial control and one more as a phage only control. Similar number of rabbits 
and controls were used for administration of phages12 h prior and after infection. The 
post infection application of phages recovered 2 log10 lower bacterial numbers than 
the bacterial control. Recently, the adult mouse model was used to test oral phage 
cocktail therapy of cholera (Jaiswal, Koley et al. 2014). The efficacy of a cocktail of 
phages administered at the MOI of 0.1 was compared to that of ciprofloxacin 
antibiotic. They used sixteen mice, four each in phage treated, antibiotic treated, ORS 
trated and control groups. In phage treated animals the bacterial numbers were 
reduced by 3 log10 (p <0.05) while ciprofloxacin showed 5 log10 (p <0.05) reductions 
in bacterial numbers compared to control group animals.  
 
The data presented above indicates that it is a logical choice to use the infant rabbit 
model for this project. 
 
1.6.4 Bacterial resistance to bacteriophage 
The emergence of phage resistant mutants was observed soon after the discovery of 
phage and this phenomenon was thought to be a potential problem to phage therapy 
(Summers 2001). Smith and Huggins (Smith and Huggins 1983) noticed very few 
phage resistant mutants in their study of phage therapy for E. coli diarrhoea in calves, 
piglets and lambs using mixture of two phages but these mutants tended to be less 
virulent than the original strains, while use of single phage did not produce any phage 
resistant mutants. In most of the Gram-negative pathogens bacteriophage resistance is 
due to the changes in phage receptors on the bacteria (Matsuzaki, Rashel et al. 2005). 
For example T even phages recognise outer membrane proteins (Omp) of E. coli as 
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receptors. If one Omp is changed by bacterial mutation, the phage may mutate to use 
another Omp and if that is also changed then phage again may mutate to use one more 
Omp or even to use lipopolysaccharide as receptor (Montag, Riede et al. 1987, 
Drexler, Riede et al. 1989). 
 
Bacteria produce restriction enzymes which cleave phage DNA at specific sites and 
thereby restrict the phage from infecting them (Roberts 2005). Bacteria protect their 
own DNA from these enzymes by modifying or adding a methyl group to their 
adenine or cytosine bases using the enzyme methylase. Not all bacteria contain this 
Restriction ± Modification (RM) system but for those which have such systems, 
phages have also evolved an anti-restriction system. In this activity phages undergo 
mutations to erase the sites in their genome which are the recognition sites for 
endonuclease (Labrie, Samson et al. 2010). Mutation is one possible way of getting 
around this, although it seems unlikely that all of the sites will be removed in one 
round (or even multiple rounds) of replication. It is likely that if a large number of 
bacteriophages infect a single bacterium at one time, some of the phage will be able to 
replicate despite the presence of RM enzymes. If that is the case, then the DNA of the 
bacteriophage may be acted on by the methylases, rendering daughter phage resistant 
to restriction (Atterbury 2003). 
 
Many bacteria also use the CRISPR-cas system which is an immunity system that 
targets phage nucleic acid. It is a locus of genes having clustered regularly interspaced 
short palindromic repeats (CRISPR) as well as CRISPR associated (cas) genes. It 
contains 21±48 bp repeats interspaced by 26±72 bp non-repetitive spacers and these 
are generally flanked by variable number of cas genes (usually 4 to 20 in numbers) 
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(Labrie, Samson et al. 2010). When lytic phages attack sensitive bacterial strains, a 
small number of Bacteriophage Insensitive Mutants (BIMs) arise which contain the 
repeat spacer unit identical to the short conserved nucleotide motif called Proto spacer 
Associated Motif (PAM) on the phage genome. When these BIMs are attacked by 
phage carrying a proto-spacer which is identical to its repeat spacer the phage will be 
inactivated. Phages again undergo mutations in their PAM regions to circumvent this 
resistance (Andersson and Banfield 2008). If we compare this resistance to antibiotic 
resistance, the rate of developing resistance to phage is up to 10 times lower than to 
antibiotics (Carlton 1999). The use of several phages in one preparation i.e. a phage 
cocktail which are virulent against different targeted pathogen strains, helps to 
overcome the resistance synergistically as with antibiotics (Sulakvelidze, Alavidze et 
al. 2001).    
   
1.6.5 Ideal properties of phage therapy candidates  
In order to maximise the potential success of bacteriophage therapy, the phages 
selected should fulfil a number of criteria.  First, the phage should have the ability to 
infect a wide range of susceptible host bacteria (broad host range/lytic profile) and 
replicate only through the lytic life cycle. In addition, the phage should have a short 
latent period and high burst size. The phage should not carry genes which encode 
virulence factors or are involved in antibiotic resistance. Thus, temperate phages 
which possess many of such characteristics should be avoided for phage therapy (Gill 
and Hyman 2010). Phages should ideally be selected which attach to specific surface 
virulence deteminants such that any resistant mutants that emerge would show 
reduced virulence or avirulence (Smith and Huggins 1982). 
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1.7  Characterisation of bacteriophage 
1.7.1 Biological characterisation 
To identify the ideal properties of phage for phage therapy, the host range, latent 
period and burst size of the candidate phage are needed. The host range profile of the 
phage is defined by lysis of a range of bacterial host strains. The host growth curve 
provides a mid exponential phase and generation time (§ 2.3) which is further utilized 
to devise a protocol for phage one step growth curve which will then provide an 
estimation of the burst size and latent period (§ 1.5). 
 
1.7.2 Physical characterisation 
Although bacteriophage can be seen under ordinary and phase microscope (Hofer 
1947), an electron microscopy is used and can magnify the image up to 400,000 times 
(Douglas 1974). Electron microscopy allows the morphological classification of 
bacteriophage.  
 
As per the International Committee on Taxonomy of Viruses (ICTV), the phages are 
classified as one order, ten families and forty genera (ICTV 2011) (Table 1). The 
symmetries of the phage classified are binary (having two divisions), cubical, helical 
or pleomorphic. Most of the phage genome may have double stranded DNA but a few 
may contain single stranded DNA and even double or single stranded RNA as their 
genome. A few phage may have a lipid envelope surrounding the capsid. Most of the 
phage are classified in to the order Caudovirales which have binary symmetry and are 
tailed phage. There are three phylogenetically related families in the order 
Caudovirales viz. the contractile-tailed Myoviridae, the long non-contractile tailed 
Siphoviridae and the short tailed Podoviridae (Ackermann 2006). 
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Order   Family   Genome   Genome  Envelope  Morphology   Virion size 
        size (Kb)  
Caudovirales  Myoviridae  dsDNA  31-317  No  Icosahedral  Icosahedral heads: 60-45 nm; 
     linear      head with    Elongated heads: 80-110 nm; 
            tail   Tail: 16-20 × 80-455 nm 
 
Caudovirales  Podoviridae  dsDNA  16-78  No  Icosahedral  Icosahedral heads: 60-70 nm; 
     linear      head with   Tail: 10-20 nm 
            short tail   
 
Caudovirales  Siphoviridae  dsDNA  21-134  No  Icosahedral  Icosahedral heads: 40-80 nm; 
     linear      head with   Tail: 5-10 × 100-210 nm 
            tail   
 
Unassigned  Corticoviridae  dsDNA  10  No  Icosahedral  60 nm 
     circular 
     supercoiled        
 
Unassigned  Plasmaviridae  dsDNA  12  Yes  Quasi-spherical,  50-125 nm 
      circular      pleomorphic 
      supercoiled 
 
Unassigned  Tectiviridae  dsDNA  15  No  Icosahedral  66 nm 
     linear        
 
Unassigned  Inoviridae   ssDNA (+) Inoviruses:  No  Inoviruses:  Inoviruses: 7 × 700-3500 nm; 
     circular  5.8-12.4    filamentous   Plectroviruses: 15 × 200-400 nm 
        Plectroviruses:   Plectroviruses: 
        4.5-8.2    rod shaped 
 
Unassigned  Microviridae  ssDNA (+) 4.4-6.1   No  Icosahedral  25-27 nm    
      circular        
        
Unassigned  Cystoviridae  dsRNA  6.4-7.1;  Yes  Spherical   85 nm 
      three linear 3.6-4.7;       
      segments  2.6-3.2 
 
Unassigned  Leviviridae  ssRNA (+)  3.5-4.3  No  Icosahedral  26 nm 
 
 
Table 1: Classification of phages as per ICTV. 
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1.7.3 Genomic characterisation 
In order to differentiate phages, the genome size is estimated by pulsed field gel 
electrophoresis (PFGE) and restriction analysis is done using different restriction 
enzymes (Gill and Hyman 2010). Using genome sequencing, the potential phage 
therapy candidates can be screened for harmful genes associated with virulence, 
antimicrobial resistance or lysogeny-related genes (Skurnik, Pajunen et al. 2007). 
Pulse field gel electrophoresis is useful for sizing large DNA fragments; in this 
technique, the direction of an electric field is periodically switched which helps in 
separation of DNA fragments of up to 5Mb (Carle and Olson 1984, Schwartz and 
Cantor 1984).  
 
The sequencing of microbial genomes has become more efficient and cost-effective 
over the past decade, resulting in a significant increase in the number of published 
genomes in online databases such as Gen bank. Notwithstanding these advances, the 
number of bacteriophage genomes available in such databases is approximately 750, 
as compared with over 5,000 individual phages which have been isolated (Hatfull and 
Hendrix 2011). High throughput sequencing platforms have been introduced since 
2005. After next generation sequencing, genome annotation is done to identify 
predicted open reading frames (ORFs) or CDSs (CoDing Sequences) which can code 
for particular proteins (Kropinski, Borodovsky et al. 2009). By assigning the functions 
to different phage genes through CDSs provides an insight in the phage type which we 
are dealing with so that we can decide whether to use it for phage therapy purpose or 
not. 
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1.8  Aims 
It is clear from the above considerations that there is little definitive work 
demonstrating efficacy of lytic phages against experimental cholera using an 
appropriate animal model. The main reason for this could be inadequate assessment of 
phages in vitro prior to their evaluation in vivo combined with the use of a model 
which is less than optimal. Drawing on the expertise acquired by Smith and his 
colleagues with well controlled animal experiments using a comparable enteric 
infection of neontal animals and in which the phages were assessed thoroughly in 
vitro beforehand, we decided to collect a small panel of phages from various sources 
and to evaluate these in vitro followed by assessment in experimental infection in the 
infant rabbit model. 
 
The main aim of this project is thus to explore the use of bacteriophage for biocontrol 
of V. cholerae with the following activities to be undertaken: 
1. Isolation of bacteriophages which could be used as bio-control agents for V. 
cholerae. 
2. In vitro characterisation of the bacteriophages and selection of candidate 
bacteriophages for biocontrol. 
3. Determination of the efficacy of biocontrol by candidate bacteriophage in 
therapeutic experiments using the infant rabbit model.  
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2 MATERIALS AND METHODS 
2.1  Preparation of media and buffers  
2.1.1 Media for growth of V. cholerae 
2.1.1.1 Alkaline Peptone Water (APW) broth:  
For enrichment of V. cholerae Alkaline Peptone Water (APW) broth [CM 1117, 
Oxoid limited, Basingstoke, Hampshire, UK] was prepared according to 
mDQXIDFWXUHU¶V LQVWUXFWLRQ )RU WKLV  J RI $3: SRZGHU ZDV DGGHG WR  OLWUH RI
Reverse Osmosis (RO) water. After dispensing in to smaller volumes it was 
autoclaved at 121 °C for 15-20 m. Sterile APW was stored at room temperature until 
used. Concentrated (five times) APW broth was prepared by adding 40 g of APW 
powder to 200 ml of RO water. 
 
2.1.1.2 Luria Bertani (LB) broth:  
For routine culturing of the V. cholerae strains, Luria Bertani (LB) broth [L3152 
Fluka, LB broth, Miller, Sigma Aldrich Ltd., Gillingham, Dorset, UK] was used. For 
preparing the broth, 25 g LB broth powder was added to 1 litre of RO water and 
autoclaved 121 °C for 15-20 m. Sterile broth was stored at room temperature until 
used.   
 
2.1.1.3 Thiosulphate Citrate Bile Salt (TCBS) agar:  
Thiosulphate Citrate Bile Salt (TCBS) agar [CM 0333, Oxoid limited, Basingstoke, 
Hampshire, UK] is a selective differential medium for isolation and culturing of halo-
tolerant V. cholerae ,WZDVSUHSDUHGDFFRUGLQJ WR WKHPDQXIDFWXUHU¶V LQVWUXFWLRQ LH
88 g of TCBS agar powder was added to 1 litre of RO water which was boiled without 
autoclaving, cooled down to below 50 °C and poured into the petri plates. The plates 
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were dried in to the drying cabinet overnight before shifting them to the cold room (4 
°C) and used within few weeks.  
 
2.1.1.4 Maximum Recovery Diluent (MRD): 
Maximum Recovery Diluent (Oxoid CM0733) was used for serial dilutions of 
bacterial cultures and also for sample collection during isolation of V. cholerae. It was 
SUHSDUHG DV SHU WKH PDQXIDFWXUHU¶V GLUHFWLRQ )or this 9.5 g of MRD powder was 
dissolved in 1 litre of distilled water and sterilized by autoclaving at 121 °C for 15 m. 
It was stored at room temperature till further use. 
 
2.1.2 Media and buffers for phage isolation and characterisation 
2.1.2.1 Salt Magnesium (SM) buffer:  
Salt Magnesium (SM) buffer is used for storage and dilution of phages. For preparing 
SM buffer, 5.8 g/L sodium chloride (NaCl); 2 g/L of magnesium sulphate hexahydrate 
(MgSO4.7H2O); 5 ml/L of 2 % w/v Gelatin solution and 6 g/L of 1M Tris-Cl/TRIS 
was added to one litre of the RO water and pH was adjusted to 7.5. After autoclaving 
at 121 °C for 15-20 m, it was stored at room temperature till used. 
  
2.1.2.2 Luria Bertani (LB) base medium and top agar:  
LB base medium (1 %):  
LB base medium was prepared by adding 1 g Sigma select agar per 100 ml of LB 
broth (§ 2.1.1.2) and then autoclaved at 121 °C for 15-20 m. The agar was cooled to 
below 50 °C and then poured into petri plates. The plates were stored in to cold room 
at 4 °C after they were dried in a drying cabinet.  
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Suplemented LB base medium (1 %):  
LB base medium (1 %) was prepared as mentioned in the preceding paragraph and 
was supplemented with 0.3 % Glucose, 0.075 mM CaCl2 and 2 mM MgSO4 
(Sambrook and Russell 2001). The Glucose reduces phage loss by adsorption to 
bacterial debris; calcium helps to reduce loss by reabsorption, while magnesium is 
essential for attachment of the phage to the receptor structures on bacteria.  
LB top agar (0.5 %) overlay:  
Top agar was prepared for overlaying it on the 1 % base agar while making the 
bacterial lawns. For this 0.5 g Sigma select agar was added per 100 ml of LB broth (§ 
2.1.1.2) and autoclaved at 121 °C for 15-20 m. The top agar was stored at room 
temperature until required. 
 
2.1.2.3 TE buffer:  
10× TE buffer was prepared by adding 12.1 g/L Trizma base and 3.7 g/L EDTA to 1 
litre of RO water. 10× TE buffer was diluted 1:9 with RO water for 1× TE buffer. 
 
2.1.2.4 Lysis buffer for PFGE:  
Lysis buffer was prepared by adding 50mM Tris-HCl (pH 8.0), 50mM EDTA, 1% 
Lauryl Sarcosine i.e. Sarcosyl detergent and 100 µg/ml Proteinase K to 20 ml of 
sterile RO water. The buffer was used fresh for one PFGE run. 
 
2.1.2.5 Wash buffer for PFGE:  
Wash buffer was prepared by adding 50mM Tris-HCl (pH 8.0) and 50mM EDTA to 
20 ml of sterile RO water. The buffer was used fresh for each PFGE run. 
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2.1.2.6 TAE buffer for Gel electrophoresis: 
The 1L of 50× TAE buffer (pH 8.0) was prepared by adding 242 g Tris base, 5.7 ml 
Glacial acetic acid and 100 ml 0.5 M EDTA (pH 8.0). For 1 L of 1× TAE buffer, 20 
ml of 50× TAE buffer was added in 980 ml of RO water. 
 
2.1.2.7 EDTA (0.5 M, pH 8.0): 
For this 186.1 g of disodium EDTA 2H2O was added 800 ml of RO water and stirred 
vigorously on a magnetic stirrer. The pH was adjusted to 8.0 with NaOH and sterilized 
by autoclaving.  
 
2.1.2.8 MgCl2 (1M): 
MgCl2 (1M) was prepared by dissolving 203.3 g of MgCl2.6H2O into 800 ml of RO 
water and then adjusting volume to 1 L by RO water. Sterilization was done by 
autoclaving and stored at room temperature.  
 
2.1.2.9 Tris-EDTA i.e. TE (pH 8.0):  
This was prepared by using Tris-Cl (pH 8.0) 100 mM and EDTA (pH 8.0) 10 mM in 
an appropriate quantity of RO water and sterilised by autoclaving. 
 
2.1.2.10 Ammonium Acetate (10M): 
A stock solution of Ammonium Acetate (10M) was prepared by dissolving 77 g of 
Ammonium Acetate to 70 ml of RO water and then adjusting volume to 100 ml by RO 
water. Sterilization was done by filtering through 0.22 µm syringe filter and stored at 
4 °C. 
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2.2  Bacteria and bacteriophages 
2.2.1 V. cholerae 
A total of 91 V. cholerae strains were used for this project (Table 2) and they were 
obtained from four sources as mentioned below: 
1. London School of Hygiene and Tropical Medicine, London, UK: 
Professor Brendan Wren and Mr. Muhammad Ali of London School of Hygiene and 
Tropical Medicine kindly provided 86 V. cholerae strains of which 71 were V. 
cholerae O1 El Tor Ogawa while the remaining 15 were V. cholerae non-O1 and non-
O139.  
2. University of Bristol, UK: 
Two V. cholerae isolates O395NT and M14 were obtained from Dr. Neil Williams, 
University of Bristol. M14 was V. cholerae O1 El Tor Inaba, while O395NT is non-
toxin producing V. cholerae O1 El Tor Ogawa.  
3. )HOL[G¶+HUHOOH5HIHUHQFH&HQWUHIRU%DFWHULDO9LUXVHV&DQDGD: 
V. cholerae 1051, which was a classical O1 serotype was obtained from the Felix 
G¶+Hrelle Reference Centre for Bacterial Viruses, Québec, Canada.  
4. China Agricultural University, Beijing, China: 
The strains 2095 and 2134 were obtained from Dr. Jingliang Su, China Agricultural 
University, Beijing, China. Strain 2095 was V.cholerae 01 El Tor Inaba (NT) and 
2134 was V. cholerae O139 (NT). 
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Seri-
al 
No. 
Bacteria Strain Seri-
al 
No. 
Bacteria Strain  
1 V.cholerae non-
O1/non-O139 
238 47 V.cholerae 01 El Tor 
Ogawa 
D-1 
2 V.cholerae 01 El Tor 
Ogawa 
257 48 V.cholerae non-O1/non-
O139 
D-13 
3 Vibrio spp. but not V. 
cholera 
404 49 V.cholerae non-O1/non-
O139 
D-15 
4 Vibrio spp. but not V. 
cholera 
406 50 V.cholerae 01 El Tor 
Ogawa 
D-25 
5 V.cholerae 01 El Tor 
Ogawa 
709 51 V.cholerae 01 El Tor 
Ogawa 
D-30 
6 V.cholerae 01 El Tor 
Ogawa 
719 52 V.cholerae 01 El Tor 
Ogawa 
D-56 
7 V.cholerae 01 El Tor 
Ogawa 
722 53 V.cholerae 01 El Tor 
Ogawa 
D-59 
8 V.cholerae 01 El Tor 
Ogawa 
729 54 V.cholerae 01 El Tor 
Ogawa 
DN-4 
9 V.cholerae 01 El Tor 
Ogawa 
732 55 V.cholerae 01 El Tor 
Ogawa 
F-5 
10 V.cholerae 01 El Tor 
Ogawa 
736 56 V.cholerae 01 El Tor 
Ogawa  
F-6 
11 V.cholerae 01 El Tor 
Ogawa 
739 57 V.cholerae non-O1/non-
O139 
FB-01 
12 V.cholerae 01 El Tor 
Ogawa 
742 58 V.cholerae non-O1/non-
O139 
FN-2 
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13 V.cholerae 01 El Tor 
Ogawa 
750 59 V.cholerae 01 El Tor 
Ogawa 
FN-4 
14 V.cholerae 01 El Tor 
Ogawa 
751 60 V.cholerae non-O1/non-
O139 
FN-5 
15 V.cholerae 01 El Tor 
Ogawa 
752 61 V.cholerae 01 El Tor 
Ogawa 
GB-39 
16 V.cholerae 01 El Tor 
Ogawa 
753 62 V.cholerae 01 El Tor 
Ogawa 
HH-1 
17 V.cholerae 01 El Tor 
Ogawa 
754 63 V.cholerae 01 El Tor 
Ogawa 
HH-14 
18 V.cholerae 01 El Tor 
Ogawa 
755 64 V.cholerae 01 El Tor 
Ogawa 
HH-15 
19 V.cholerae 01 El Tor 
Ogawa 
756 65 V.cholerae 01 El Tor 
Ogawa 
HH-4 
20 V.cholerae 01 El Tor 
Ogawa 
758 66 V.cholerae non-O1/non-
O139 
Ht-10 
21 V.cholerae 01 El Tor 
Ogawa 
759 67 V.cholerae 01 El Tor 
Ogawa 
Ht-10A 
22 V.cholerae 01 El Tor 
Ogawa 
760 68 V.cholerae non-O1/non-
O139 
J-1 
23 V.cholerae 01 El Tor 
Ogawa 
761 69 V.cholerae 01 El Tor 
Ogawa 
KCH-18 
24 V.cholerae 01 El Tor 
Ogawa 
762 70 V.cholerae 01 El Tor 
Ogawa 
KPD-3 
25 V.cholerae 01 El Tor 
Ogawa 
763 71 V.cholerae non-O1/non-
O139 
KtH-4 
26 V.cholerae 01 El Tor 764 72 V.cholerae 01 El Tor KTH-7 
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Ogawa Ogawa 
27 V.cholerae 01 El Tor 
Ogawa 
765 73 V.cholerae 01 El Tor 
Ogawa 
N-10 
28 V.cholerae 01 El Tor 
Ogawa 
767 74 V.cholerae 01 El Tor 
Ogawa 
N-5 
29 V.cholerae 01 El Tor 
Ogawa 
768 75 V.cholerae 01 El Tor 
Ogawa 
N-7 
30 V.cholerae 01 El Tor 
Ogawa 
769 76 V.cholerae 01 El Tor 
Ogawa 
NP-14 
31 V.cholerae 01 El Tor 
Ogawa 
770 77 V.cholerae 01 El Tor 
Ogawa 
NP-3 
32 V.cholerae 01 El Tor 
Ogawa 
771 78 V.cholerae 01 El Tor 
Ogawa 
NP-5 
33 V.cholerae 01 El Tor 
Ogawa 
772 79 V.cholerae 01 El Tor 
Ogawa 
NP-6 
34 V.cholerae 01 El Tor 
Ogawa 
773 80 V.cholerae 01 El Tor 
Ogawa 
NP-7 
35 V.cholerae 01 El Tor 
Ogawa 
774 81 V.cholerae non-O1/non-
O139 
O5 
36 V.cholerae 01 El Tor 
Ogawa 
775 82 V.cholerae non-O1/non-
O139 
P-1 
37 V.cholerae 01 El Tor 
Ogawa 
776 83 V.cholerae 01 El Tor 
Ogawa 
PS-18 
38 V.cholerae non-
O1/non-O139 
10 84 V.cholerae 01 El Tor 
Ogawa 
PS-25 
39 V.cholerae 01 El Tor 
Ogawa 
A-4 85 V.cholerae 01 El Tor 
Ogawa 
PS-7 
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40 V.cholerae 01 El Tor 
Ogawa 
BW-5 86 V.cholerae 01 El Tor 
Ogawa 
RG-6 
41 V.cholerae 01 El Tor 
Ogawa 
CS-1 87 V.cholerae 01 El Tor 
Inaba 
M14 
42 V.cholerae 01 El Tor 
Ogawa 
CS-12 88 V.cholerae 01 El Tor 
Ogawa 
O395NT 
43 V.cholerae 01 El Tor 
Ogawa 
CS-15 89 V.cholerae O1 strain 1051 
44 V.cholerae 01 El Tor 
Ogawa 
CS-16 90 V.cholerae 01 El Tor 
Inaba (NT) 
2095 
45 V.cholerae 01 El Tor 
Ogawa 
CS-18 91 V.cholerae O139 (NT) 2134 
46 V.cholerae non-
O1/non-O139 
CW-1    
 
Table 2: V. cholerae strains used for this project. 
Serial No. 1-86: Obtained from London School of Hygiene and Tropical Medicine, 
London, UK; Serial No. 87-88: Obtained from the University of Bristol, UK; Serial 
No. 8 2EWDLQHG IURP )HOL[ G¶+HUHOOH 5HIHUHQFH &HQWUH IRU %DFWHULDO 9LUXVHV
Canada; Serial No. 90-91: Obtained from China Agricultural University, China; NT: 
Non-toxigenic. 
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2.2.1.1 Freezing of V. cholerae strains: 
A single colony from a freshly cultured TCBS plate was grown in 10 ml LB broth up 
to mid-exponential phase i.e. approx. 4 hours at 37 °C. An aliquot of this culture (660 
µl) was added to a sterile 2 ml graduated skirted Cryo tube (Starlabs, Milton Keynes, 
UK) to which 1 ml of sterile 50 % glycerol was added. The tube was vortexed briefly 
to mix the contents thoroughly and immediately frozen at ± 80 °C.  
 
2.2.2 Bacteriophages 
2.2.2.1 Phages from Public Health England (PHE): 
Four phage isolates (ĭ1, ĭ2, ĭ3 and ĭ4) were obtained from Dr. Tom Cheasty 
[Former Head, Gastrointestinal Infections Reference Unit, Public Health England 
(PHE)] without their host strains.  
 
2.2.2.2 Phages from Canadian Culture collection: 
7ZRSKDJHVDQG;ZHUHSXUFKDVHGIURPWKH)HOL[G¶+HUHOOH5HIHUHQFH&HQWUH
for Bacterial Viruses (Canada) together with the host strain V. cholerae 1051.  
 
2.2.2.3 Phage isolation in China:  
Seven more V. cholerae specific phages were isolated from China using Vibrio 
cholerae 2095 which is an O1 Inaba strain. The locations of the sample collection 
from South Eastern China (Table 3) were as below: 
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Sr. 
No. 
Sample location No. of 
samples 
collected 
Sample codes 
 %HL[LDRKHVHZDJHWUHDWPHQW
SODQW%HLMLQJ 
 %6 
 %HLMLQJULYHU  %5- 
 4LQJ+HULYHU%HLMLQJDQG&XL
-LD<DRULYHUPLOHVDZD\ 
 4+&-<16+-
6=- 
 )X-LD:DQ<H=KL+XDQG1DQ
+XODNHVRI:XKDQ+XEHL 
 +++ 
 -LDQJ[L1DQFKDQJ<XGDL+H
ULYHU 
 ---- 
 +HQDQSURYLQFH=KHQJ]KRX
FLW\ 
 ==== 
 7RWDO   
 
Table 3: The locations of the sample collection from South Eastern China.   
 
A total of 25 samples were collected from six different locations from south eastern 
China. The sampling locations based on the Cholera prediction map (Xu, Cao et al. 
2013) are given in the Figure 7. The location maps and images of sampling sites from 
where phages were isolated are shown in the Figures 8 to 11. 
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Figure 7: Cholera prediction map, based on which sampling plan was derived is 
shown in this figure. The high risk areas for cholera disease as indicated by red colour 
were chosen for sample collection. 
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Figure 8: Sample location map and site image for Qing He river sampling site (QH). 
The location on the map at the top LVLQGLFDWHGE\µ$¶DQGSLFWXUHEHORZLVDsampling 
site image. 
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Figure 9: Sample location map and site image for Cui Jia Yao river sampling site 
(CJY). The distance between Cui Jia Yao and Qing He river (QH) sample locations, 
which is approx. 50 miles can be seen on the map at the top and picture below is a site 
photograph during sample collection. 
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Figure 10:  Sample locations map at top and sampling site images below for Fu Jia 
Wan (H1), Ye Zhi Hu (H2) and Nan Hu (H3) lakes from Wuhan, Hubei. 
H1 H2
H3
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Figure 11: Sample locations map at top for Jiangxi, Nanchang, Yudai He river 
samples wherein 1 is J1; 2 is J2; 3 is J3 and 4 is J4. The image below is of J2 sample 
collection site. 
 
 
 
1
2
3
4
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2.2.2.4 Phage isolation in the UK: 
Bacteriophage isolation was attempted twice from sewage samples collected from a 
local wastewater treatment plant i.e. Severn Trent Sewage Works, Raynesway, Derby 
(Figure 12) which deals with the sewage from approx. 165,000 people in the region. 
The reason for choosing this site was the fact that cholera is a human diarrhoeal 
disease and imported cases occur within the UK annually. 
 
 
Figure 12: Severn Trent Sewage Works, Raynesway, Derby as indicated by arrow on 
the map. 
 
2.2.2.5 Protocol used for isolation of phages:  
For V. cholerae phage isolation from sewage, river, or lake samples, the method of 
Van Twest and Kropinski, 2009 (Van Twest and Kropinski 2009) was used with 
following modifications: 
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a) Filter units (0.45 µm) were used instead of 0.22 µm filter units as the large 
sized phage may not have been able to pass through 0.22 µm filter units. 
b) The filtrate was not stored in the presence of chloroform as some phage may 
have been sensitive to the chloroform. 
c) APW broth was used instead of LB broth as it is a selective broth for V. 
cholerae. 
 
Sewage from settlement tanks or river or lake water samples (500 ml) were collected. 
After bringing the sample to the lab it was clarified by centrifugation at 10,000 × g for 
30 m and filtered through 0.45 µm syringe filter units (Millipore, Millex). The 30 ml 
of filtrate was mixed with 9 ml of 5x APW, 1 ml of 1 M CaCl2 (i.e. 20 mM in 50 ml) 
and 10 ml of V. cholerae overnight culture. This reaction mixture was incubated in a 
250 ml screw capped flask at 37 °C for 48 h shaking at 50 RPM. 
  
The culture was clarified by centrifugation at 10,000 × g for 10 min and the 
supernatant was filtered with 0.45 µm filter to remove the unwanted bacterial cells. 
An aliquot (10 µl) of filtrate was spot inoculated on the lawn of the target V. cholerae 
strain used for isolation and incubated at 37 °C overnight. Next day the lawns were 
checked for zones of lysis or individual plaques.   
 
2.2.2.6 Plaque purification 
Individual plaques were further purified using a streak plating method described by 
phage hunting protocols (Phagesdb.org 2013). An isolated single plaque was picked 
by touching the centre of the plaque once with a pipette tip and aseptically releasing 
the attached phages in to 100 µl of SM buffer. Then, a new sterile tip was swirled in to 
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a buffer with picked phages and streaked as per the Figure 13. The streaked plate was 
brought to room temperature; a top agar containing the host strain was poured 
carefully at the most diluted spot on the plate and slightly tilted for top agar to spread 
slowly across the plate. After the top agar was solidified, the plate was incubated at 37 
°C for 24 h. After incubation, a single plaque was identified and again picked and 
streak plate purification was repeated two more times. 
 
Figure 13: Schematic representation of streaking pattern for streak plate plaque 
purification. 
A: Picked phages were streaked confluently on to a fresh cold LB plate back and forth 
across 20 % of the top plate.; B: With a new tip starting out of the confluently streaked 
area, the 40 % more area was streaked without overlapping the strokes at the corner.; 
C: Again with a new tip starting out of the earlier 40 % streaked area, the remaining 
40 % was streaked without overlapping the strokes at the corner. 
 
2.3  Growth kinetics of V. cholerae host strains 
For the growth curve study the frozen stock of V. cholerae strain was streaked on 
three TCBS agar plates and incubated at 37 °C for 24 h. Next day a single colony 
from each plate was inoculated into 10 ml LB broth and incubated at 37 °C, shaking at 
150 rpm for 3 h. At the same time 50 ml LB broth was added to three 250 ml screw 
capped flasks and incubated at 37 °C for three hours. After 3 h 0.5 ml of a mid-
A B
C
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exponential culture (time for mid exponential phase derived from the a pilot 
experiment) from 10 ml LB universals was added to 50 ml pre-warmed broth in flasks 
and incubated at 37 °C shaking at 150 rpm. This point is considered to be zero hour 
for taking first sample for plating (i.e. after diluting the culture up to the desired 
dilutions as decided by pilot experiment) the 100 µl was spread plated on 1 % LB agar 
medium in duplicate and the OD600 readings were taken on the spectrophotometer 
(Biochem, Libra S22). 
 
Plating and OD readings were done every 2 h until 12 h, and the plates incubated at 37 
°C overnight. Data was pooled from three trials and analysed after converting 
bacterial counts to log10 values and determining the standard deviation. The mid 
exponential phase was identified and the generation time at this point was calculated 
as per the formula in Pelzar et al (Pelczar, E.C.S. et al. 1993). The generation/doubling 
time is the time taken by the number of cells in the culture to double. It is calculated 
from the counts taken from the log phase of growth as the cells would be in the 
uniform phase of growth. The formula used was as below: 
G = t/n 
Where G = Generation time 
t = the log phase time interval in minutes 
n = number of generations  
The total population of bacterial culture that begins with one cell is expressed as:  
b = B ± 2n 
Where B = number of bacteria at the beginning of time interval 
b = number of bacteria at the end of time interval 
n = number of generations 
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The above equation is rearranged by using Log10 values as below: 
log10 b = log10 B + n log10 2  
n = log10 b - log10 B/ log10 2 
n = log10 b - log10 B/0.301 
n = log10 b - log10 B × 3.3 
This equation is incorporated in to original equation as below: 
G = t/3.3 (log10 b-B) 
 
2.4  Characterisation of bacteriophage isolates 
2.4.1 Liquid lysates of phage 
A single colony of a V. cholerae host strain was picked from a fresh TCBS plate and 
inoculated in to 10 ml of LB broth and incubated at 37 °C with shaking at 150 RPM. 
At mid-exponential phase the culture was inoculated with 0.1 ml of phage stock and 
incubated overnight at 37 °C. Next day the culture was centrifuged at 10,000 × g for 
10 m and then filtered through a 0.45 µm syringe filter. The filtrate was stored at 4 °C 
after determining its titre. 
 
2.4.2 Preparation of bacterial lawn 
The V. cholerae culture, 350 µl at mid-exponential phase was added to 5 ml of 
soft/top agar (0.5 % LB media) and overlaid on a 1 % LB media plate (§ 2.1.2.2). The 
top agar was maintained at 50 °C in water bath before overlaying. The bacterial 
culture was mixed in to the soft/top agar by gentle swirling and then poured. The lawn 
was dried up to 30 m and then used for phage spotting. 
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2.4.3 Plate lysates of phage 
Phage stock was diluted to a dilution which gave just semi-confluent plaques touching 
each other with visible bacterial growth and gauzy webbing of plaques. A 100 µl 
aliquot of the chosen dilution of phage was mixed with 350 µl of V. cholerae culture 
taken from a mid-exponential phase culture. To this bacteria-phage mixture 5 ml of 
molten 0.5 % LB top agar was added, mixed and overlaid on 1% supplemented LB 
agar plates (§ 2.1.2.2) which were freshly prepared. The plates were incubated without 
the normal inversion (Sambrook and Russell 2001) at 37 °C for not more than 10-12 h 
(Kutter, Raya et al. 2003, Carlson 2004). Plates were not inverted to prevent the top 
agar from slipping and also to encourage sweating of fluid on the surface of the agar. 
 
7KHWRSDJDUZDVUHPRYHGZLWKDGLVSRVDEOHµ/¶VKDSHGVSUHDGHUDQGZDVWUDQVIHUHG
into a 250 ml centrifuge tube along with 5 ml of SM buffer which had been used to 
wash the scraped plate. Phages were eluted from the agar by incubating the centrifuge 
tubes at 4 °C overnight with gentle shaking. Next day the tubes were centrifuged at 
4000 × g for 10 m at 4 °C. The supernatant was removed and centrifuged again at 
4000 × g for 10 min at 4 °C. After the second centrifugation the supernatant was 
filtered through a 0.45 µm syringe filter. The filtrate was diluted serially (tenfold) and 
spot-inoculated onto V. cholerae lawns on 1% LB agar plates The plates were 
incubated inverted at 37 °C for at least 8 h to see the titre of the phage  (§ 2.4.2.1) 
recovered through plate lysate. 
  
2.4.3.1 Titration of phage  
Tenfold serial dilutions of the phage were done in the SM buffer.  Volumes (10 µl) of 
each dilution were spotted onto lawns of the propagating host V. cholerae strain (§ 
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2.4.2). After the spots were dried in to the agar, the plates were incubated in an 
inverted position at 37 °C for 24 h and examined for plaques. Plaques were counted 
on the lowest dilution. The titre was calculated by multiplying the number of plaques 
with the dilution factor of the serial dilution taking into account the aliquot plated.   
 
2.4.4 Concentration of phage stocks 
The protocol followed was modified from a standard protocol (Sambrook and Russell 
2001), with centrifugation speed modified from 110,000 × g to 40,000 × g. The 
Beckman J2-21 centrifuge was pre-cooled to 4 °C before use (Beckman, High 
Wycombe, UK). Polypropylene centrifuge tubes of 50 ml capacity were filled with 
phage lysate. The tubes were balanced and then centrifuged at 40,000 × g for 2 h at 4 
°C in a Beckman JA25 rotor using aforesaid centrifuge machine. After centrifugation, 
the supernatant was discarded carefully and the glassy pellet was resuspended in 1 ml 
of SM buffer and left overnight at 4 °C on a rocking platform to elute phages into the 
buffer. The following day, the phage yield was determined by spotting decimal 
dilutions of the phage on to lawns of the appropriate V. cholerae host strain. 
 
2.4.5 Polyethylene Glycol (PEG) precipitation 
The protocol followed was modified from a standard protocol (Sambrook and Russell 
2001). A single colony of the V. cholerae host strain was inoculated into 10 ml of LB 
broth and incubated overnight at 37 °C. The following day, 1 ml of overnight culture 
was inoculated into each of four 500 ml LB broth in 2 litre screw cap flasks and 
incubated at 37 °C shaking at 150 rpm. On reaching mid-exponential phase all four 
flasks were inoculated with 1 ml of > 107 phage and incubated at 37 °C for 24 h. After 
24 h cultures were brought to room temperature and 10 ml of chloroform was added to 
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each flask, mixed and again incubated for further 10 m at 37 °C and then brought to 
room temperature again. 
 
To each 500 ml culture 29.2 g of NaCl (final concentration 1M) was added and mixed 
using a magnetic stirrer until it dissolved completely. The cultures were stored on ice 
for 1 h. Bacterial debris was removed by centrifugation at 11,000 × g for 10 mins at 4 
°C. The supernatants from four cultures were combined in a 2 litre flask and to it PEG 
6000 was added to a final concentration of 10% w/v. The PEG was dissolved by slow 
stirring with a magnetic stirrer at room temperature for 1 h. The suspension was 
transferred to polypropylene 250 ml centrifuge tubes and placed on ice for 1 h to 
precipitate the phage particles. 
 
The precipitated phage particles were recovered by centrifugation at 11000 × g for 10 
m at 4 °C. The supernatant was discarded, any residual fluid was removed by pipette 
and bottles were allowed to stand inverted in a tilted position for 5 m to allow all the 
remaining fluid to drain away from the pellet. A wide bore pipette was used to 
resuspend the phage pellet gently in SM buffer (8 ml each for earlier 500 ml of 
suspension). Then centrifuge tubes were placed on their sides at room temperature for 
1 h so that SM covered the pellets. The walls of the centrifuge tubes were washed 
gently with SM buffer to recover any phages stuck to the walls. 
 
The PEG and cell debris from the phage suspension were extracted by adding an equal 
volume of chloroform. The contents were mixed thoroughly by gentle shaking. The 
organic and aqueous phases were separated by centrifugation at 3000 × g for 15 m at 4 
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°C. The aqueous phase at the top was recovered. The titre of the recovered phages was 
determined.    
  
2.4.6 Snap freezing of phage 
In a 2 ml screw cap Nunc sterile cryo-vial, 0.5 ml of phage lysate was mixed with 0.5 
ml of sterile glycerol. The cryo-vial was placed in liquid nitrogen. After 5 m, the vials 
were transferred to a freezing container (Mr. Frosty, Thermo Scientific) and then 
transfered to -80 °C for long term storage. 
 
2.4.7 Host range of the phage 
The host range of the phage was determined based upon their ability to form plaques 
on the lawns of all available isolates of V. cholerae. For this, 10 ml aliquots of LB 
broth were inoculated with single colonies of each V. cholerae isolate from TCBS 
plates and incubated overnight at 37°C. Next day lawns (§ 2.4.2) were prepared from 
each V. cholerae isolate.  A 10 µl aliquot of each phage to be tested was spot-
inoculated onto each V. cholerae lawn. After the spots were dried the plates were 
incubated in an inverted position for 24 h at 37 °C and next day they were checked for 
plaques. 
 
2.4.8 Pulsed field gel electrophoresis 
Aliquots of 50 µl of phage suspension with a count of 108 PFU/ml of phage were 
mixed with 10 µl of proteinase K (10 mg/ml, Sigma Aldrich, UK) and then to it was 
added an equal volume of molten 1.2 % agarose in TE buffer (§ 2.1.2.3). This was 
mixed well and dispensed into moulds and allowed to solidify. The solidified agarose 
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plugs were carefully removed from the moulds and transferred to Eppendorf tubes 
containing 1 ml lysis buffer (§ 2.1.2.4) and incubated for 18 h at 55 °C.  
 
The next day the lysis buffer was discarded and 1 ml of sterile water was added and 
incubated for 15 mins at 55 °C. The plugs were then washed 3 times for 18 m at 55 °C 
in wash buffer and stored at 4 °C until used. A 1.2 % agarose gel, made by adding 0.6 
g PFGE grade agarose (Bio Rad, USA) to 50 ml TE buffer (pH 8), was cast with a 10 
well comb in the gel casting tray and allowed to set. After the gel was set the comb 
was removed. The plugs were sliced to 2 mm width and inserted into the wells. For 
comparison of the phage DNA size with a genome marker, the Pulse Marker 50-1000 
Kb (Sigma Aldrich, UK) was used, which was sliced with a clean sharp blade up to 
two small graduations of syringe.  
 
The gel was transferred to a PFGE gel tank containing 1 litre of 1 x TAE (see 2.1.2.6; 
1× TAE buffer was prepared 2 litres i.e. 40 ml of 50 × TAE was added to 1960 ml of 
RO water and stored at 4 °C until required). The PFGE was run using the CHEF DRII 
system (Bio Rad, USA) for 17 h at 6 V with switch time of 10-30 s. After PFGE was 
complete the gel was stained in running buffer (100 ml) containing 20 µl of ethidium 
bromide for 30 m. The image was taken on an automated imaging system called Gel 
Doc (Bio Rad, USA). The approximate genome size was calculated by plotting a 
standard curve of distance migrated by the phage DNA. 
 
2.4.9 CsCl purification of phages for electron microscopy 
The phage particles were purified for electron microscopy by using CsCl density 
gradient centrifugation (Sambrook and Russell 2001). CsCl was added to high titre 
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phage lysate (> 109) to provide a concentration of 0.75 g/ml and dissolved. This 
mixture was transferred to 3.5 ml Beckman Ultra centrifuge tube using 2.5 ml 
syringes with a 16 gauge needle and the tube was heat-sealed. This solution was 
centrifuged with a Beckman Ultra centrifuge (TL100) at 70,000 rpm for 24 h at 10 °C. 
The single band of concentrated phage particles visible as a faint blue band was 
extracted using a 20 bore needle attached to a tuberculin syringe.  
 
In order to remove the residual CsCl, the yield was passed through the column of an 
Amicon Ultra-0.5, 30 kDa MWCO centrifugal filter unit, 500 µl, (Millipore Ltd). To 
do this, after transferring the extracted band to the filter unit, this was capped and 
placed in to centrifuge rotor, aligning the cap strap towards the centre of rotor and 
counter balanced with a similar unit and centrifuged for 10 mins at 14000 × g. To 
recover the concentrated solute, the filter device was inverted in a clean micro 
centrifuge tube which was then placed in the centrifuge rotor aligning the open cap 
towards the centre of the rotor. It was counter balanced with a similar device and 
centrifuged for 2 m at 1000 × g to transfer the concentrated sample from the device to 
tube. The ultra-filtrate was stored at 4 °C for further usage after the titre yielded had 
been determined. 
  
2.4.10 Electron Microscopic imaging of the phages 
Following CsCl purification of phages electron microscopic imaging was done. The 
processing of samples for imaging was done by late Stefan Hyman in the Electron 
Microscopy Laboratory at the University of Leicester. The grid used to hold phage 
suspensions was a carbon-coated Pioloform grid which was glow-discharged 
(ionisation of Argon gas in to plasma under vacuum which glows while discharging 
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upon the grid) to eliminate its hydrophobicity before adding the phage sample. A 5 µl 
aliquot of phage suspension (> 108 PFU/ml) was transferred to the grid with a Gilson 
pipette and negatively stained for 5 mins with 8 µl of 1 % w/v uranyl acetate. The 
excess stain was quickly removed by touching the filter paper to the edge of the grid at 
a right angle. After staining the grids were air dired for 20 m and images were 
captured with a JEOL (Japanese Electron Optic Ltd.) JEM-1400 EM transmission 
electron microscope which was set at 80 kV. 
 
2.4.11 Adsorption curve of phage 
A loopful of frozen stock culture was streaked to TCBS plate and incubated overnight 
at 37 °C overnight to obtain single colonies. One isolated colony was picked and 
transferred to 10 ml of LB broth in a 50 ml Falcon tube which was incubated at 37 °C 
with shaking at 150 rpm for 2 h in a water bath incubator. The OD600 was checked 
after 2 h, which was approx. 0.3, indicating that the bacterial count was approx. 3 × 
107 CFU/ml (calculated from the bacterial host strain growth curve; § 2.3). At this 
VWDJH  PO RI EDFWHULDO FXOWXUH ZDV FROOHFWHG LQWR DQ (SSHQGRUI WXEH PDUNHG µ&¶
(Control without phage) which was placed on ice. 
 
Immediately after collecting the uninfected control sample, a 1 ml aliquot of 
approximately 3 × 107 PFU/ml of phage stock was added and mixed well. Very 
quickly after that, 0.1 ml of the infected culture was collected in an Eppendorf tube 
PDUNHGµ¶IRUWLPH]HURDQGZKLFKFRQWDLQHGPORI60buffer. This sample was 
DOVR SODFHG RQ WR LFH $IWHU WLPH µ¶ DW HYHU\ PLQXWH D VDPSOH ZDV WDNHQ LQ WXEHV
marked from 1 to 10 (which contained 0.9 ml of SM buffer) and kept on the ice. 
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7KHXQLQIHFWHGFRQWUROEDFWHULDOVDPSOHFROOHFWHGLQWXEHµ&¶ZDVGLOuted tenfold down 
to 10-5 and the 0.1 ml quantity of the 10-4 and 10-5 dilutions were plated on the 
duplicate LB agar plates using the spread plate method. The plates were incubated 
inverted at 37 °C overnight. The samples from the tubes marked with 0 to 10 were 
diluted tenfold down to 10-4 and a 0.1 ml volume of 10-4 dilution was mixed into 5 ml 
of 0.5 % LB overlay agar on to the 1 % LB agar plates in duplicate. The plates were 
incubated inverted at 37 °C for overnight. Next day the bacterial numbers were 
estimated for the uninfected control sample to know the actual bacterial numbers at 
the time when phage was inoculated. The phage counts for infected samples were 
enumerated to plot a curve. Based on the curve the adsorption time was noted which is 
the time corresponding to the lowest point on the curve when the phage counts were 
reduced and after which the counts started to rise again. 
 
2.4.12 One step growth curve of phage 
The protocol used for the one step growth curve of phage was based on the protocol 
provided by Karin Carlson (Carlson 2004). Three 50 ml Falcon tubes labelled with G, 
G2 and G3 with 10 ml, 10 ml and 20 ml LB broth, respectively were placed in a water 
bath incubator. A single well-isolated colony from a fresh TCBS plate with the growth 
of V. cholerae host strain was inoculated into the tube labelled G, while G2 and G3 
were kept uninfected but all three were incubated shaken at 150 RPM at 37 °C in a 
water bath. After 2 h, the OD600 was checked for tube G, which was approx. 0.3, 
indicating that the bacterial count was approx. 3 × 107 CFU/ml (calculated from the 
bacterial host strain growth curve; § 2.3). At this stage 0.5 ml of the bacterial culture 
ZDVFROOHFWHGLQWRDQ(SSHQGRUIWXEHPDUNHGµ&¶&RQWUROZLWKRXWSKDJHZKLFKZDV
placed on to ice. 
Chapter 2 
_____________________________________________________________________ 
67 
 
 
Immediately after collecting the uninfected control sample, a 1 ml aliquot of 
approximately 3 × 107 PFU/ml of phage stock was added and mixed well. Very 
quickly after that, 0.1 ml of the infected culture was collected in an Eppendorf tube 
PDUNHGµ6¶IRUVDPSOHDW]HURWLPHDQGZKLFKFRntained 0.9 ml of SM buffer. This 
sample was also placed on to ice. After collection of the S0 sample, the tube G was 
again incubated until time D, which is the adsorption time obtained from the 
adsorption curve studies (§ 2.4.11). At time D, 0.1 ml of the infected culture was 
transferred from tube G to tube G2 and mixed well which gave a 102 fold dilution. 
Immediately after that, 0.2 ml from G2 was transferred to G3 and mixed well which 
gave a 104 fold dilution. At this point, the G and G2 tubes were discarded and 0.1 ml 
RI WKHFXOWXUH IURP*ZDV FROOHFWHG LQ DQ(SSHQGRUI WXEHPDUNHG µ6¶ZKLFKDOVR
contained 0.9 ml of SM buffer and placed on to ice. Tube G3 was again incubated and 
at 5 min S2 sample was collected i.e. 0.1 ml of the culture was collected in an 
(SSHQGRUI WXEHPDUNHG µ6¶ZKLFKFRQWDLQHGPORI60EXIIHUDQGSODFHGRQ WR
ice. Similarly, at 5 m intervals the samples were collected and placed on ice until 90 
mins with tubes labelled S3, S4, S5 and so on. 
 
The samples collected from the G3 tube were already diluted down to 10-4 and thus an 
aliquot i.e. 0.1 ml (100 µl) was overlaid in to the lawns made from bacterial host strain 
on duplicate plates (§ 2.4.2 but in this case phage was overlaid together with bacteria 
in top agar instead of spotting it later). The plates were incubated at 37 °C inverted 
RYHUQLJKW7KHVDPSOHLQWKHWXEHODEHOOHGµ&¶ZDVGLOXWHGGRZQWR-5 in MRD as a 
diluent and then 10-5 dilution was spread-plated in duplicate on LB agar plates. The 
VDPSOH ODEHOOHG µ6¶ ZKLFK ZDV DOUHDG\ GLOXWHG WR -1 in SM buffer was further 
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diluted down to 10-4 and 100 µl of 10-4 dilution was overlaid in duplicate on LB agar 
plates. Next day the plaques and colonies were enumerated. The phage counts were 
plotted graphically to check whether they gave a standard phage growth curve. The 
bacteriophage burst size was determined by using following formula: 
Burst size = P- x/I-x 
where: 
P = maximum phage titre after lysis complete (PFU/ml) 
x = number of phage from the original inoculum which did not adsorb (PFU/ml) 
I = titre of the original inoculum (PFU/ml) 
The latent period was noted from the phage growth curve which corresponded to the 
time period until the rise of phage numbers after the initial decline.  
 
2.4.13 Phage genomic DNA extraction 
The phage genomic DNA was extracted using modified Promega Wizard method 
adopted from the Center for Phage Technology, Texas A&M University, USA 
(Summer 2009). 
 
A 10-20 ml volume of phage lysate with a density of greater than 109 PFU/ml was 
SODFHG LQ WKHVWHULOHFHQWULIXJH WXEHDQGȝOPORIQXFOHDVHVROXWLRQ'1DVe I, 20 
mg/ml and RNase A, 20 mg/ml) was added to get rid of free bacterial DNA/RNA and 
incubated at 37 ºC for 30 min. The precipitant solution (30% v/v PEG-8000 and 3M 
NaCl) was added to the lysate at a rate of 1:2 precipitant:lysate. This was mixed gently 
by inversion and incubated at 4 ºC overnight. The precipitated phage lysate was 
centrifuged at 10,000 x g and 4 ºC for 10 min. The supernatant was carefully poured 
off and the pellet, which usually spread up the side of the tube, was retained.  
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The pellHW ZDV UHVXVSHQGHG LQ  ȝO RI UHVXVSHQVLRQ EXIIHU 0J624, 5 mM) by 
pipetting gently up and down and by rinsing down the sides of the tube. The 
resuspended phage was transferred to a labelled 1.5 ml microcentrifuge tube and 
centrifuged for 5-10 s to pellet any insoluble particles. The supernatant was 
transferred to a new 2 ml microcentrifuge tube. To expose the DNA, phage capsids 
were broken by addition of proteinase K (Sigma Aldrich, UK7RHDFKȝODOLTXRW
RIUHVXVSHQGHGSKDJHȝORI0('7$S+ZDVDGGHGDQGSURWHLQDVH.ZDV
DOVRDGGHGWRDILQDOFRQFHQWUDWLRQRIȝJPO7KHPL[WXUHZDVLQFXEDWHGDW&
for 30 m and allowed to cool down to room temperature.  
 
The purification resin from the Promega Wizard DNA Cleanup kit (cat# A7280) was 
swirled gently without shaking and 1 ml of it was added to the phage suspension 
(Figure 14). The content was mixed by inverting 5-6 times. The new 1.5 ml 
microcentrifuge tube was placed in a tube rack and a Wizard minicolumn (Silicon 
carbide) was placed into the tube. The plunger was removed from a 3 ml syringe and 
placed on a clean paper towel on the bench. The syringe barrel was attached to the 
minicolumn in the tube rack and left standing in the tube rack. The resin/lysate mix 
was pipetted into the syringe. Holding the syringe over a waste beaker, the syringe 
barrel was inserted and the resin was pushed into the minicolumn until all the liquid 
was forced through the resin. The minicolumn was detached from the syringe and 
placed back into its microcentrifuge tube. The plunger was removed from the syringe 
and then the syringe barrel was reattached to the minicolumn. The column was 
washed by adding 2 ml of 80% isopropanol to the syringe and holding the syringe 
over a waste beaker, the syringe barrel was pushed to force the isopropanol through 
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the minicolumn. The syringe was then removed from the minicolumn and discarded. 
The Isopropanol increases the affinity of phage DNA to the column and without this 
DNA yield will be low. 
 
The lid of a 1.5 ml microcentrifuge tube was cut off and labelled. The minicolumn 
was placed into this tube and centrifuged for 2 min at 13,000 x g at room temperature 
to dry the resin. The lid of a new 1.5 ml microcentrifuge tube was cut off and labelled. 
7KH PLQLFROXPQ ZLWK GU\ UHVLQ ZDV SODFHG LQWR WKLV WXEH DQG  ȝO RI ZDWHU
preheated to 80 ºC, was aliquoted to the top of each column and immediately 
centrifuged at 13,000 x g at room temperature for 1 min to elute the DNA. If the 
volume of eluaWHZDVPXFKOHVVWKDQȝOWKHQDQRWKHUȝORIKHDWHGZDWHUZDV
added and centrifuged again. The eluted DNA was transferred into the new 1.5 ml 
microcentrifuge tube. The minicolumn was discarded and the extracted DNA was 
stored at -20 ºC. 
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Figure 14: Schematic representation of phage genomic DNA extraction method. 
A: DNA cleanup resin added to sample and mixed by inversion; B: Syringe barrel attached to 
minicolumn, resin/DNA mixture pipetted and pushed with plunger in to minicolumn; C: Minicolumn 
transferred to microcentrifuge tube and centrifuged; D: Minicolumn transferred to new microcentrifuge 
tube, prewarmed water/TE added and centrifuged to elute DNA 
 
A
B
C
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2.4.14 Ethanol precipitation of phage DNA 
The protocol used for ethanol precipitation was adopted from the method of Green 
and Sambrook (Green and Sambrook 2012). 
 
Ammonium acetate (§ 2.1.2.10) was added to the extracted DNA to a final 
concentration of 2.5M and was mixed well. Ice cold ethanol (95%) was added in twice 
the volume of the ammonium acetate-DNA solution mix, mixed well and then 1M 
MgCl2 (2.1.2.8) was added to it. This solution mix was stored at -20 °C for overnight 
to enable precipitation. 
 
Next day the DNA was recovered by centrifugation at 0 °C at 20000 RPM speed for 
30 m. The supernatant was carefully removed without disturbing the pellet which was 
invisible. The microcentrifuge tubes with the pellet were filled half the way with 70 % 
ethanol (at room temperature) and recentrifuged at 20000 RPM speed for 2 m at 4 °C. 
Again, the supernatant was carefully removed without disturbing the pellet. The tubes 
with DNA pellets were stored open at room temperature for approx. 15 m until the last 
traces of fluid had evaporated. 
 
The DNA pellet was dissolved in 10 µl of TE buffer pH 8.0 (§ 2.1.2.9) by carefully 
rinsing the walls of the tube with buffer. After quantification of the DNA yield using a 
NanoDrop-8000 spectrophotometer (Thermo Scientific, USA), the DNA was stored at 
-20 °C until further use. 
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2.4.15 Restriction analysis of phage DNA 
The restriction enzymes to be used for restriction analysis were identified by using 
NEBcutter (Vincze, Posfai et al. 2003). The protocol available on the Promega 
website 
(http://www.promega.com/~/media/files/resources/protocols/technical%20manuals/10
1/restriction%20enzymes%20protocol.pdf?la=en) was used. The digestion was done 
in 20 µl final volume which contained 16.3 µl of sterile deionised water, 2 µl of an 
appropriate RE 10 × Buffer, 0.2 µl of acetylated BSA (10 µg/µl) and 1 µl of DNA (1 
µg/µl) which was mixed by pipetting. To this mixture 0.5 µl of the Restriction enzyme 
(10 u/ µl) was added, again mixed gently by pipetting and centrifuged for few seconds 
in a micro centrifuge. This digestion mixture was then incubated at 37 °C for up to 4 h 
in the heating block which was pre-heated to 37 °C. The loading buffer (6 ×) was 
added, 4 µl to each of the digest before gel analysis. The gel electrophoresis was done 
as per the protocol given in the next section. 
 
2.4.16 Gel electrophoresis 
To prepare a small sized gel, 1 g of agarose (Sigma Aldrich, UK) was dispensed in 
100 ml 1 × TAE Buffer (§ 2.1.2.6) in a 250 ml conical flask. The gel was dissolved by 
placing it in a microwave for approximately 3 m on a high setting with intermittent 
mixing. The agarose gel was cooled to around 50 °C before adding 2 µl per 50ml of 
NANCY-520 (Sigma Aldrich, UK) as a safer alternative to ethidium bromide which is 
mutagenic, followed by mixing. The gel was poured into the minigel cast (Anachem, 
UK) trying to avoid the formation of air bubbles. The comb (1.5 mm size) was placed 
into position and allowed to set for 30 m. Once the gel was completely set the comb 
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was carefully removed by pulling it straight upwards. The gel was placed into an 
electrophoresis tank filled with 1 × TAE Buffer.  
 
Phage DNA samples, either pure DNA or DNA digested with restriction enzymes, 
were mixed with loading buffer (bromophenol blue, 0.01% w/v, glycerol, 50% v/v, 
EDTA, 0.025 M pH 8.0) at the ratio of 4:1 (sample:buffer) before loading into the 
wells. The DNA ladder marker, if needed, was loaded without DNA loading dye. 
After loading the samples and ladder, the lid of the electrophoresis tank was closed 
and attached to a power pack. The electrophoresis was run at an appropriate voltage of 
80 V for 2 h until the dye front was 2 cm from the end of the gel. The power was 
switched off and the electrophoresis tank was disconnected from the power pack. The 
gel was carefully removed from the caster and imaging was done using the Gel doc 
imaging system (Bio Rad, USA). 
 
2.4.17 DNA sequencing, assembly and annotation of phage genome 
After phage genomic DNA was extracted using the Promega DNA extraction kit 
(A7280 Wizard DNA Clean-Up System) [§ 2.4.13] and after further purification by 
ethanol precipitation [§ 2.4.14]. Next generation sequencing was performed by Source 
Biosciences, UK and NU-OMICS, Northumbria University, UK using the Illumina 
Miseq platform, 2 x 250-bp paired-end run. The sequence data was assembled by the 
8QLYHUVLW\RI1RWWLQJKDP¶V$GYDQFHG'Dta Analysis Centre (ADAC) using de novo 
assembly and single cotigs for the phages were generated using the SPAdes v. 3.1.0 
assembler (Bankevich, Nurk et al. 2012) with 120× coverage. Quality of the data was 
checked using FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) 
and reads were quality trimmed/filtered; while the depth of assembly also ensured that 
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sequencing errors were minimised. Owing to above quality checks and due to shared 
SNPs; the SNPs identified were real and not artefacts of the method. Genome 
annotation was carried out with the help of Andrew Warry of ADAC using RAST 
(Aziz, Bartels et al. 2008) and Geneious (V6.1.7, Biomatters, Auckland, NZ) software 
with some manual curation, which provided the translated sequences of protein coding 
regions. These sequences were then used to interrogate the NCBI database using 
BLASTP (Altschul, Gish et al. 1990). Conserved protein motifs were identified using 
a HHpred search of the pfam database (Punta, Coggill et al. 2012). In case of 
BLASTP search for protein motifs atleast 90% identity was sought to be conserved 
within the motif to assign a protein to a gene sequence (Kropinski, Borodovsky et al. 
2009). This cutoff value for homology detection instilled a confidence in annotation. 
The tRNA annotation was done using tRNAscan-SE (Schattner, Brooks et al. 2005) 
and ARAGORN (Laslett and Canback 2004). Post annotation the genomes were 
submitted to the GenBank using the online BankIt 
(http://www.ncbi.nlm.nih.gov/WebSub/?form=login&tool=genbank) pathway after 
following the instructions available on the NCBI website. 
 
2.5  Phage therapy experiments 
2.5.1 The phage and host strain 
Phage ĭ1 was selected for therapeutic purposes owing to its suitability in terms of its 
broad host range and lytic ability pertaining to burst size and latent period as discussed 
in chapter 3 and also its genomic traits showing a strictly lytic nature as discussed in 
the chapter 4. The phage was concentrated up to 109 PFU/ml by plate lysates (§ 2.4.2) 
and stored at 4°C until used.  
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The host strain for phage ĭ1, V. cholerae 1051 is a classical O1 serotype and was 
used as a streptomycin resistant (SmR) mutant generated by Dr. J. Ritchie (JR) at the 
University of Surrey. The bacterial inoculum was prepared by harvesting overnight 
broth cultures incubated at 37°C by centrifuging and then resuspending the residual 
pellet at a final concentration of ~2 × 109 CFU/ml in a sodium bicarbonate solution 
(2.5 g in 100 ml with pH 9) as an antacid for oral inoculation. 
  
2.5.2 Animal model used for phage therapy 
The infant rabbit cholera model (§ 1.5.3) developed by Dr. Jenny Ritchie (JR) was 
used (Ritchie, Rui et al. 2010). All the laboratory work was done by author while 
samples (§ 2.5.5) were collected by JR. The New Zealand white rabbit pregnant does 
were obtained from Harlan Laboratories (Harlan laboratories, UK /WG6KDZ¶VIDUP
Blackthorn, Bicester, Oxon, England). The work was carried out under the HO project 
licence number PPL 70/7495. 
 
2.5.3 Number of animals and their dosing  
The control and treatment group litters were housed separately along with their 
mothers (litter size varied from five to nine kittens with average of eight). The control 
group contained 18 infant rabbits from three litters born on three separate occasions 
used for experiments 1, 2 and 3; while the treatment group involved 15 infant rabbits 
from two litters born on two separate occasions used for experiments 2 and 3. The 
control and treatment groups were dosed on different days within an experiment 
owing the cross contamination of phage from phage treated animals to control group 
animals which was noticed in a pilot study. The number of rabbits per litter, the 
bacterial dose and the phage dose used for treatment were as per Table 4. Prior to 
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infection with bacteria, animals were given Ranitidine (a histamine H2-receptor 
antagonist that inhibits stomach acid production) at the dose rate of 5mg/100g body 
weight by the intraperitoneal route. 
 
For the control group, two day old infant rabbits were infected with 0.5 ml of V. 
cholerae 1051 SmR only (not treated with phage). To each of the treated animals 1 ml 
of SKDJHĭZDs administered between 6-8 h post-bacterial infection. Size 5 French 
i.e. 1.6 mm diameter polyurethane catheters (Product code PR-05041, Arrow 
International, USA) of 50 cm length were used for oral inoculation using separate 
catheters for administration of phage and bacterial cultures to avoid cross 
contamination. 
Experi
ment 
No * 
Gouping of animals 
No. of 
rabbits 
per litter  
Bacterial 
dose 
(CFU/ml) Ȇ 
Phage dose 
(PFU/ml) 
Phage 
MOI 
1(% 
Control group 5 1 × 108 - - 
Treatment group - - - - 
2 
Control group 6 3 × 108  - - 
Treatment group 9 5 × 108 1 × 109 2 
3 
Control group 7 5 × 106 - - 
Treatment group 6 4 × 108 1 × 109 5 
 
Table 4: The litter size, the bacterial dose, the phage dose and phage MOI 
(multiplicity of infection) during therapeutic experiments.  
* Experiments were separated by several weeks; (%For experiment 1 only control group 
was done in order to check the colonisation of the SmR V. cholerae 1051; Ȇ Bacterial 
dose was varied due to separate overnight cultures and thus affected by differences in 
conditions. 
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As per the clinical signs observed the animals were categorised in the following 
groups based on the measured clinical signs which were uniform across studies in the 
literature (Ritchie and Waldor 2005, Ritchie, Rui et al. 2010) by using the descriptors 
mentioned below: 
Normal ± rabbit free from faecal contamination on its body and upon handling 
produced hard, dark green, formed faecal pellets (if any); on dissection the intestines 
looked normal (no significant fluid accumulation in caecum; hard, formed 
digesta/stool in the lower colon). 
Mild diarrhoea ± small smears or faecal material evident on body and/or upon 
handling the rabbit produced soft, usually yellow coloured, faecal material (loose 
stool); on dissection the intestines also contained fluid above what would normally be 
expected to be seen and this was in the caecum and lower small intestine; any digesta 
(i.e. pellets in the lower colon) was soft to touch. 
Severe diarrhoea ± rabbit fur around anus had clear signs of faecal or watery/faecal 
contamination (i.e. watery diarrhoea), usually this was evident by staining on the fur; 
on dissection the intestines looked abnormal i.e. swollen and contained fluid (caecum 
and/or small intestine); no formed digesta was present in the lower colon. 
 
2.5.4 Calculation of Multiplicity of Infection (MOI): 
It was calculated as a ratio of number of phage (volume in ml × PFU/ml) to the 
number of host bacteria (volume in ml × CFU/ml). 
 
2.5.5 Samples collected 
Based on the infant rabbit model of cholera (Ritchie, Rui et al. 2010), after 24 h of 
infection, animals were euthanized by inhalation of Isoflurane (Isoflo®, 100% 
Isoflorane, Abbott, Maidenhead, UK) until non-responsive to toe pinch and then 
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euthanized by intracardiac KCl (MercuryPharma, City West Business Park, Co 
Dublin, Ireland), 15 % w/v solution given as overdose at 2.5 ml per 100 g of rabbit 
body weight.  
 
After euthanization samples were collected post mortem in pre-weighed Eppendorf 
tubes containing 2 ml of sterile phosphate buffered saline (PBS). The tissue samples, 1 
square cm in size and approx. 0.02 g, were collected from the upper, middle and lower 
small intestine and mid colon by dissection. Caecal fluid was collected from the 
caecum by gravity and approx. 0.4-0.8 ml fluid was drained. 
 
2.5.6 Processing of the samples  
After collection of the samples (both tissues and caecal fluid), all the Eppendorf tubes 
were reweighed and the tissue samples were homogenised between sterile microscopic 
glass slides in 2 ml sterile PBS and the homogenate was used for serial dilutions. 
The samples collected were processed as below: 
a) Enumeration of the bacterial counts: 
Following homogenisation, the samples were decimal-diluted down to 10-6. A 0.1ml 
aliquot of the following dilutions (as shaded in table 5 below) were spread-plated in 
duplicate onto TSA (Tryptone Soya Agar, Oxoid 0131) with streptomycin (200 ug/ml) 
plates using glass beads/L shaped spreaders. The bacterial counts recovered were 
corrected for tissue/fluid weights. 
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Segment 
Dilutions plated 
10-0 10-1 10-2 10-3 10-4 10-5 10-6 
Upper small intestine 
       
Mid small intestine 
       
Lower small intestine 
       
Caecal fluid 
       
Mid colon 
       
 
Table 5: Dilutions used for bacterial enumeration. 
b) Enumeration of phage:  
The sample homogenates of tissue samples and the caecal fluids after using for 
dilutions of bacterial enumeration were centrifuged at 10000 × g for 5 m in a table top 
micro-centrifuge and filtered through a 0.45 µm syringe filter. After filtration the 
samples were tenfold diluted down to 10-8 and 5 µl of each dilution was spotted on to 
the lawns of host strain (§ 2.4.3). The phage counts recovered were corrected for 
tissue/fluid weights. 
c) Fluid accumulation ratio (FAR): 
Fluid Accumulation Ratio (FAR), was calculated as the ratio of the weight of caecal 
fluid drained to the weight of caecal tissue (Ritchie, Rui et al. 2010).  
 
2.5.7 Statistical analysis 
The bacterial counts for control and treatment groups were compared statistically. 
There was no phage-only control and thus the phage counts recovered from the 
treatment group could not be compared statistically with this particular control. 
Geometric means were calculated by Log10 transformation of bacterial counts/ml 
before statistical analysis which was done using GraphPad Prism statistical software 
(version 6.05, GraphPad Prism, San Diego, CA). As the bacterial count data was 
continuous and unpaired but not normally distributed (confirmed by checking for the 
Gaussian distribution), the non-parametric Mann Whitney U test was conducted to 
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obtain a probability/significance value as we were comparing only two groups 
(control and treatment). 
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3 ISOLATION OF PHAGES AND THEIR BIOLOGICAL AND PHYSICAL 
CHARACTERISATION  
3.1  Introduction 
Bacteriophages are quite abundant in the fresh/ocean waters and their concentration is 
as high as 107 per millilitre (Rohwer 2003, Van Twest and Kropinski 2009). Sewage 
samples are always ideal for isolation of phages for enteric bacteria as they contain 
diverse enteric bacterial hosts. Additional promising sampling locations include 
surface water such as lakes, rivers and canals since these frequently receive faecal 
material from animals. The isolation protocols vary slightly according to the type of 
sample collected and have been discussed in the preceding chapter. Once the phages 
are isolated, they need precise characterisation and a battery of these phages should be 
available for choosing a few of them for further therapeutic evaluation. In order to 
know the host range, latent period and burst size of the candidate phage its biological 
characterisation pertaining to host range profile and host as well as phage growth 
curve is necessary. The mid-exponential phase and generation time derived from the 
host growth curve are necessary to devise a protocol for the one step growth curve of 
each phage. The one step growth curve provides us with an estimation of the burst size 
and latent period both of which have been explained in chapter 1 (§ 1.5). A short 
latent period and higher burst size increases the effectiveness of phage therapy 
(Mateus, Costa et al. 2014) as a greater number of progeny phages are produced in a 
shorter time. Determination of the host range of the isolated phages is also required in 
order to select the candidates with a broad host range for phage therapy trials. Electron 
microscopy is desirable for morphometry and classification of phages so that it is 
known what type of phage being used therapeutically. Thus, isolation and biological 
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as well as physical characterisation of phages are important elements for recruiting the 
right candidate for phage therapy studies. 
 
3.2  Results  
3.2.1.1 Isolation of phages in UK 
Isolation of bacteriophages specific to O1 strain of V. cholerae from sewage (Derby 
sewage treatment plant), a lake (Nottingham University park lake) and river water 
(Kegworth river) samples from UK was unsuccessful. All the samples were negative 
for any phages specific to V. cholerae O1 strains. 
 
3.2.1.2 Isolation of phages in China 
Seven phages were isolated from China and the locations from which the positive 
samples were collected are as per Table 6. Of seven positive sample locations two 
were in Beijing, isolated from the Qing He river and Cui Jia Yao rivers, three in 
Wuhan, Hubei, isolated from the Fu Jia Wan, Ye Zhi Hu and Nan Hu lakes, while two 
more were isolated from Nanchang, Jiangxi province from the Yudai He river. The 
plaque morphologies of the phages isolated in China were as per the Table 6. Six of 
the seven phages were -PPDQGFOHDUwhile the seventh, phage J3, was pinpoint 
in size. All of them had regular margins except for phage QH. The plaques obtained 
during isolation were relatively pure but three rounds of plaque purification was done 
to purify them further by picking a plaque with streak plate purification (§ 2.2.2.6).   
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Serial 
No. 
Phage Sample location Plaque morphology 
 QH 4LQJ+H4+ULYHU%HLMLQJ -PPFOHDUZLWKLUUHJXODU
PDUJLQ 
 CJY &XL-LD<DR&-<ULYHU
PLOHVDZD\IURP%HLMLQJ 
-PPFOHDUZLWKUHJXODU
PDUJLQ 
 H1 )X-LD:DQODNHLQ:XKDQ
+XEHL+ 
-PPFOHDUZLWKUHJXODU
PDUJLQ 
 H2 <H=KL+XODNHLQ:XKDQ
+XEHL+ 
-PPFOHDUZLWKUHJXODU
PDUJLQ 
 H3 1DQ+XODNHLQ:XKDQ
+XEHL+ 
-PPFOHDUZLWKUHJXODU
PDUJLQ 
 J2 <XGDL+HULYHU1DQFKDQJ
-LDQJ[L- 
-PPFOHDUZLWKUHJXODU
PDUJLQ 
 J3 <XGDL+HULYHU1DQFKDQJ
-LDQJ[L- 
3LQSRLQWFOHDUZLWKUHJXODU
PDUJLQ 
 
Table 6: Locations for positive samples and their plaque morphology. 
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3.2.2  Characterisation of V. cholerae  
3.2.2.1 Growth kinetics of the V. cholerae   
The growth kinetics, which involved the establishment of a growth curve for the V. 
cholerae host strains used for propagation of different phages were studied to 
ascertain the mid-exponential phase and the generation time which in turn were useful 
for phage growth curve studies. The host strains used in this study were V. cholerae 
F5, 1051, 2095, C6706 and 238. 
 
The generation time and mid-exponential phase for various V. cholerae host strains 
were as per the Table 7. Figure 15 depicts a representative growth curve of V. 
cholerae 1051 and the raw data is presented in Appendix A. The mid-exponential 
phase for these V. cholerae host strains ranged between 132 ± 0.00 m for C6706 to 
188 ± 18.33 m for 2095. The generation time for V. cholerae F5 was small i.e. 18.68 ± 
0.14 m; while the largest generation time amongst studied host strains was of strain 
2095 i.e. 43.35 ± 13.6 m. 
Host strain Mid-exponential 
phase (m ± SD) 
Generation time 
(m ± SD) 
F5 172 ± 3.46 18.68 ± 0.14 
1051 152 ± 18.33 37.70 ± 8.59 
2095 188 ± 18.33 43.35 ± 13.6 
C6706 132 ± 0.00 36.46 ± 1.95 
238 156 ± 20.78 29.64 ± 2.50 
 
Table 7: The mid-exponential phase and generation time for various V. cholerae host 
strains. 
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Figure 15: Representative growth curve of V. cholerae strain 1051. 
 
3.2.3  Biological Characterisation of phages 
3.2.3.1 One step growth curve of phages 
Phage growth curves were done to determine the latent period and burst size. The 
latent period and burst size for different phages under study are as per Table 8. Figure 
16 shows a representative one step growth curve of ĭ1 and the raw data tables are in 
Appendix B. The latent periods of the phages under study ranged between 4 to 15 m 
and the burst sizes of these phages were between 6 to 664 PFU/cell.  
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Figure 16: Representative one step growth curve of V. cholerae phage ĭ1. 
V. cholerae 
Phage 
V. cholerae host 
strain 
Latent period 
(m) 
Burst size  
(PFU/cell) 
ĭ1 1051 12 ± 0.0  43 ± 05  
ĭ2 F5 14 ± 1.6  06 ± 01 
ĭ3 1051 13 ± 4.1  54 ± 26  
Phage 24 1051 04 ± 0.0  87 ± 26  
ĭX29 1051 07 ± 0.0  664 ± 50  
ĭQH 238 12 ± 4.0  92 ± 09  
ĭCJY 238 13 ± 4.3  182 ± 62 
ĭH1 238 06 ± 2.3  89 ± 32  
ĭH2 238 15 ± 1.6  63 ± 13 
ĭH3 238 07 ± 3.5  126 ± 18 
ĭJ2 238 05 ± 0.6  34 ± 13 
ĭJ3 238 14 ± 1.5  56 ± 17 
(n= 3*; ±  Standard Error of Mean i.e. SEM; * For X29, H3 and J3 n= 2) 
Table 8: The latent periods and burst sizes for different phages 
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3.2.3.2 Host range profiles 
The host range profile of fourteen bacteriophages was determined. Broad spectrum 
phages are considered suitable candidates for phage therapy trials since they will be 
able to be used against a wide range of strains (Viertel, Ritter et al. 2014). The 
knowledge of host range could also help to identify the propagating bacterial host for 
producing large volumes of phage for downstream characterisation. The host strain on 
which a particular phage could produce a confluent clear lysis was used as the 
SURSDJDWLQJEDFWHULDOKRVWHJĭFRXOGRQO\SURGXFHFRQIOXHQWFOHDUO\VLVZLWKWKHV. 
cholerae F5 strain and therefore this host strain was used. The host ranges are given in 
Table 9. The zones of lysis were visible upon the lawns prepared from the susceptible 
KRVW VWUDLQV7KHEURDGHUKRVW UDQJHVZHUHGLVSOD\HG IRUSKDJHĭĭĭ4+ĭ+
DQGĭ-ZKLFKZHUHDEOHWRO\VHDQG % of the 
total 91 strains, respectively.  
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-, no lysis; +, opalescent lysis; ++ semi confluent lysis; +++, confluent clear lysis;  non O1/O139 strain;  O139 strain 
Table to be continued « 
Ɍ ? Ɍ ? Ɍ ? Ɍ ? Ɍ ? ? Ɍy ? ? JA1 ɌY, Ɍ:z Ɍ, ? Ɍ, ? Ɍ, ? Ɍ: ? Ɍ: ?
238 - - - - - - - +++ +++ +++ +++ +++ +++ +++
757 + - + - - - - ++ - - - - - -
404 - - - - - - - - - - - - - -
406 - - - - - - - + + + + + + -
709 + - + - - - - ++ - + - +++ - +++
719 + - + - - - - ++ - - - +++ - +++
722 + - - - - - - +++ - + - ++ - +++
729 +++ + - - - +++ - - - + - +++
732 +++ - - - - - - +++ - + - ++ - +++
736 + - + - - - - - - - - - - -
739 - - - - - - - ++ - + - ++ - +++
742 +++ - - - - - - +++ + ++ - + - ++
750 - - - - - - - +++ - ++ - ++ - +++
751 +++ - - - - - - +++ - + - ++ - +++
752 ++ - + - - - - + - - - + - ++
753 +++ - + - - - - ++ - + - ++ - +++
754 ++ - + - - - - + - - - - - ++
755 + - + - - - - + - - - - - ++
756 + - + - - - - + - - - + - ++
758 + - + - - - - + - - - ++ - +++
759 + - + - - - - + - - - + - ++
760 - - - - - - - - + - - - + -
761 + + + - - - - ++ - - - + - +++
Vibrio 
strain
Bacteriophages
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-, no lysis; +, opalescent lysis; ++ semi confluent lysis; +++, confluent clear lysis;  non O1/O139 strain;  O139 strain 
Table to be continued « 
Ɍ ? Ɍ ? Ɍ ? Ɍ ? Ɍ ? ? Ɍy ? ? JA1 ɌY, Ɍ:z Ɍ, ? Ɍ, ? Ɍ, ? Ɍ: ? Ɍ: ?
762 ++ - + - - - - + - - - + - ++
763 - - - - - - - - - - - - - -
764 + + + - - - - + - - - + - +
765 - - - - - - - + + - + - + +
767 + - + - - - - + - - - ++ - +++
768 ++ - + - - - - + - - - ++ - +++
769 +++ + + - - - - +++ - + - ++ - ++
770 + - + - - - - + - - - - - ++
771 + - + - - - - ++ - - - + - ++
772 + - + - - - - + - - - + - +++
773 + - - - - - - + - - - - - +
774 + - + - - - - ++ - - - + - +++
775 - - - - - - - + - - - - - -
776 - - - - - - - + - - - - - -
10 - - - - - - - - - - - - - -
A-4 +++ - + - - - - +++ - + - +++ + +++
BW-5 + - + - - - - + - - - + - ++
CS-1 + - - - - - - + + - - ++ - ++
CS-12 + - + - - - - + - - - + - ++
CS-15 ++ - + - - - - + - - - - - +
CS-16 + - + - - - - ++ - - - + - ++
CS-18 + - + - - - - + - - - - - +
CW-1 - - - - - - - + + + + + + +
Vibrio 
strain
Bacteriophages
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-, no lysis; +, opalescent lysis; ++ semi confluent lysis; +++, confluent clear lysis;  non O1/O139 strain;  O139 strain 
Table to be continued « 
Ɍ ? Ɍ ? Ɍ ? Ɍ ? Ɍ ? ? Ɍy ? ? JA1 ɌY, Ɍ:z Ɍ, ? Ɍ, ? Ɍ, ? Ɍ: ? Ɍ: ?
D-1 - - - - - - - - - - - - - -
D-13 - - - - - - - - - - - - - -
D-15 - - - - - - - - - - - - - -
D-25 +++ - + - - - - + - - - + - +++
D-30 ++ - + - - - - + - + - + - +
D-56 ++ - + - - - - ++ - - - ++ - +++
D-59 ++ - ++ - - - - + - - - ++ - +++
DN-4 ++ - + - - - - + - - - ++ - +++
F-5 + +++ + - - - - + - - - ++ - +++
F-6 ++ - + - - - - + - - - + - +
FB-01 - - - - - - - - - - - - - -
FN-2 - - - - - - - - - - - - - -
FN-4 - - - - - - - - - - - - - -
FN-5 - - - - - - - + ++ + ++ - ++ -
GB-39 ++ - + - - - - +++ - + - ++ - +++
HH-1 ++ - + - - - - ++ + + + + + ++
HH-14 + - + - - - - ++ - + - + - ++
HH-15 ++ - + - - - - ++ - + + ++ - ++
HH-4 + - + - - - - ++ - + + ++ - ++
Ht-10 - - - - - - - - - - - - - -
Ht-10A - - - - - - - + - - - - - -
J-1 - - - - - - - - - - - - - -
KCH-18 ++ - + - - - - + - + + + - ++
Vibrio 
strain
Bacteriophages
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-, no lysis; +, opalescent lysis; ++ semi confluent lysis; +++, confluent clear lysis;  non O1/O139 strain;  O139 strain 
Table 9:  Host range profile of the V. cholerae phages. 
All non highlighted Vibrio strains are V. cholerae O1 strains. 
Ɍ ? Ɍ ? Ɍ ? Ɍ ? Ɍ ? ? Ɍy ? ? JA1 ɌY, Ɍ:z Ɍ, ? Ɍ, ? Ɍ, ? Ɍ: ? Ɍ: ?
KPD-3 ++ - + - - - - + - + - + - ++
KtH-4 + - + - - - - + - + - + - ++
KTH-7 ++ - + - - - - + - + + + - ++
N-10 - - - - - - - + - + - + - ++
N-5 ++ - ++ - - - - ++ - - - ++ - ++
N-7 ++ - + - - - - + - - - ++ - ++
NP-14 - - - - - - - + + ++ ++ ++ + +
NP-3 ++ - + - - - - +++ - + - ++ - ++
NP-5 ++ - + - - - - + - - - ++ - +++
NP-6 - - + - - - - + - + + ++ + +++
NP-7 ++ - + - - - - + - - - ++ - +++
O5 - - - - - - - - - - - - - -
P-1 - - - - - - - +++ ++ +++ +++ +++ ++ +++
PS-18 - - - - - - - + ++ ++ ++ ++ ++ ++
PS-25 ++ - + - - - - + - - - + - ++
PS-7 +++ - ++ - - - - + - - - + - +++
RG-6 ++ - + - - - - + - + - ++ - +++
M14 +++ - +++ - - - - +++ - - - - - -
O395NT +++ - +++ - - ++ - +++ + + + + + ++
1051 +++ - +++ - +++ +++ - +++ - - - - - -
2095 - - + - - - - +++ +++ +++ +++ +++ +++ +++
2134 - - - - - - +++ +++ +++ +++ +++ +++ +++ +++
Vibrio 
strain
Bacteriophages
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3.2.4 Physical characterisation by electron microscopy  
Electron micrographs of phages were obtained in order to determine their 
morphological features and to classify them as per the International Committee on 
Taxonomy of Viruses (ICTV) classification (§ 1.7.1 and table 1). The morphometry 
and classification of phages under study are as per the Table 10. Out of 12 phages 
under study, three belonged to the Myoviridae family (Figure 17) YL] SKDJH Ɏ2, 
phage 24 and phage X29; one belonged to the Siphoviridae family (Figure 18) phage 
Ɏ3, and remaining eight phages were of the Podoviridae family (Figure 19). Two of 
the Myoviridae phages had a similar head diameter viz. 64 nm for phage 24 and X29, 
ZKLOH Ɏ2 had longer tail of 118 nm than the other two. Amongst the Podoviridae 
SKDJHVɎ1 had smaller head with head diameter 34 nm, while the rest (all Chinese 
Podoviridae phages) had head diameter ranging between 51 to 57 nm. 
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Phage Head 
diameter 
(nm ± SD) 
Neck 
(nm ± SD) 
Tail length 
(nm ± SD) 
Classification 
 
ĭ2 53 ± 0.16 8 ± 0.04 118 ± 0.36 Myoviridae 
Phage 24 64 ± 0.06 8 ± 0.04 69 ± 0.14 Myoviridae 
ĭX29 64 ± 0.05 16 ± 0.11 95 ± 0.32 Myoviridae 
ĭ3 75 ± 0.07 - 156 ± 0.23 Siphoviridae 
ĭ1 34 ± 0.18 - 13 ± 0.08 Podoviridae 
ĭQH 51 ± 0.07 - 12 ± 0.02 Podoviridae 
ĭCJY 54 ± 0.07 - 10 ± 0.04 Podoviridae 
ĭH1 56 ± 0.07 - 11 ± 0.04 Podoviridae 
ĭH2 57 ± 0.08 - 12 ± 0.03 Podoviridae 
ĭH3 55 ± 0.06 - 12 ± 0.03 Podoviridae 
ĭJ2 54 ± 0.05 - 12 ± 0.03 Podoviridae 
ĭJ3 52 ± 0.05 - 11 ± 0.02 Podoviridae 
 
Table 10: Morphometry and classification of V. cholerae phages. 
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Figure 17: Representative electron micrograph of Myoviridae V. cholerae SKDJHɎ 
 
Figure 18: Representative electron micrograph of Siphoviridae V. cholerae SKDJHɎ 
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Figure 19: Representative electron micrograph of Podoviridae V. cholerae SKDJHɎ
H1. 
 
3.3  Discussion 
Isolation of V. cholerae O1 specific phages in the UK environment was not successful 
but seven phages could be isolated in China. The negative outcome in the UK could 
be due to the fact that the cholera is no longer an endemic disease in England and 
Wales (NHS 2014). Developed countries in Europe and North America usually have 
imported cases, reported from travellers visiting areas where the cholera is endemic, 
and returning back with the disease (Morger, Steffen et al. 1983, PHE 2013). Thus it 
might be expected that O1 cholera-specific phages might be isolated from sewage 
from large metropolitan areas. There were some reports of isolation of low numbers of 
V. cholerae both O1 and non O1 strains in the UK environment (i.e. water and aquatic 
birds) between 1976 and 1980 (Lee, Bashford et al. 1982, West and Lee 1982). The 
authors believed that aquatic birds i.e. gulls were acting as vectors. Later in 1997, 
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Little and colleagues (Little, Monsey et al. 1997) reported the presence of non-cholera 
Vibrio spp. in mollusc products in the UK. There were reports of non-O1/non-O139 V. 
cholerae from other European countries (Aldova, Laznicko.K et al. 1968, Visser, 
Vellema et al. 1999, Andersson and Ekdahl 2006, Huhulescu, Indra et al. 2007). 
Looking in to the aforesaid reports, although it has been possible to isolate phages 
specific to non-O1/non-O139 V. cholerae from the UK environment (Sarkar pers 
comm); this was of no value for this project which was to develop a treatment for 
cholera caused by O1 and or O139 serotypes of V. cholerae. It is also worth 
mentioning that our bacterial strain collection was biased with O1 serotypes as they 
were dominantly represented, while O139 serotypes were under represented owing to 
availability of only one O139 strain. The isolation of phages specific to O139 strains 
could have been possible if they were represented well in our strain collection. 
 
It was thus imperative to isolate cholera phages from cholera endemic areas. China is 
a country where cholera is endemic and south eastern China is a predicted high risk 
area (Xu, Cao et al. 2013).  The isolation of phage is an indicator of the presence of V. 
cholerae in the sampled environment (Leclerc, Edberg et al. 2000). Thus, the isolation 
of seven V. cholerae specific phages in the environmental samples from China might 
be an indicator of cholera prevalence in that country. Moreover, only two host strains 
were used to isolate phages in China. This might have limited the type of phages 
isolated as there might have been much wider range of phages in samples but not 
selected due to a very limited host strain range. Isolation of bacteriophages for Vibrio 
spp. other than V. cholerae have been reported earlier from China (Zhao, Wang et al. 
2005, Lin, Chiu et al. 2012, Peng, Ding et al. 2013, Wang, Kan et al. 2013, Yu, Gong 
et al. 2013). Reports on the prevalence of cholera in China are also available (Wang, 
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Lou et al. 2012, Hu, Zheng et al. 2013, Liang, Zhao et al. 2014, Yue, Gong et al. 2014, 
Zhang, Li et al. 2014, Zhao, Zhang et al. 2014, Zhou, Zhao et al. 2014) with 
incidences reported from the seventh pandemic in China between 1961-2010 with the 
cases from south eastern china.  
 
After isolation, for further characterisation of phages the knowledge of host strain 
growth parameters was essential because the host strain growth curve gave us the mid 
exponential phase and generation time, requisites for phage one step growth curve 
experiments (Carlson 2004, Viscardi, Perugini et al. 2008). The generation times of 
the host strains under study ranged between 18 to 43 m. These estimated generation 
times concur with the findings of previous studies which suggest the generation time 
ranging between <30 to 40 m for V. cholerae (Finkelstein 1996, Martinez, Megli et al. 
2010, Microbewiki 2014).  
 
Phage one step growth curves are affected by culture conditions and variations 
between phage species (Brussow and Kutter 2005, Hendon-Dunn 2011). The latent 
period is the time between the initial infection and release of the phage progeny (i.e. 
lysis). The latent period may be affected by the density of the bacterial host, and a 
lower density of host bacteria will give a longer latent period (Abedon, Herschler et al. 
2001, Abedon, Hyman et al. 2003). In the present study the shortest latent period was 
4 ± 0.0 m for phage 24 revealing a much shorter adsorption time involved in this 
specific infection cycle. As discussed earlier, there can be an impact of bacterial 
numbers on latent period and the bacterial hosts used for this study were in mid 
exponential phase and the phages showing shorter latent periods might be prolific 
propagators as evidenced by their burst sizes. According to the literature the shortest 
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latent periods of phages specific to Vibrio spp. were shown by the Vibrio phages P8D 
and pVp-1 which were 10 and 15 mins, respectively (Yu, Gong et al. 2013, Jun, Shin 
et al. 2014). The range of latent periods of phages specific to Vibrio spp. fall between 
10 to 120 min; majority of them above 30 m (Phumkhachorn and 
Rattanachaikunsopon 2010, Cohen, Joseph Pollock et al. 2013, Yu, Gong et al. 2013, 
Jun, Shin et al. 2014, Lee, Choi et al. 2014, Mateus, Costa et al. 2014) but the range of 
latent periods for phages in this study are between 4 to 15 m which is in the lower 
range compared to the phages infecting the same species of host strains. The report on 
less than 10 min latent period i.e. 9 min was reported for Acinetobacter baumannii 
lytic phage (Jin, Li et al. 2012). Even the historical literature of Hershey and Chase 
experiments mentions less than 10 min latent period for phages (Konforti 2001). 
Though it is possible to have short latent periods which are less than 10 min for 
phages, an experimental error cannot be ruled out inspite of three independent trials 
showing similar results. In fact, these phages with shorter latent periods (SLPs) are 
likely to be specialists for propagation in high density bacterial host populations, 
owing to their faster adsorption and ability to exploit the bacteria growing at higher 
density (Abedon, Hyman et al. 2003).  
 
The burst size is the number of progeny phages released by a single infected bacterial 
host cell.  Larger burst sizes are more desirable in bacteriophages which are used to 
treat infections as they might eradicate bacterial infections quickly. The smallest burst 
size in the preseQWVWXG\ZDVRISKDJHɎ2 with 6 ± 1 PFU per cell. Similar small burst 
sizes were revealed for Vibrio SKDJHVɎH17-FDQGɎ+-9b with their respective 
burst sizes being 5.4 and 5.5 PFU/cell (Okano, Yoshikawa et al. 2007). The largest 
burst size in the present study was for phage X29 which yielded 664 ± 50 PFU/cell but 
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the range of phage EXUVWVL]HVH[FHSWIRUSKDJHɎ2 were between 34 to 664. The range 
of burst sizes shown in the present study are in agreement with the literature on range 
of burst sizes shown for the Vibrio phages which were in between 23 to 500 
(Baudoux, Hendrix et al. 2012, Cohen, Joseph Pollock et al. 2013, Yu, Gong et al. 
2013, Jun, Shin et al. 2014, Lee, Choi et al. 2014, Mateus, Costa et al. 2014).  
 
The phages studied in this project showed discriminatory lytic spectra and thus the 
diversity amongst them based on their host range was established. Lee and Furniss 
(Lee and Furniss 1981) studied the host range of 41 different phages against over 1500 
Vibrio strains but only 14 of the phages could lyse some of the host strains. Similarly, 
LQ RXU VWXG\ SKDJH ĭ4, obtained from Public Health England (§ 2.2.2.1) which 
arrived without a host strain did not lyse any of the V. cholerae strains used for this 
study and thus it could not be characterised further.  The present study involved 15 
non O1/O139 V. cholerae strains in lytic spectra analysis and 6 out of 15 were lysed 
by different phages, predominantly those isolated in China.  In the earlier study, phage 
ĭ3ZDVDOVRDEOHWRO\VHRXWRIQRQ2QRQ2VWUDLQVDORQJZLWKO1 strains 
(Talledo, Rivera et al. 2003). Payne and colleagues (Payne, Oakey et al. 2004) found 
that the Vibrio harveyi myovirus-like (VHML) bacteriophage was able to infect one 
out of 8 V. cholerae isolates. It was interesting to note that phage specific to V. 
harveyi could infect other Vibrio spp. but the host range was narrow for V. cholerae 
isolates in comparison. Various authors suggested that this ability of a phage to infect 
other Vibrio spp. could be due to common receptor proteins. Capsular O antigen was 
identified as the receptor for some Vibrio phages (Seed, Bodi et al. 2011, Fouts, 
Klumpp et al. 2013) whilst lipopolysaccharides (LPS) on the cell wall of host strains 
were demonstrated to be the phage receptors for others (Maiti and Choudhuri 1979, 
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Chatterjee and Chaudhuri 2003). Thus, the ability of many phages in the present study 
to infect both O1 and non O1 V. cholerae strains could be due to common receptor 
proteins or carbohydrates including O antigens or LPS. Conversely, Al-Fendi and 
colleagues (Al-Fendi, Shueb et al. 2014) checked the host range of VPUSM 4, 
VPUSM 7 and VPUSM 8 phages using various strains of Vibrio spp. and other 
common enteric pathogens but all these phages were able to infect and lyse only one 
strain V. cholerae O1 El Tor Inaba. One out of six Vibrio phages isolated by 
Alagappan and coworkers (Alagappan, Deivasigamani et al. 2010) was able to lyse all 
the eight strains of V. parahaemolyticus used during isolation, indicating its broad host 
range. None of the phages in our study were able to lyse 100% of the host strains. The 
present study used 91 host strains for lytic spectra analysis of phages and the broader 
KRVW UDQJH SKDJHV ĭ ĭ ĭ4+ ĭ+ DQG ĭ- FRXOG O\VH XS WR  RI WKHP
Similarly, 125 host strains were used to determine the host range of phages uVh1, 
uVh2, uVh3, and uVh4 infecting V. harveyi and they could lyse 78 to 98% of the host 
strains (Thiyagarajan, Chrisolite et al. 2011). Surekhamol and colleagues 
(Surekhamol, Deepa et al. 2014) found the lytic spectra of six broad spectrum phages 
to be between 50 to 70 %. 
 
All the phages under study belong to the order Caudovirales as they have binary 
symmetry and tails (Ackermann 2006) (§ 3.2.4). Out of twelve, three phagHVSKDJHɎ
2, phage 24 and phage X29) were classified in the Myoviridae family owing to their 
ULJLGWDLOV2QHSKDJHSKDJHɎZDVFODVVLILHGLQWKHSiphoviridae family as it had a 
long flexible tail. Eight more phages belonged to the Podoviridae family owing to 
their short tails, thought to be non-contractile. Although most of the phages in this 
study are Podoviridae family, the podoviruses are not very common amongst the 
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Vibrio phages, especially in V. parahaemolyticus viruses (VpVs) and in aquatic 
ecosystems (Comeau, Chan et al. 2006, Thiyagarajan, Chrisolite et al. 2011). Average 
head dimensions of the podoviruses studied in this project ranged between 34 ± 57 nm 
and the tail length ranging between 11 ± 13 nm which is at the lower range of the 
average dimensions noted earlier for Podoviridae Vibrio phages i.e. 50 to 72 nm for 
head and 15 to 27 nm for tail (DePaola, Motes et al. 1998, Comeau, Chan et al. 2006, 
Thiyagarajan, Chrisolite et al. 2011, Fouts, Klumpp et al. 2013). Of these few reports 
on podoviruses DePaola et al. (1998) reported an unusual podovirus with elongated 
capsid measuring 258 nm.  
 
The typical dimensions of tailed phages range 30-160 nm for the capsid and 80-800 
nm for tail length (Ackermann 2005). The Myoviridae phages studied in this project 
had an average range of 53-64 nm head size and 69-118 tail length, while only 
6LSKRYLUXVVWXGLHG LHSKDJHɎKDVQPKHDGDQGQP tail length. Average 
dimensions of the phages studied are in agreement with the average dimensions 
reported earlier for Myoviridae phages infecting Vibrio spp. which have 43 to 107 nm 
heads and 85 to 221 nm tails (Sen and Ghosh 2005, Shivu, Rajeeva et al. 2007, 
Crothers-Stomps, Hoj et al. 2010, Surekhamol, Deepa et al. 2014). Similarly, the 
dimensions of Siphovirus studied falls under the average range of dimensions 
mentioned for Siphoviridae phages specific to Vibrio spp. which have shown their 
head sizes between 53 to 115 nm and tails lengths between 126 to 329 nm (Sen and 
Ghosh 2005, Shivu, Rajeeva et al. 2007, Crothers-Stomps, Hoj et al. 2010, 
Thiyagarajan, Chrisolite et al. 2011, Khemayan, Prachumwat et al. 2012, Yu, Gong et 
al. 2013, Surekhamol, Deepa et al. 2014). Apart from the phage particles other 
vesicle/membranous capsule like structures were visible in some of the electron 
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micrographs, likely to be bacterial outer membrane blebs after lysis of host cells 
(Young 1992).   
 
The phages studied in this project were different from other Vibrio specific phages 
owing to their ability to infect non-O1 strains of V. cholerae. Chinese phages, apart 
from their infectivity to non-O1 V. cholerae strains were all classified as podoviruses 
with smaller heads compared to other Vibrio phages. Interestingly, amongst the 
SRGRYLUXVHVVWXGLHGLQWKLVSURMHFWSKDJHɎKDGVPDOOHVWKHDGVL]HRIQP 
 
Thus, overall this chapter discussed the isolation and biological as well as physical 
characterisation of phages. Seven phages were isolated in China, attempts to isolate in 
the UK environments were unsuccessful and five more phages were obtained from 
various sources (§ 2.2.2). In total twelve phages were characterised for the one step 
growth curves following their host strain growth curves, their lytic spectra and by 
electron microscopy. These characterisations could help in selecting the candidate 
bacteriophage for phage therapy trials as discussed in the further chapters in this 
dissertation. Based on the data produced in this chapter, the broader host range phages 
ZHUHĭĭĭ4+ĭ+DQGĭ-ZKLFKFRXOGO\VH
and 76.9 % of host strains. The probable phage therapy candidate would be the one 
with broader host range with a priority for O1/O139 lytic one, owing to cholera being 
caused by these two serotypes. The phages X29, CJY and H3 had larger burst sizes of 
664 ± 50, 182 ± 62 and 126 ± 18 PFU/cell, respectively and most of them had shorter 
latent period; thus the selection would be among these phages after further scrutiny of 
their genome characteristics which is discussed in the next chapter.  
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4 GENOMIC CHARACTERISATION OF PHAGES 
4.1  Introduction 
When we consider phage for therapeutic purposes it is important to check for its 
genome characteristics as the phages to be used for phage therapy may possess 
harmful genes such as those associated with virulence, antimicrobial resistance and 
lysogeny (Barrow and Soothill 1997, Skurnik, Pajunen et al. 2007). The genome size 
and restriction profile helps for differentiating phages (Gill and Hyman 2010). The 
virulence of Shiga-Toxigenic E. coli (STEC) is encoded by Shiga toxin-encoding 
(Stx) phages (Herold, Karch et al. 2004, Allison 2007). )LODPHQWRXVSKDJHV&7;ĭ
are responsible for genes encoding cholera toxin (Waldor and Mekalanos 1996, 
Wagner and Waldor 2002, Davis and Waldor 2003). Some phages are associated with 
transduction which can transfer antibiotic resistance between bacteria (Abedon, Kuhl 
et al. 2011). Such concerns regarding usage of phages with harmful genes mentioned 
above can be addressed by detailed genomic characterisation of the phages with 
genome sequencing, annotation of genome and determining the functions of genes. 
Having an idea about the gene functions helps us to decide whether the phage is 
suitable for therapy or not. Genome analysis for undesirable genes as per  
specifications of the US Food and Drug Administration (FDA) Code of Federal 
Regulations (CFR) in 40 CFR §725.421 (Abedon, Kuhl et al. 2011); listed in its 
section D (available at http://www.law.cornell.edu/cfr/text/40/725.421) is advisable. 
This USFDA CFR section specifically mentions that the genomes to be free from 
certain sequences which encode harmful toxins; for example in the context of this 
project the sequences for toxins affecting membrane function such as V. cholerae 
cholera toxin (choleragen) should not be present in the potential phage therapy 
candidate. 
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Few phage genomes have been sequenced to date (Ackermann and Kropinski 2007) 
even though the first sequenced genomHZDVSKDJHĭ; sequenced in 1976 (Air, 
Sanger et al. 1976, Sanger, Air et al. 1977, Sanger, Coulson et al. 1982). Very few 
references are available for the complete Vibrio phage genome sequences in the 
databases (Liu, Lin et al. 2014). In this chapter the characterisation of V. cholerae 
specific phages by PFGE, restriction profile and whole genome sequencing will be 
discussed in order to understand the phages in greater detail and determine the 
suitability of these phages for therapeutic application. 
 
4.2  Results  
4.2.1 Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) was performed to assess the DNA size of the 
phages studied. For PHE (Public Health England) phages the largest estimated 
JHQRPHVL]HZDVIRUSKDJHĭLHNEIROORZHGE\SKDJHĭZLWK 74 kb genome 
VL]HDQGSKDJHĭZKLFKZDVOHVVWKDQNE (Figure 20). The two Canadian phages 
as well as all the Chinese phages were below 48.5 kb (Figure 21-22).  
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Figure 20: PFGE analysis of genomic DNA of PHE phages  
Lane 1 marked M = 50-NESXOVHPDUNHU+LJKPDUNHUȜFRQFDWHPHUVRINE
increments) 
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Figure 21: PFGE analysis of genomic DNA of Canadian phages  
Lane 1 marked M = 50-NESXOVHPDUNHU+LJKPDUNHUȜFRQFDWHPHUVRINE
increments) 
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Figure 22: PFGE analysis of genomic DNA of Chinese phages  
Lane 1 marked M = 50-NESXOVHPDUNHU+LJKPDUNHUȜFRQFDWHPHUVRINE
increments) 
 
4.2.2 Phage DNA extraction 
The amount of DNA extracted using Promega Wizard DNA extraction kit and further 
ethanol purification (§ 2.4.14) was as per the Table 11. The minimum DNA 
concentration required for sequencing purpose is 150 ng/µl and the extracted and 
M
48.5
97.0
145.5
MQH CJY H1 H2 H3 J2 J3
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ethanol purified DNA yields for all the phages under study were beyond the minimum 
concentration required.  
 
V. cholerae phage 
Concentration of DNA 
extracted (ng/µl) 
Ɏ 453 
Ɏ 237 
Ɏ 521 
24 345 
X29 300 
QH 215 
CJY 287 
H1 173 
 H2 305 
H3 196 
J2 250 
J3 4043 
 
Table 11: Concentration of the DNA extracted from V. cholerae phages 
 
4.2.3 Restriction analysis of phage DNA 
The macrorestriction profiles of the phages under study was performed (§ 2.4.15) by 
using the restriction endonuclease enzymes which cut the DNA at restriction site as 
per Table 12. 
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Endonuclease 5HVWULFWLRQVLWH¶WR¶ 
PstI CTGCA/G 
SacI GAGCT/C 
XbaI T/CTAGA 
EcoRI G/AATTC 
HpaII C/CGG 
 
Table 12: Endonucleases used for the restriction analysis of phage DNA 
 
The DNA digest patterns for the phages under study are shown in the Figures 23 to 
27. Xba, FXW WKH'1$ IRUSKDJHɎDQG JDYHGLVWLQFWEDQGVEXW the Ɏ DNA was 
resistant to digestion by PstI and SacI. Phage 24 was cut by the restriction enzyme 
PstI but was resistant to digestion by SacI and Xba,3KDJHVɎɎDQG;ZHUHFXW
by all three restriction enzymes PstI, SacI and XbaI. The seven Chinese phages 
produced a smeared pattern for PstI, SacI and XbaI. They were digested using EcoRI 
and HpaII. For EcoRI they again showed the smearing of DNA on the gel but all 
phages were distinctly cut by HpaII with the exception of phage QH which remained 
uncut without smearing (Figures 26-27).  
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Figure 23: Restriction digests of phage genomes under study by using restriction enzyme PstI.  
M1: lambda DNA ladder. 
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Figure 24: Restriction digests of phage genomes under study by using restriction enzyme SacI.  
M1: lambda DNA ladder. 
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Figure 25: Restriction digests of phage genomes under study by using restriction enzyme XbaI.  
M1: lambda DNA ladder.
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Figure 26: Restriction digests of Chinese phages by using restriction enzyme EcoRI. 
M1: lambda DNA ladder, M2: 1 kb DNA ladder 
 
 
Figure 27: Restriction digests of Chinese phages by using restriction enzyme HpaII. 
M1: lambda DNA ladder, M2: 1 kb DNA ladder 
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4.2.4 Sequencing and annotation of phage genomes 
Further sequencing of the genomic DNA and genome analysis helps us to know 
whether the candidate to be used for phage therapy harbours any genes that encode for 
antimicrobial resistance and or toxin/virulence genes. For this purpose the phage DNA 
were extracted using the Promega DNA extraction kit (§ 2.4.13) and further purified 
by Ethanol precipitation (§ 2.4.14). Next generation sequencing was performed on the 
Illumina Miseq platform (§ 2.4.17). The annotation of genome sequences revealed the 
precise genome size for the sequenced phages, no. of genes, coding sequences and 
percent G+C content (Table 13).  
 
The details of the functional genes are highlighted in the Tables 14-19. In these tables 
the functional genes were grouped in to the early to mid genes and late genes as well 
as other groups depending on the functions of proteins encoded by them. The groups 
were as below: 
1. Lysogeny related (Early to mid genes) 
2. DNA metabolism and replication (Early to mid genes) 
3. Head morphogenesis (Late genes) 
4. Tail morphogenesis (Late genes) 
5. Host cell lysis (Late genes) 
6. Other conserved protein domains 
7. Unknown function 
8. Regulatory proteins  
The numbers corresponding to these groupings were mentioned in the tables in 
parenthesis after the name of the protein encoded by these genes. 
Chapter 4 
_____________________________________________________________________ 
118 
 
V. cholerae 
Phage 
GenBank 
accession no. 
Genome 
Length (bp) 
No. of 
genes* 
G+C (%) 
ĭ .3    
ĭ .-    
ĭ .3    
ĭ .-    
ĭ; .-    
ĭ4+ .0    
ĭ&-< .0    
ĭ+ .0    
ĭ+ .0    
ĭ+ .0    
ĭ- .0    
ĭ- .0    
 
Table 13: Details of the phage genomes under study post sequencing and genome 
analysis.  
* Figures in parenthesis indicate no. of genes to which functions were assigned 
 
7KHJHQRPHVL]HRISKDJHĭZDVNEDQGWKHQXPEers of genes identified were 
110 but of which only 20 genes could be assigned functions. Most of the functional 
genes i.e. 12 out of 20 were early to middle genes associated with the DNA 
metabolism and replication. Six genes could be grouped in to the late genes associated 
with head morphogenesis (three genes) and host cell lysis (three genes). Two more 
genes encoded conserved bacteriophage proteins of unknown function (Table 14 and 
Figure 28%ODVW1DQDO\VLVRIWKHĭUHYHDOHGWKDWLWLVJHQHWLFDOO\VLPLODUWRVibrio 
Chapter 4 
_____________________________________________________________________ 
119 
 
phages JA1 (GenBank: NC_021540.1) and VCO139 (GenBank: KC438283.1) with 
97% pairwise identity. Comparison of the genome homRORJ\ EHWZHHQ WKH ĭ -$
and VCO139 is shown in Figure 29 and it depicts the zones of similarty as indicated 
E\ WKH UHG UHJLRQV 7KH ODUJHVW SURWHLQ µ9LURQ-HQFDSVXODWHG 51$ SRO\PHUDVH¶ LV
encoded by a gene SBVP1_0074 which was 9723 bp in length and was found to be 
FRPPRQ LQ DOO WKUHH JHQRPHV 7KH PHDQ *& FRQWHQW RI ĭ ZDV  ZKLFK LV
similar to JA1 and VCO139 as both of them have 34.6% G+C content. No tRNA was 
GHWHFWHGLQWKHĭJHQRPHLQFRQWUDVWWRVLQJOHW51$HDFKLQ-$DQG9&21R
lysogeny related genes were detected for ĭ 
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Name of the protein 
encoded by gene  Start  End  Length Direction 
1 DNA-directed RNA polymerase RNAP1 (2) 4,427 5,368 942 forward 
2 DNA-directed RNA polymerase RNAP2 (2) 6,918 7,703 786 forward 
3 N-acetylmuramoyl-L-
alanine amidase (5) 9,203 9,727 525 reverse 
4 PF10947 family protein (7)  10,735 11,154 420 forward 
5 Putative lipoprotein (5) 11,151 11,453 303 forward 
6 Thymidylate synthase (2) 11,641 12,492 852 forward 
7 PF11753 family protein (7)  16,553 16,846 294 forward 
8 Metallopeptidase domain protein (5) 20,900 22,126 1,227 forward 
9 DNA helicase (2) 22,698 23,858 1,161 forward 
10 DNA polymerase (2) 24,424 25,992 1,569 forward 
11 Putative HNH homing 
endonuclease (2) 27,085 27,618 534 forward 
12 DNA polymerase (2) 27,878 28,735 858 forward 
13 Phosphoribosyl-ATP diphosphatase (2) 29,469 29,918 450 forward 
14 AAA domain protein (2) 33,399 34,136 738 forward 
15 ssDNA binding protein (2) 34,198 34,920 723 forward 
16 
Crossover junction 
endodeoxyribonuclease 
RusA (2) 
34,920 35,717 798 forward 
17 Viron-encapsulated RNA polymerase (2) 36,190 45,912 9,723 reverse 
18 N4-gp56 family major 
capsid protein (3) 50,947 52,260 1,314 reverse 
19 Portal protein (3) 53,682 55,799 2,118 reverse 
20 Terminase large subunit (3) 59,671 61,269 1,599 reverse 
 
Table 14: )XQFWLRQDOJHQHVLGHQWLILHGIRUĭ 
Figures in the parenthesis after protein name indicate 1. Lysogeny related; 2. DNA metabolism and 
replication; 3. Head morphogenesis; 4. Tail morphogenesis; 5. Host cell lysis; 6. Other conserved 
protein domains; 7. Unknown function; 8. Regulatory proteins 
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Figure 28: *HQRPHPDSRIĭJHQHUDWHGXVLQJ*HQRPH9[DYDLODEOHDW
http://wolfe.gen.tcd.ie/GenomeVx (Conant and Wolfe 2008). The unlabelled genes 
encode hypothetical proteins. Genes on outside are forward strand genes and genes 
inside are reverse strand genes. 
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Figure 29: Artemis Comparison Tool (ACT) display RIWKHJHQRPHVRI-$WRSĭPLGGOHDQG9&2ERWWRPZones of 
similarty are indicated by intensity of red colour. 
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3KDJHĭKDGDJHQRPHVL]HRINEDQGFRGLQJVHTXHQFHVZHUHIRXQGRXWRI
which functions could be assigned to 27 genes (Table 15 and Figure 30). The 
functional genes identified could be grouped in to early to mid and late genes. Eleven 
genes were classified as early to mid genes, of which 5 encoded lyogeny related 
proteins viz. Integrase family site specific recombinase, Putative excisionase family 
protein, Cro-like protein, Antirepressor protein and Intergrase; while 6 were related to 
DNA metabolism and replication. The late genes were associated with head 
morphogenesis (4), tail morphogenesis (9) and host cell lysis (1). One gene encoding 
VHS1122-like protein was of unknown function; while one more gene which encodes 
ATP-binding sugar transporter family protein was grouped in to the other conserved 
proteiQGRPDLQ8SRQ%ODVW1VHDUFKĭZDVIRXQGWREHJHQHWLFDOO\identical to 
another Vibrio SKDJHĭ;ZKLFKLVEHLQJVWXGLHGLQWKLVSURMHFW+RPRORJ\RIWKH
VHTXHQFHVEHWZHHQĭDQGĭ;ZHUHFRPSDUHGE\$&7FRPSDULVRQWRRODVVKRZQ
in Figure 313KDJHĭUHYHDOHGDULERVRPDOVOLSSDJH (an error during translation due 
to addition or deletion of bases on mRNA causing shift i.e. slippage in the codon 
reading frame) at the coordinates 12760..13202 in the coding sequences upstream of 
WKH WDSH PHDVXUH SURWHLQ ZKLFK ZDV FRQVHUYHG LQ ĭ; DV Zell. The mean G+C 
FRQWHQWRIĭZDVZKLFKZDVVLPLODUWRWKDWRISKDJH;ZKLFKFRQWDLQHG
% of G+C regions. 
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Name of the protein 
encoded by gene  Start  End  Length Direction 
1 DNA modification 
methylase (2) 140 745 606 Forward 
2 Terminase large subunit (3) 1,375 3,225 1,851 Forward 
3 VHS1122-like protein (7) 3,369 3,695 327 Reverse 
4 Portal protein (3) 4,393 5,976 1,584 Forward 
5 Clp protease-like protein (3) 5,963 7,066 1,104 Forward 
6 Major capsid E family protein (3) 7,473 8,513 1,041 Forward 
7 
ATP-binding sugar 
transporter family 
protein (6) 
8,824 9,153 330 Forward 
8 Minor tail protein Z (4) 9,168 9,734 567 Forward 
9 Tail protein (4) 10,502 11,971 1,470 Forward 
10 Major tail tube protein (4)  11,986 12,507 522 Forward 
11 Tail length tape-
measure protein (4) 13,217 15,853 2,637 Forward 
12 Late control D family protein (4) 16,056 17,084 1,029 Forward 
13 Putative baseplate protein (4) 17,087 17,818 732 Forward 
14 GpU-like protein (4) 17,827 18,213 387 Forward 
15 Baseplate (4) 18,517 19,641 1,125 Forward 
16 Tail protein I (4) 19,634 20,212 579 Forward 
17 N-acetylmuramoyl-L-
alanine amidase (5) 22,878 23,573 696 Forward 
18 
Integrase family site 
specific recombinase 
(1) 
25,103 26,167 1,065 Forward 
19 Methyltransferase (2) 26,239 26,742 504 Forward 
20 Putative excisionase family protein (1) 27,786 27,989 204 Forward 
21 Cro-like protein (1) 28,005 28,217 213 Forward 
22 Antirepressor protein (1)  28,391 29,191 801 forward 
23 Replication protein (2) 29,205 30,002 798 forward 
24 DNA replication protein DnaC (2) 29,989 30,768 780 forward 
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25 Integrase (1) 30,768 31,967 1,200 forward 
26 
DNA recombination-
dependent growth factor 
C (2) 
32,053 32,964 912 forward 
27 Single-stranded DNA-binding protein (2) 38,194 38,601 408 forward 
 
Table 15: )XQFWLRQDOJHQHVLGHQWLILHGIRUĭ 
Figures in the parenthesis after protein name indicate 1. Lysogeny related; 2. DNA metabolism and 
replication; 3. Head morphogenesis; 4. Tail morphogenesis; 5. Host cell lysis; 6. Other conserved 
protein domains; 7. Unknown function; 8. Regulatory proteins 
 
 
 
Figure 30: *HQRPHPDSRIĭJHQHUDWHGXVLQJ*HQRPH9[DYDLODEOHDW
http://wolfe.gen.tcd.ie/GenomeVx (Conant and Wolfe 2008). The unlabelled genes 
encode hypothetical proteins. Genes on outside are forward strand genes and genes 
inside are reverse strand genes. 
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Figure 31: Artemis Comparison Tool (ACT) display RIWKHJHQRPHVRIĭWRSDQGĭ;ERWWRP=RQHVRIVLPLODUW\DUHLQGLFDWHGE\
intensity of red colour. 
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3KDJHĭ3 had the largest genome size of 116.1 kb among the phages under this study. 
The number of genes identified were also large i.e. 156 and out of which 53 genes 
could be assigned with functions (Table 16 and Figure 32). The early to mid genes for 
DNA metabolism and replication were 22 in number, while late genes involved in 
head morphogenesis, tail morphogenesis and host cell lysis were 6, 10 and 1 gene, 
respectively. There was one gene encoding protein of unknown function and five 
coded for other conserved protein domains. Phage ĭ3 had two terminal repeats with 
left repeat spanning between 1 to 7769 and right terminal repeat between the 
cooridinates 108,370 and 116,138. Amongst all the phages under study only phage ĭ3 
had eight tRNAs viz. tRNA-Arg(tct), tRNA-His(gtg), tRNA-Arg(acg), tRNA-
Phe(gaa), tRNA-Met(cat), tRNA-Ile(gat), tRNA-Val(tac) and tRNA-Arg(cct). The 
*&FRQWHQWRIĭZDVDQGXSRQWKH%ODVW1VHDUFKLWFRXOGVKRZVLPLODULW\
WRVibrio phage pVp-1 with SDLUZLVHLGHQWLW\%RWKĭ3 and pVp-1 being T5 like 
phages, they were compared with T5 using the ACT comparison tool and light red 
colour bands show zones of similarity (Figure 33). The figure also shows that there is 
no left terminal UHSHDWLQS9SZKLOHĭ3 shows identical terminal repeats both on left 
as well as right sides. 3KDJHĭ3 did not posses any lsogeny related genes.  
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Name of the protein 
encoded by gene  Start  End  Length Direction 
1 
Deoxynucleoside-5'-
monophosphatase (2) 133 762 630 reverse 
2 A1 protein (3) 1,184 2,896 1,713 reverse 
3 A2 protein (2) 3,033 3,524 492 reverse 
4 
Nicotinate 
phosphoribosyltransferas
e (2) 
16,112 17,725 1,614 reverse 
5 
Ribose-phosphate 
pyrophosphokinase  (2) 18,265 19,170 906 reverse 
6 
Putative RNA ligase/tail 
attachment protein (4) 21,016 21,513 498 reverse 
7 
Calcineurin-like 
phosphoesterase family 
protein (2) 
21,588 22,331 744 reverse 
8 
Peptidase M15 family 
protein (2) 26,904 27,287 384 reverse 
9 Putative holin (5) 27,287 27,955 669 reverse 
10 Tail protein (4) 29,866 30,195 330 reverse 
11 Putative hydrolase (6) 30,316 30,969 654 reverse 
12 tRNA-Arg(tct)  32,533 32,608 76 reverse 
13 tRNA-His(gtg)  33,160 33,236 77 reverse 
14 
Dihydrofolate reductase 
(4) 36,190 36,645 456 reverse 
15 Thymidylate synthase (4) 36,655 37,518 864 reverse 
  Chapter 4 
_____________________________________________________________________ 
129 
 
16 tRNA-Arg(acg)  38,491 38,566 76 reverse 
17 tRNA-Phe(gaa) 38,573 38,648 76 reverse 
18 tRNA-Met(cat)  38,949 39,025 77 reverse 
19 tRNA-Ile(gat)  39,032 39,107 76 reverse 
20 tRNA-Val(tac)  39,903 39,980 78 reverse 
21 tRNA-Arg(cct)  40,663 40,739 77 reverse 
22 
Putative 
exodeoxyribonuclease (2) 43,036 43,728 693 reverse 
23 Ribonuclease H (2) 45,334 45,810 477 reverse 
24 PhoH-like protein (2) 46,523 47,176 654 reverse 
25 
Putative replication origin 
binding protein (2) 55,958 58,750 2,793 forward 
26 D2 protein (6) 59,570 60,412 843 forward 
27 D3 protein (7) 60,426 60,848 423 forward 
28 
NAD-dependent DNA 
ligase subunit A (2) 63,087 63,308 222 forward 
29 
NAD-dependent DNA 
ligase subunit B (2) 64,008 64,799 792 forward 
30 D5 protein (6) 64,792 65,559 768 forward 
31 
Putative replicative DNA 
helicase (2) 65,615 67,039 1,425 forward 
32 DNA primase (2) 67,026 67,916 891 forward 
33 DNA polymerase (2) 68,005 70,587 2,583 forward 
34 
Putative ATP-dependent 
helicase (2) 71,173 72,531 1,359 forward 
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35 D11 protein (6) 73,017 73,820 804 forward 
36 
Putative recombination 
endonuclease subunit 
D12  (2) 
74,237 75,220 984 forward 
37 
Putative exonuclease 
subunit (2)  75,210 77,081 1,872 forward 
38 D14 protein (6) 77,074 77,553 480 Forward 
39 Flap endonuclease (2) 77,550 78,446 897 Forward 
40 
Putative deoxyUTP 
pyrophosphatase (2) 78,433 78,885 453 Forward 
41 Tail protein (4) 85,239 87,467 2,229 Reverse 
43 Phage tail-3 (4) 87,464 90,319 2,856 Reverse 
44 
Pore-forming tail tip 
protein (4) 91,100 94,174 3,075 Reverse 
45 Minor tail protein (4) 95,818 96,702 885 Reverse 
46 Major tail protein (4) 96,709 98,172 1,464 Reverse 
47 
Major head protein 
precursor (3) 
100,04
0 101,449 1,410 Reverse 
48 
Putative prohead protease 
(3) 
101,45
3 102,064 612 Reverse 
49 Portal protein (3) 102,296 103,516 1,221 Reverse 
50 
Terminase large subunit 
(3) 
104,08
4 105,406 1,323 Reverse 
51 
Deoxynucleoside-5'-
monophosphatase (2) 
108,50
2 109,131 630 Reverse 
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52 A1 protein (3) 109,553 111,265 1,713 Reverse 
53 A2 protein (2) 111,402 111,893 492 Reverse 
 
Table 16: )XQFWLRQDOJHQHVLGHQWLILHGIRUĭ 
Figures in the parenthesis after protein name indicate 1. Lysogeny related; 2. DNA metabolism and 
replication; 3. Head morphogenesis; 4. Tail morphogenesis; 5. Host cell lysis; 6. Other conserved 
protein domains; 7. Unknown function; 8. Regulatory proteins 
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Figure 32: *HQRPHPDSRIĭJHQHUDWHGXVLQJ*HQRPH9[DYDLODEOHDW
http://wolfe.gen.tcd.ie/GenomeVx (Conant and Wolfe 2008). The unlabelled genes 
encode hypothetical proteins. Genes on outside are forward strand genes and genes 
inside are reverse strand genes. 
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Figure 33: Artemis Comparison Tool (ACT) display RIWKHJHQRPHVRISKDJH7WRSĭPLGGOHDQGS9S-1 (bottom). Zones of 
similarty are indicated by intensity of red colour. Blue band represents similarity on the opposite strand, while yellow represents 
highlighted region.  
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The genome size of phage 24 was 44.3 kb with mean G+C content as  
$QQRWDWLRQ RI JHQRPH VHTXHQFH UHYHDOHG  JHQHVFRGLQJ VHTXHQFHV of which 19 
could be assigned with functions. Seven genes were related to early genes for DNA 
metabolism and replication, followed by late genes which were comprised of six head 
morphogenesis and four tail morhogenesis ones. Two more genes were grouped as 
encoding for other conserved protein domains (Table 17 and Figure 34). The phage 24 
has 99 % identity with Vibrio phage CP-T1 (NC_019457.1) but has 75 bp in-frame 
deletion in the pentapeptide repeat-containing protein. The Figure 35 depicts the 
comparison of phage 24 and CP-T1 by ACT comparison with intense red colour 
indicating similar zones on their genomes with a strip of ClustalO (Sievers, Wilm et 
al. 2011) output at the bottom of the figure deciphering the in-frame deletion in the 
pentapeptide repeat-containing protein of phage 24. It was noticed that any lysogeny 
related genes were absent in phage 24. 
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Name of the protein 
encoded by gene  Start  End  Length Direction 
1 
Putative exonuclease  
(2) 189 722 534 Reverse 
2 
Putative DNA 
polymerase (2) 727 3,063 2,337 Reverse 
3 Putative helicase  (2) 6,842 9,823 2,982 Forward 
4 
DNA-cytosine 
methyltransferase  (2) 10,320 11,621 1,302 Forward 
5 Putative methylase (2) 11,618 12,319 702 Forward 
6 
Putative transcriptional 
regulator (6) 12,359 12,673 315 Forward 
7 
Pentapeptide repeat-
containing protein (6) 12,900 13,322 423 Forward 
8 Putative primase (2) 14,378 16,858 2,481 Forward 
9 
Putative small-subunit 
terminase  (3) 17,762 18,394 633 Forward 
10 
Terminase large subunit 
(3) 18,384 19,844 1,461 Forward 
11 
Putative portal protein 
(3) 20,016 21,485 1,470 Forward 
12 
Putative head protein 
(3) 23,282 24,103 822 Forward 
13 Putative helicase (2) 24,392 24,895 504 Reverse 
14 Putative head protein 25,770 26,897 1,128 Forward 
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(3) 
15 
Putative major capsid 
protein (3) 27,409 28,422 1,014 Forward 
16 
Putative tail-
fiber/lysozyme protein 
(4) 
34,611 35,975 1,365 Forward 
17 
Putative baseplate 
protein (4) 38,110 38,808 699 Forward 
18 
Putative baseplate 
protein (4) 39,148 40,371 1,224 Forward 
19 
Putative tail-fiber 
protein (4) 41,013 42,044 1,032 Forward 
 
Table 17: )XQFWLRQDOJHQHVLGHQWLILHGIRUĭ 
Figures in the parenthesis after protein name indicate 1. Lysogeny related; 2. DNA metabolism and 
replication; 3. Head morphogenesis; 4. Tail morphogenesis; 5. Host cell lysis; 6. Other conserved 
protein domains; 7. Unknown function; 8. Regulatory proteins 
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Figure 34: Genome map of phage 24 generated using GenomeVx available at 
http://wolfe.gen.tcd.ie/GenomeVx (Conant and Wolfe 2008). The unlabelled genes 
encode hypothetical proteins. Genes on outside are forward strand genes and genes 
inside are reverse strand genes.
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Figure 35: Artemis Comparison Tool (ACT) display of the genomes of phage 24 (top) and CP-T1 (bottom). Zones of similarty are 
indicated by intensity of red colour. ClustalO output at the bottom shows the in-frame deletion.
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The Canadian phage X29 had a genome length of 41.5 kb and 67 numbers of 
genes/coding sequences could be identified. Out of 67 genes 34 could be assigned 
with functions which more compared to the 27 number of genes which were identified 
witKIXQFWLRQVIRUVLPLODUSKDJHĭ2 under this study (Tables 18 and 15; Figure 36). 
Eleven of these genes could be grouped in to early to mid genes with 2 genes for 
lysogeny which encoded the proteins integrase family site specific recombinase and 
an integrase; while 9 genes for DNA metabolism and replication. Out of remaining 
genes, 15 were belonging to late genes which had 4 genes for head morphogenesis, 9 
for tail morphogenesis and 2 for host cell lysis. Interestingly phage X29 has shown 6 
regulatory proteins of Helix-turn-helix domain and one protein each with unknown 
function and other conserved protein domain. As discussed earlier, the phage X29 has 
99 % similarity with ĭ2 and the ACT comparison is depicted in the Figure 30. The 
mean G+C content of phage X29 was 46.0 % which was slightly lower than ĭ2 which 
contains 46.1 % G+C content. 
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Name of the protein 
encoded by gene  Start  End  Length Direction 
1 
DNA modification 
methylase (2) 140 745 606 forward 
2 
Terminase large subunit 
(3) 1,375 3,225 1,851 forward 
3 Portal protein (3) 4,393 5,976 1,584 forward 
4 Protease-like protein (3) 5,963 7,066 1,104 forward 
5 
Major capsid E family 
protein (3) 7,473 8,513 1,041 forward 
6 Tail sheath protein (4) 10,502 11,971 1,470 forward 
7 
Tail tube FII family 
protein (4) 11,986 12,507 522 forward 
8 
Tail length tape-
measure protein (4) 13,217 15,853 2,637 forward 
9 
Late control D family 
protein (4) 16,056 17,084 1,029 forward 
10 
Putative baseplate 
protein (4) 17,087 17,818 732 forward 
11 Lysozyme (5) 18,213 18,524 312 forward 
12 
Baseplate J-like protein 
(4) 18,517 19,641 1,125 forward 
13 Tail protein I (4) 19,634 20,212 579 forward 
14 Tail fiber protein (4) 20,275 21,927 1,653 forward 
15 Tail fiber assembly-like 21,938 22,429 492 forward 
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protein (4) 
16 
N-acetylmuramoyl-L-
alanine amidase (5) 22,878 23,573 696 forward 
17 
Prokaryotic membrane 
lipoprotein lipid 
attachment site protein 
(6) 
24,551 24,757 207 forward 
18 
Integrase family site 
specific recombinase 
(1) 
25,103 26,167 1,065 forward 
19 Methyltransferase (2) 26,239 26,742 504 forward 
20 
Helix-turn-helix domain 
protein (8) 27,149 27,421 273 forward 
21 
Helix-turn-helix domain 
protein (8) 27,786 27,989 204 forward 
22 
Helix-turn-helix domain 
protein (8) 28,005 28,217 213 forward 
23 
Antirepressor protein 
KilAC domain (2) 28,391 29,191 801 forward 
24 
Helix-turn-helix domain 
protein (8) 29,205 30,002 798 forward 
25 
IstB-like ATP binding 
protein (7) 29,989 30,768 780 forward 
26 Integrase (1) 30,768 31,967 1,200 forward 
27 DNA recombination- 32,053 32,964 912 forward 
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dependent growth factor 
C  (2) 
28 
Exonuclease:ribonuclea
se T  (2) 33,650 34,582 933 forward 
29 
Cro/C1-type HTH 
DNA-binding domain 
protein (8) 
35,908 36,144 237 forward 
30 DNA clamp protein (2) 36,162 36,791 630 forward 
31 
ASCH domain protein 
(2) 36,812 37,516 705 forward 
32 
DNA N-6-adenine-
methyltransferase  (2) 37,526 38,194 669 forward 
33 
Single-stranded DNA-
binding protein (2) 38,194 38,694 501 forward 
34 
Helix-turn-helix domain 
protein (8) 39,753 39,908 156 forward 
 
Table 18: )XQFWLRQDOJHQHVLGHQWLILHGIRUĭ; 
Figures in the parenthesis after protein name indicate 1. Lysogeny related; 2. DNA metabolism and 
replication; 3. Head morphogenesis; 4. Tail morphogenesis; 5. Host cell lysis; 6. Other conserved 
protein domains; 7. Unknown function; 8. Regulatory proteins 
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Figure 36: Genome map of phage X29 generated using GenomeVx available at 
http://wolfe.gen.tcd.ie/GenomeVx (Conant and Wolfe 2008). The unlabelled genes 
encode hypothetical proteins. Genes on outside are forward strand genes and genes 
inside are reverse strand genes. 
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Out of seven Chinese phages, the genome size of ĭQH and J3 were both 39.7 kb and 
rest all were 39.5 kb. Annotation of these genomes revealed that phage J3 possessed 
49 genes and the other phages had 48 genes each (Table 13). The percent G+C content 
for Chinese phages was similar with 50.5 % for all of them (Table 13). The genes 
identified were assigned with functions and for ĭQH nine genes were given functions 
(Figure 37), while for phages CJY/H1/H2/H3/J3 eight genes each and for ĭJ2, seven 
genes were functionally identified (Table 19). All these phages had early to mid genes 
in common which contained one lysogeny related gene each encoding for Integrase 
and also four genes associated DNA metabolism and replication. Amongst the late 
genes the head morphogenesis related genes were two each but for tail morphogenesis 
some phages lacked few genes. Two genes encoding the tail components were 
possessed by ĭQH and phages CJY/H1/H2/H3/J3 had one each; while none was 
identified for ĭJ2.   
    
BlastN search for all the Chinese phages revealed that they are closely related to 
Vibrio phages VP2 (NC_005879.1), VP5 (NC_005891.1) and phiVC8 (JF712866.1). 
Both VP2 and VP5 showed 97-98 % pairwise identity with all the Chinese phages; 
while phiVC8 showed 86-87 % identity. The Phages H1, H2, H3 and J2 being exactly 
the same length were also shown to be highly similar, differing only by a range of 
SNPs (Figure 38). The slightly more divergent CJY sequence could also be grouped 
with H1, H2, H3 and J2 with a 12 base insertion further differentiating it. Phages QH 
and J3 were more divergent and they shared an additional 79 aa CDS 
(QH_0045/J3_0046) of unknown function which was also found in VP2, VP5 and 
phiVC8 but absent in rest all Chinese phages under study. Similar to VP2, VP5 and 
phiVC8, all the Chinese phages had 53 aa CDS of unknown function (e.g. H1_0024) 
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except in phage QH. Phage QH had major tail subunit (QH_0014) which was absent 
in all other phages. They also share an enzyme adenylosuccinate synthase, a purine 
bio-synthesis enzyme with VP2, VP5 and phiVC08. 
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Name of the protein 
encoded by gene  Direction 
QH CJY/H1/H2/H3/J3 J2 
Start  End  Length Start  End  Length Start  End  Length 
1 
Terminase (3) forward 1,135 2,841 1,707 1,137 2,843 1,707 1,137 2,843 1,707 
2 
Major tail subunit (4) forward 9,330 11,561 2,232             
3 
Tail fiber (4) forward 19,362 20,435 1,074 19,367 20,440 1,074       
4 
Outer capsid protein (3) forward 20,437 21,819 1,383 20,442 21,824 1,383 20,442 21,824 1,383 
5 
Adenylosuccinate synthetase 
(2) Reverse 23,448 24,479 1,032 23,604 24,635 1,032 23,604 24,635 1,032 
6 
Integrase (1) Reverse 24,521 26,809 2,289 24,677 26,965 2,289 24,677 26,965 2,289 
7 
DNA polymerase I (2) Reverse 26,799 28,700 1,902 26,955 28,856 1,902 26,955 28,856 1,902 
8 
Single stranded DNA-
binding protein (2)  Reverse 28,709 29,185 477 28,865 29,341 477 28,865 29,341 477 
9 
Superfamily II DNA/RNA 
helicase (2) Reverse 30,711 32,180 1,470 30,867 32,336 1,470 30,867 32,336 1,470 
 
Table 19: Functional genes identified for Chinese phages 
Figures in the parenthesis after protein name indicate 1. Lysogeny related; 2. DNA metabolism and replication; 3. Head morphogenesis; 4. Tail morphogenesis; 5. 
Host cell lysis; 6. Other conserved protein domains; 7. Unknown function; 8. Regulatory proteins 
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Figure 37: Genome map of Vibrio phage QH generated using GenomeVx available at 
http://wolfe.gen.tcd.ie/GenomeVx (Conant and Wolfe 2008). The unlabelled genes 
encode hypothetical proteins. Genes on outside are forward strand genes and genes 
inside are reverse strand genes. 
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Figure 38: Clustal omega alignments of Chinese phage genome sequences with SNP 
variations. 
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4.3  Discussion 
In order to characterise the genomes of the phages under study the genome size was 
estimated using PFGE (§ 2.4.8). The predicted genome sizes revealed the largest 
JHQRPHLHNEIRUSKDJHĭZKLFKKDSSHQVWREHDSiphoviridae type phage (§ 
3.2.4). Similar genome sizes were observed by Comeau and colleagues (Comeau, 
Chan et al. 2006) for the Siphoviridae type phages of V. parahaemolyticus which 
showed larger sizes between 106 to 125 kb. The only Siphovirus (ĭ) studied under 
this project had larger genome size as the Siphoviruses infecting Vibrio spp. range 
between 44 to 94 kb size (Shivu, Rajeeva et al. 2007); while the Siphoviridae phage 
ĭ9KJHQRPH was 107 kb in size (Thiyagarajan, Chrisolite et al. 2011). The Chinese 
phages (§ 3.2.4) were of relatively smaller genome sizes and all of them were below 
48.5 kb which was similar to the size of between 44 to 46 kb reported by other 
workers (Comeau, Chan et al. 2006)2QHPRUH3RGRYLUXVSKDJHɎLQWKLVVWXG\KDG
comparatively larger genome size of 74 kb and the other report on Vibrio specific 
3RGRYLUXV SKDJH ĭ9K KDG JHQRPH VL]H RI  NE (Thiyagarajan, Chrisolite et al. 
2011). The remaining three Myoviridae SKDJHVĭSKDJHDQGSKDJH;DOVRKDG
smaller genome sizes i.e. below 48.5 kb. Al-Fendi and colleagues (Al-Fendi, Shueb et 
al. 2014) noticed the similar genome size of 33.5 kb for Myoviridae phages specific to 
Vibrio spp. but the genome size of 83 kb was also reported by other researchers 
(Shivu, Rajeeva et al. 2007) and thus the Myoviridae phages under study seem to be 
small myoviruses.  
 
The estimated genome sizes revealed through PFGE correspond well with the actual 
genome sizes of the phages determined through DNA sequencing of these phages. The 
3)*( JHQRPH VL]H RI SKDJH Ɏ ZDV  NE ZKLOH WKH DFWXDO JHQRPH VL]H DIWHU
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VHTXHQFLQJZDVNE7KH3)*(HVWLPDWHRI WKHJHQRPHVL]HIRUɎZDVkb 
ZKLOHWKHDFWXDOVL]HDIWHUVHTXHQFLQJZDVNE7KHVL]HVRIWKHSKDJHVɎWKH
Canadian phages and all the Chinese phages were below 48.5 kb and it was confirmed 
by sequencing that they all fell below 48.5 kb. The precise size estimation of genomes 
under 48.5 kb through PFGE was difficult with 50-1000 kb pulse high marker and 
thus, low marker of 0.1 ± 200 kb could have been useful but the DNA sequencing 
could resolve this issue by determining the actual size. 
  
Further to genome size estimations the phage nucleic acids (DNA) were extracted (§ 
2.4.14) for additional genomic characterisation. As mentioned in the section 4.2.2 the 
minimum requirement for the sequencing purpose was 150 ng/µl but with newest 
methods one can rapidly sequence the DNA containing phage genomes even from a 
single plaque (Kot, Vogensen et al. 2014).  
 
Before sending the samples for sequencing the phage genomes were discriminated by 
restriction fragment length polymorphisms (RFLP). Looking in to the digestion 
patterns of all phages under study it revealed that there were genomic differences 
between them which gave different restriction profiles. Restriction endonuclease PstI 
could cut the phage 24 DNA in this study and in an earlier study the Vibrio harveyi 
phage PW2 was also digested by PstI ascertaining its double stranded nature and 
genome size estimate (Phumkhachorn and Rattanachaikunsopon 2010) 3KDJH ĭ
genome was digested by XbaI and there was a report on digestion of the genomic 
DNA of four lytic phages infecting Vibrio harveyi by XbaI showing distinct restriction 
profiles (Thiyagarajan, Chrisolite et al. 2011). They used 12 different restriction 
enzymes but only two could digest the phage DNA while remaining 10 enzymes could 
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not cut the DNA. In our study, the restriction enzymes PstI and SacI could not cut 
SKDJH ĭ ZKLOH SKDJH  UHPDLQHG XQFXW E\ SacI and XbaI. This could be due to 
DNA methyltransferases encoded by these phages which catalyse the conversion of 
cytosine to hydroxymethyl cytosine protecting their DNA from digestion (Atterbury 
2003). This was confirmed after genome sequencing by detection of the DNA 
methyltransferase in phage 24 genome at the coordinates 10,320..11,621 (Table 17). 
For Chinese phages the restriction enzymes PstI, SacI and XbaI could cut the genomes 
so much that there were not any distinct bands but smeared pattern was generated for 
all of them. Though there was smearing, the pattern of smearing remained different 
for each phage suggesting the difference amongst them but a clear discrimination was 
necessary so the new enzymes EcoRI and HpaII were used. The digestion pattern by 
HpaII could differentiate the Chinese phages but EcoRI showed smearing pattern for 
all the Chinese phage genomes. HpaII could digest DNA of all the phages to yield 
discriminatory patterns when it was used for restriction analysis of seven Vibrio 
harveyi bacteriophage DNAs (Shivu, Rajeeva et al. 2007).  
 
After obtaining the discriminatory restriction fragment length polymorphism the 
phage DNA was sequenced, assembled and annotated (§ 2.4.17). Knowledge of 
functional genes through genome sequencing and further annotation helps to predict 
whether phage has a lysogenic life cycle e.g. the genes encoding lysogeny viz. 
Integrase family site specific recombinase, Putative excisionase family protein, Cro-
OLNHSURWHLQ$QWLUHSUHVVRUSURWHLQDQG ,QWHUJUDVHDVGHWHFWHG LQĭZKLOH LQWHJUDVH
IDPLO\VLWHVSHFLILFUHFRPELQDVHDQGDQLQWHJUDVHLQĭ;29 and an integrase detected 
in all Chinese phages. As we need strictly lytic phages for phage therapy purpose, the 
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absence of genes associated with lysogeny and/or virulence/antimicrobial resistance 
genes is a crucial factor in deciding the potential phage therapy candidate.  
 
The PHE phages ĭ 1, ĭ 2 and ĭ 3 are three completely different phages 
morphologically as they fall in to three different classifications viz. Podoviridae, 
Myoviridae and Siphoviridae families, respectively (§ 3.2.4). All these three phages 
were of Russian origin as per the personal communication of Dr. Tom Cheasty, then 
Head of Gastrointestinal Infections Reference Unit at then Health Protection Agency 
now Public Health England. Vibrio SKDJHɎLV1OLNH i.e. Escherichia phage family 
and is genetically similar to Vibrio phages JA1 (GenBank: NC_021540.1) and 
VCO139 (GenBank: KC438283.1), both specific to Vibrio cholerae O139 (Fouts, 
Klumpp et al. 2013)3KDJHɎLVV. cholerae O1-specific though very similar to the 
RWKHU2VSHFLILFSKDJHV7KLVFRXOGEHGXHWRWKHIDFWWKDWSKDJHɎZDVLVRODWHG
several years ago in Russia as it was obtained from the archives of PHE and the 
prevalent host strain at the time of isolation was V. cholerae O1. Later, the O139 
serotype emerged as a pandemic strain (Swerdlow and Ries 1993) and the phages JA1 
and VCO139 were isolated after the O139 serotype EHFDPHSUHYDOHQW3KDJHɎhas a 
large protein, viron-encapsulated RNA polymerase with a molecular mass of about 
360 kDa and was encoded by 9722 bp gene SBVP1_0074. The presence of this 
protein indicates that it belongs in the N4 like as it is a characteristic of this family 
(Falco, Zehring et al. 1980). All other genes aVVLJQHGZLWKIXQFWLRQVIRUSKDJHɎGLG
not reveal any lysogeny/antimicrobial resistance related as stated in the preceding 
paragraph and/or virulence/toxin related genes i.e. cholera toxin encoding genes (e.g. 
ctxAB, zot and ace); which would otherwise render it unsuitable for therapeutic use. 
Of the other two PHE SKDJHV SKDJH Ɏ ZDV LGHQWLILHG DV D Myoviridae phage (§ 
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 DQG ZDV   VLPLODU WR Ɏ; DW JHQHWLF OHYHO %RWK WKHVH SKDJHV have a 
conserved translational frameshift which was analogous to the lambda gpG/gpGT 
proteins and was present in the coding sequences upstream of their tape measure 
protein (Xu, Hendrix et al. 2004). From a phage therapy perspective these two phages 
were not promising as their genomes contained integrases and Cro protein homologs 
which are lysogeny related proteins. The third PHE SKDJHɎZDVWKHRQO\7OLNH
phage classified in to Siphoviridae family (§ 3.2.4) having terminal repeats at both the 
ends similar to the T5 genome (Wang, Jiang et al. 2005). Amongst all the phages 
XQGHUVWXG\RQO\SKDJHɎ has eight tRNAs. Phage pVp-1 had 19 tRNAs (Kim, Jun et 
al. 2012). Phage pVp-1 proved to be therapeutically effective for the treatment of 
multiple antibiotic resistant Vibrio parahaemolyticus infection in a mouse model (Jun, 
Shin et al. 2014) DQG WKXV SKDJH Ɏ FRXOG EH D SRWHQWLDO SKDJH WKHUDS\ FDQGLGDWH
owing to the absence of any genes related to lysogeny/antimicrobial resistance and/or 
virulence/toxin as discussed above.  
 
The Canadian phages in this study were of Myoviridae family and the phage X29 was 
a temperate phage as discussed in the preceding paragraph. The phage 24 has 99% 
identity with Vibrio phage CP-T1 (Comeau, Tremblay et al. 2012) but has 75 bp in-
frame deletion in the pentapeptide repeat-containing protein of unknown function 
(Vetting, Hegde et al. 2006). There was not any gene related to lysogeny/antimicrobial 
resistance nor was any gene associated toxin production found. Thus, phage 24 was 
also considered to be suitable for therapeutic applications.   
 
The Chinese phages isolated, sequenced and annotated in this study all belonged to the 
Podoviridae family (§ 3.2.4) and genome analysis showed that they clustered with 
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members of VP2-like phage group of the Podoviridae family (Lavigne, Seto et al. 
2008). The other members of this VP2-like phage group were phiVC8 (JF712866.1), 
VP2 (NC_005879.1) and VP5 (NC_005891.1). All seven Chinese phages share an 
integrase protein with the members of the VP2-like phage group which indicates that 
they were temperate in nature. They also share an enzyme adenylosuccinate synthase, 
a purine bio-synthesis enzyme with all the VP2-like phages mentioned above.  
 
Though most of the Chinese phages were of similar length, phages H1, H2, H3 and J2 
were of exactly the same length and have 99 % sequence similarity. In spite of the 
high sequence similarity they are dissimilar as per the restriction analysis owing to 
different banding patterns though they were cut by one restriction enzyme HpaII 
except for phage QH (see 4.2.3), and moreover they were all isolated from 
independent locations. Phages H1, H2 and H3 were isolated from Fu Jia Wan, Ye Zhi 
Hu and Nan Hu lakes, respectively from Wuhan city of Hubei province and these 
water bodies were separated by land masses. J2 was isolated from the Yudai He river 
in a different city, Jiangxi, in Nanchang province. Phage CJY was differentiated by a 
12 base insertion at the N-terminal region of CDS CJY_0035. VP2 and VP5 phages 
were lacking this insertion in to the equivalent CDS. Phages QH and J3 were more 
divergent and they share an additional 79 aa CDS (QH_0045/J3_0046) which is of 
unknown function and was also found in phiVC8, VP2 and VP5 but absent in the 
remaining Chinese phages. Similar to phiVC8, VP2 and VP5, all the Chinese phages 
had 53 aa CDS of unknown function (e.g. H1_0024) except in phage QH. Phage QH 
had a major tail subunit (QH_0014) which is absent in all other phages. None of the 
Chinese phages were considered to be suitable for phage therapy because of their 
temperate nature. 
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Overall, the genomic characterisation of all the phages under study revealed the 
relative suitability of these phages for biocontrol of V. cholerae.  Considering the 
genomic features of all these phages only three SKDJHVYL]SKDJHɎɎDQGSKDJH
24 were found to be suitable for phage therapy. These three phages meet the criteria (§ 
4.1) as they do not possess any undesirable genes associated with 
lysogeny/antibacterial resistance and also any cholera toxin genes. Thus, they are fit 
for use in therapeutic preparations either alone or in a cocktail. An assessment of their 
efficacy in the treatment of V. cholerae infection must be assessed in an appropriate 
animal model. This is covered by and discussed in chapter 5. 
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5 PHAGE THERAPY EXPERIMENTS 
5.1  Introduction 
Phages have been used for therapy since soon after their discovery in the early 
twentieth century. The  Indian river waters of Ganges and Jamuna showed bactericidal 
activity against the cholera bacterium (Hankin 1896) but the exact nature of this 
bactericidal property was not known. Later, phages were discovered by Twort (1915) 
DV ZHOO DV G¶+HUUHOOH  DQG GLVFRYHU\ RI SKDJHV DOORZHG WKH XVH RI Shage for 
prophylaxis and treatment of bacterial diseases for the first time. Some initial reports 
were unclear on the effectiveness of phages in general and for treating cholera 
(Monsur, Rahman et al. 1970, Marcuk, Nikiforov et al. 1971) but later the 
effectiveness of phage therapy was demonstrated by the excellent and well 
documented clinical experiments of +:LOOLDPV6PLWK¶VJURXS (Smith and Huggins 
1983, Smith, Huggins et al. 1987). In one of their studies a single dose of phage was 
superior to multiple doses of prevalent antibiotics viz. tetracycline, ampicillin, 
chloramphenicol or trimethoprim plus sulphafurazole in treating enterotoxigenic E. 
coli enteritis.  
 
Smith suggested that as the pathogenesis of cholera is very similar to that of 
enterotoxigenic E. coli enteritis, the phage treatment should also be successful with 
cholera (Smith, Huggins et al. 1987). For better understanding of phage host 
interactions in vivo, a good animal model of cholera phage therapy is required. The 
animal models which have been used for evaluation of phage therapy of V. cholerae 
are rabbits and mice (§ 1.6.3.2). Infant rabbits produce the clinical signs of disease 
similar to human cholera (Pierce, Kaper et al. 1985, Ritchie, Rui et al. 2010). The 
colonisation of intestinal villi by V. cholerae is at a faster rate in the infant rabbits than 
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in the adults (Nelson, Clements et al. 1976) owing to goblet cells not being fully 
functional in infants. In adult rabbits the secretion of mucus layer by goblet cells acts 
as a barrier to colonisation. Although V. cholerae readily colonises intestines of the 
infant mice, they do not develop clear clinical signs of cholera as occurs in infant 
rabbits (Ritchie, Rui et al. 2010). (Ujiiye and Kobari 1970) noticed inhibition of 
gastric emptying in infant mice challenged orally or subcutaneously with cholera 
toxin. Thus, the infant rabbit model was chosen for this project.   
 
For therapeutic purposes either a single phage or a cocktail of phages could be used 
for treating cholera. A single phage gives the convenience of use and cost advantage 
pertaining to phage production; while cocktails of phages help in circumventing 
resistance development, if they are selected against different receptors. In a cocktail of 
phages, it is not known if the reduction in V. cholerae counts is due to a single phage 
in the cocktail or due to two or more phages working together. Thus, with a single 
phage one can scientifically and clearly test whether that particular phage is effective 
or not. The lytic phages with a broad host range are generally deemed most suitable 
for biological control purposes (§ 1.6.5). The characteristics of the phages under study 
pertaining to these criteria are discussed in the chapters 3 and 4. Amongst the phages 
VWXGLHGWKHSKDJHZKLFKPRVWFORVHO\ILWWHGWKHFULWHULDZDVSKDJHĭ7KHEXUVWVL]H
RIĭZDV43 ± 5.5; while the latent period was 12 mins and it had a moderately broad 
host range as it could lyse 67 % of the total 91 strains in our collection. PKDJHĭdid 
not show any undesirable genes associated with lysogeny/antibacterial resistance or 
any cholera toxin genes upon genome annotation based on the present database 
knowledge.  
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,Q WKLV FKDSWHU WKHUHIRUH SKDJH ĭ ZDV WHVWHG in vivo using the baby rabbit model 
assessing its effects on clinical condition and V. cholerae numbers in the  small 
intestines (upper, middle and lower), mid colon and caecal fluid. The control group 
animals were not administered with phage but only with V. cholerae; while the 
animals in the experimental group were given phage with multiplicity of infection 
(MOI) > 1 (§ 2.5.4). The clinical conditions and reduction in bacterial numbers were 
compared between control and treatment groups. 
   
5.2  Results 
5.2.1 Clinical findings 
The control animals (n = 18) were infected orally with V. cholerae 1051 over three 
biological replicate experiments (Table 20) and were not treated with phage. They 
showed clinical signs of disease which varied from mild to severe diarrhoea. Some 
animals appeared normal (7 out of 18 animals) (Table 20), although they were still 
well colonised by V. cholerae as indicated by caecal fluid bacterial counts (Table 21 
and 22). 
 
All the treated animals (n = 15) were also orally infected with V. cholerae 1051 during 
two separate experiments DQG ZHUH WUHDWHG ZLWK SKDJH Ɏ 1RQH RI WKH DQLPDOV
showed any signs of diarrhoea and were clinically normal at the time of euthanasia 
(Table 20).  
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Experi
ment 
No * 
Gouping of 
animals 
No. of 
rabbits per 
litter  
Bacterial 
dose 
(CFU/ml) 
Phage 
dose 
(PFU/ml) 
No. of rabbits with 
clinical signs ȹ 
Normal 
Mild 
diarrhoea 
Severe 
diarrhoea 
1(% 
Control group 5 1 × 108 - 1 4 0 
Treatment group 0 - - 0 0 0 
2 
Control group 6 3 × 108  - 2 3 1 
Treatment group 9 5 × 108 1 × 109 9 0 0 
3 
Control group 7 5 × 106 - 4 3 0 
Treatment group 6 4 × 108 1 × 109 6 0 0 
 
Table 20: The number of therapeutic experiments, number of animals used and clinical signs of the disease noted after infection. 
* Experiments were separated by several weeks. (%For experiment 1 only the control group was done in order to check the colonisation of the 
SmR V. cholerae 1051. ȹ Severity of clinical signs were scored as described in Materials and Methods (§ 2.5.3).
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5.2.2 Recovery of V. cholerae and phages  
The bacteria and phage of control and treatment groups were enumerated (§ 2.5.6). 
The mean bacterial counts for the control group in experiments 1, 2 and 3 were higher 
in the distal segments of the alimentary tract viz mid colon (MC) and caecal fluid (CF) 
than the proximal segments viz. upper small intestine (I1), middle small intestine (I2), 
lower small intestine (I3). Similarly, for experiments 2 and 3 reduction in the V. 
cholerae counts of the treatment groups in the distal segments of intestine i.e. caeca 
and mid colon was greater compared to the proximal segments (Figure 39 and 40). 
The mean bacterial counts for experiment 1 were 5.50 ± 1.09, 5.64 ± 1.25, 5.95 ± 
0.96, 7.09 ± 1.16 and 7.31 ± 1.06 respectively for I1, I2, I3, MC and CF. Experiment 2 
and 3 bacterial as well as phage counts are shown in tables 21 and 22. 
 
Statistical analysis (2.5.7) revealed very signifiant reductions (p<0.001) for 
experiment 2 while experiment 3 also showed significant reductions (p<0.005) in V. 
cholerae counts for all five intestinal sites sampled in the phage-treated animals 
compared with the control group. For experiment 2, the V. cholerae counts of caecal 
fluid were highest in the control group i.e. 8.55 ± 0.65 log10 CFU/ml; while in the 
treatment group they were 3.80 ± 0.82 log10 CFU/ml indicating a mean reduction of 
4.7 log10 CFU/ml. Similarly, the counts for mid colon were reduced by 3.9 log10 from 
7.98 ± 0.36 to 4.07 ± 0.12 log10 CFU/g. Reduction in the counts of more proximal 
segments like lower, middle and upper small intestines were comparatively lower, as 
they showed 3.3, 2.2 and 2.0 log10 reductions, respectively but were still  statistically 
very significant (p<0.001) (Figure 39; Table 21). For experiment 3, the V. cholerae 
counts of caecal fluid in the control group were 7.56 ± 1.53 log10 CFU/ml; while in the 
treatment group they were 3.44 ± 0.61 log10 CFU/ml with a mean reduction of 4.1 
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log10 CFU/ml. The counts for mid colon were reduced by 3.0 log10 CFU/g while 
reduction in the counts of lower, middle and upper small intestines were 2.4, 1.8 and 
2.1 log10 reductions, respectively which were comparatively lower but were still 
statistically significant (p<0.005) (Figure 40; Table 22).    
 
 
Figure 39: Experiment 2, comparison of mean V. cholerae counts (log10 CFU/g or ml 
± SD) in groups of rabbits treated or not treated with bacteriophage.  
The counts are given for five sections of intestine: I1=Upper small intestine; I2=Mid 
small intestine; I3=Lower small intestine; MC=mid colon; CF=caecal fluid. Bars 
marked with (*) indicate a significant reduction in bacterial counts between control 
and treated goups (p<0.001). Mean and standard deviation calculations were based on 
18 and 15 biological replicates for control and treatment group, respectively. 
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Figure 40: Experiment 3, comparison of mean V. cholerae counts (log10 CFU/g or ml 
± SD) in groups of rabbits treated or not treated with bacteriophage. 
The counts are given for five sections of intestine: I1=Upper small intestine; I2=Mid 
small intestine; I3=Lower small intestine; MC=mid colon; CF=caecal fluid. Bars 
marked with (*) indicate a significant reduction in bacterial counts between control 
and treated goups (p<0.005). Mean and standard deviation calculations were based on 
18 and 15 biological replicates for control and treatment group, respectively. 
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Sample 
location 
Control group bacterial 
counts 
(Mean Log10 CFU/g or 
ml ± SD) 
Treatment group 
bacterial counts 
(Mean Log10 CFU/g or 
ml ± SD) 
P value  
and  
significance for 
bacterial counts 
Treatment group phage 
counts 
(Mean Log10 PFU/g or ml 
± SD) 
I1 5.79 ± 0.53 3.71 ± 0.17 0.0010 (***) 6.70 ± 0.17 
I2 6.08 ± 0.30 3.79 ± 0.09 0.0004 (***) 6.70 ± 0.28 
I3 7.34 ± 0.62 3.98 ± 0.15 0.0004 (***) 7.18 ± 0.28 
MC 7.98 ± 0.36 4.07 ± 0.12 0.0010 (***) 7.26 ± 0.55 
CF 8.55 ± 0.65 3.80 ± 0.82 0.0010 (***) 7.87 ± 0.71 
 
Table 21: Experiment 2, mean V. cholerae counts (log10 CFU/g or ml ± SD) in groups of rabbits treated or not treated with bacteriophage, 
statistical significance and mean phage counts (Log10 PFU/g or ml ± SD) for treated group.  
The counts are given for five sections of intestine: I1=Upper small intestine; I2=Mid small intestine; I3=Lower small intestine; MC=mid colon; 
CF=caecal fluid; ***=very significant  
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Sample 
location 
Control group bacterial 
counts 
(Mean Log10 CFU/g or 
ml ± SD) 
Treatment group 
bacterial counts 
(Mean Log10 CFU/g or 
ml ± SD) 
P value  
and  
significance for 
bacterial counts 
Treatment group phage 
counts 
(Mean Log10 PFU/g or 
ml ± SD) 
I1 5.07 ± 0.80 2.90 ± 0.27 0.0012 (**) 6.59 ± 0.38 
I2 4.58 ± 1.10 2.78 ± 0.15 0.0012 (**) 6.71 ± 0.68 
I3 5.48 ± 1.24 3.03 ± 0.28 0.0012 (**) 6.61 ± 0.69 
MC 6.15 ± 1.29 3.09 ± 0.11 0.0012 (**) 6.90 ± 0.76 
CF 7.56 ± 1.53 3.44 ± 0.61 0.0025 (**) 8.77 ± 0.69 
 
Table 22: Experiment 3, mean V. cholerae counts (log10 CFU/g or ml ± SD) in groups of rabbits treated or not treated with bacteriophage, 
statistical significance and mean phage counts (Log10 PFU/g or ml ± SD) for treated group. 
The counts are given for five sections of intestine: I1=Upper small intestine; I2=Mid small intestine; I3=Lower small intestine; MC=mid colon; 
CF=caecal fluid; **=significant 
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The mean phage counts recovered for the treatment group in experiment 2 (n = 9) 
were higher in the distal regions of alimentary tract with 7.26 ± 0.55 in the mid colon 
and 7.87 ± 0.71 in the caecal fluid; while the proximal regions showed lower phage 
counts (Table 21 and 22). For experiment 3 (n = 6) also the more distal regions had 
higher phage counts viz. 6.90 ± 0.76 in the mid colon and 8.77 ± 0.69 in the caecal 
fluid; with lower phage counts for the the proximal regions. No phages could be 
detected in the samples from the control groups of both the experiments 2 and 3 as 
they were not administered with phage but only with bacterial dose. The presence of 
phages in control groups was tested to rule out any cross contamination and also to 
check if there were any resident/lysogenic phages already present in the guts of 
control animals. 
 
The mean fluid accumulation ratio (a ratio of the weight of caecal fluid drained to the 
weight of caecal tissue) for the control groups in the experiments 1 (n = 4), 2 (n = 6) 
and 3 (n = 6) was 0.32 ± 0.11, 0.27 ± 0.20 and 0.10 ± 0.11, respectively; while for 
treatment groups in the experiments 2 (n = 9) and 3 (n = 6) it was 0.08 ± 0.04 and 0.05 
± 0.05, respectively. Statistical analysis revealed non significant differences between 
control and treatement groups of experiments 2 and 3 for fluid accumulation ratios. 
 
As a pilot study, a single experiment was carried out for the comparison of clinical 
signs, colonisation and fluid accumulation ratio (FAR) of wildtype strain of V. 
cholerae 1051 to that of V. cholerae C6706 used in the original infant rabbit cholera 
model developed by Dr. Jenny Ritchie (Ritchie, Rui et al. 2010) (§ 2.5.2). It was 
noticed the wild type V. cholerae 1051 showed inconsistent clinical signs compared to 
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V. cholerae C6706. The colonisation was weak and also the FAR was less in the 
wildtype strain of V. cholerae 1051 compared to V. cholerae C6706 (Table 23). 
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Mean bacterial counts (Log10 CFU/g or ml) 
No. of rabbits with 
clinical signs ȹ 
I1 I2 I3 MC CF FAR Normal 
Mild 
diarrhoea 
Severe 
diarrhoea 
Wildtype V. cholerae 1051  5.45 8.25 8.43 7.97 8.19 0.81 - 2 3 
V. cholerae C6706 
 
7.86 9.74 10.05 9.15 9.15 1.1 - - 5 
 
Table 23: Comparison of clinical signs, colonisation and FAR for wildtype strain of V. cholerae 1051 to that of V. cholerae C6706 used in the 
original infant rabbit cholera model.  
I1=Upper small intestine; I2=Mid small intestine; I3=Lower small intestine; MC=mid c olon; CF=caecal fluid; FAR=fluid accumulation ratio. ȹ
Severity of clinical signs were scored as described in Materials and Methods (§ 2.5.3). 
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5.3  Discussion 
The experiments detailed in this chapter aimed to determine the efficacy of using host-
specific bacteriophage to reduce the carriage of V. cholerae in an infant rabbit model 
of cholera. The results showed that V. cholerae numbers in phage treated animals 
were significantly lower than untreated control animals. As discussed in the 
introduction, Smith proposed that phage therapy for cholera could be effective owing 
to similar pathogenesis of V. cholerae to enterotoxigenic E. coli (ETEC) as both of 
them produce watery diarrhea induced by  plasmid or phage encoded enterotoxins 
(Smith, Huggins et al. 1987). Though earlier reports on the use of phages against 
human cholera were not  effective (Pollitzer, Swaroop et al. 1959), the recent studies 
on phage therapy of cholera using animal models viz. rabbits (Sarkar, Chakrabarti et 
al. 1996, Bhowmick, Koley et al. 2009, Jaiswal, Koley et al. 2013) and mice (Jaiswal, 
Koley et al. 2014) were more encouraging. The data presented in this chapter 
demonstrated that oral infection of infant rabbits with pathogenic V. cholerae O1 
strain 1051 and subsequent oral administration of Vibrio SKDJHĭ LQSKDJH WUHDWHG
group harboured significantly fewer V. cholerae than the control and no clinical signs 
of disease were evident. The reduction in V. cholerae numbers in the phage-treated 
group was greater than previous studies wherein 2 log10 reductions in bacterial counts 
were obtained (Jaiswal, Koley et al. 2013). 
 
The animals were infected with bacteria after administration of antacid (§ 2.5.3) 
owing to the usual acid environment with low pH levels < 3.0 in the guts of rabbit 
species (Smith 1965). The antacid increases survival of Vibrio spp. and their phage 
(Koo, Marshall et al. 2001). Infected animals produced the clinical signs of disease. If 
the overt clinical signs in the control group were compared to the clinical signs 
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reported for original infant rabbit cholera model (Ritchie, Rui et al. 2010), the signs 
showed inconsistency with varied degree of diarrhoea in the control group. The 
diarrhoea score in the present study ranged from mild to severe, while some animals 
appeared normal (Table 20). This could be due to the fact that the V. cholerae strain 
1051 used in this study was different to the V. cholerae strain C6706 used in the 
original infant rabbit cholera model. In fact the pilot study was done to compare the 
clinical signs produced by wild type strain of V. cholerae 1051 with V. cholerae 
C6706 and it was noticed the wild type V. cholerae 1051 showed inconsistent clinical 
signs compared to V. cholerae C6706 (Table 23). Though V. cholerae 1051 had 
inconsistent clinical signs, it was the only option for therapeutic experiments as V. 
cholerae & ZDV QRW VXVFHSWLEOH WR Ɏ ZKLFK ZDV FKRVHQ FDQGLGDWH IRU SKDJH
therapy. Also, the phages effective on V. cholerae C6706 were not able grow in the 
liquid cultures.  Moreover, the streptomycin resistant (SmR) mutant of V. cholerae 
1051 was used for this study instead of wild type strain to increase the selectivity for 
the strain on agar plates containing antibiotics. Streptomycin resistance is conferred by 
mutations in the ribosomal subunit S12 protein (Chen, Blumentritt et al. 2013) and it 
was noted that some of the antibiotic resistant mutants were less virulent than the wild 
type (Bjorkman, Hughes et al. 1998). Further to this the dosing of control and 
treatment animals on different days owing to cross contamination of phage from 
treatment animals to control animals and dosing of different numbers of bacteria 
owing to different culture conditions on different days (§ 2.5.3) were the limitations of 
the experimental design. Sample collection time at 24 h postinfection was appropriate 
owing to development of profuse diarrhoea between 12 to 18 h postinoculation and 
death of animals by 30 h for control groups (Ritchie, Rui et al. 2010). Thus any 
sample collection time beyond 30 h could not have improved the experimental design.  
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The fluid accumulation in the caeca was also variable owing to varying degree of 
clinical signs shown and fluid accumulation ratios (FAR) are directly correlated to the 
intensity of disease production. This was the reason for bigger standard deviation in 
the control group fluid accumulation ratios while the treatment group had fluid 
accumulation similar to normal uninfected animals. The fluid accumulation ratio in 
the treatment groups i.e. 0.08 ± 0.04 and 0.05 ± 0.05 for the experiments 2 and 3, 
respectively was in agreement with recorded fluid accumulation ratio of 0.05 ± 0.05 
for non-infected animals (Ritchie, Rui et al. 2010) suggesting phage involvement in 
reducing symptoms of cholera. This result is important as the earlier report on fluid 
accumulation ratio in an adult rabbit ileal loop model for phage therapy of cholera did 
not show any difference in the FAR of the control and phage treated animals as they 
both showed the same FAR of 1.1-1.5 (Sarkar, Chakrabarti et al. 1996). The FAR is 
an indicator of the intensity of disease production which is directly correlated to the 
value of FAR.  
 
The bacterial counts in the control group were in the normal range of colonisation 
with more distal segments of intestines and caecal fluid containing more V. cholerae 
(Figure 39 and 40) as observed for an infant rabbit model of cholera (Ritchie, Rui et 
al. 2010). The surface area available in the small intestines (~300-350 cm length) is 
much more than the surface area available in the large intestine (~140 cm length) and 
caeca (~50 cm length) in adult rabbits but is proportionate in infant rabbits (Lebas, 
Coudert et al. 1997) and thus it is clear that the bacterial numbers in the more distal 
parts of alimentary tract tissues are more concentrated than proximal segments. 
Concomitantly, reduction in the bacterial counts of the treatment group in the distal 
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segments of intestinal tissues was greater than that in the proximal segments (Figure 
39 and 40) and this might be due to more colonisation and availability of the bacteria 
in this region for phage predation. The similar reductions in the bacterial counts with 
more reduced numbers in the distal segments of intestines were observed for oral 
phage therapy of E. coli infected calves (Smith and Huggins 1983). For uninfected 
two day old rabbits the caecal fluid is not possible to collect (Combes, Michelland et 
al. 2011) and hence in this study, the collection of caecal fluid and recovery of 
bacteria after infection with V. cholerae is due to disease production.  
 
V. cholerae was not totally eliminated following phage therapy. This could be due to 
various factors viz. phage resistance and physical protection of bacteria from phage. 
The potential of phage to reduce bacterial numbers is heavily dependent on the 
population densities of phage and host.  It relies on a proliferation 
threshold/replication threshold i.e. minimum bacterial density necessary for 
supporting phage growth; and inundation threshold i.e. minimum phage density 
necessary to prevent proliferation of bacteria. When the inundation threshold is 
exceeded by a phage concentration and also the proliferation threshold is exceeded by 
bacterial numbers then at this point the active replication of phage particles occurs. In 
contrast, if the inundation threshold is exceeded i.e. phages outnumber the bacteria 
with MOI of > 1 but the proliferation threshold is not reached then the bacterial 
reduction occurs by passive infection i.e. by lysis from without. In this case, once the 
phage population decreases below the inundation threshold any bacteria that are 
remaining will survive (Payne and Jansen 2001, Cairns, Timms et al. 2009). After 
initial application of phage with MOI of > 1, inside the gut the bacterial numbers 
might have increased and simultaneously the phage might have replicated at a 
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consistently higher rate than the bacteria. Thus, the mechanism of action of phage in 
this experiment could be a mixture of initial active replication and a passive 
inundation later. In the case of the latter scenario, when the phage concentration 
decreased below the inundation threshold any remaining bacteria might have survived. 
Apart from this there might be a possibility of already resistant subpopulations of 
bacteria that might have grown which was noticed for phage therapy of bacteria with a 
similar pathogenesis i.e. enterotoxigenic E. coli in oral infection of neonatal animals 
(Smith and Huggins 1983, Smith, Huggins et al. 1987). The physical protection of 
bacteria from phage results from their localisation in inaccessible sites like crypts and 
villi (Maura and Debarbieux 2012). There is evidence of V. cholerae localising in the 
inter-villous spaces and deep crypt-like structures along with epithelial surface 
(Ritchie, Rui et al. 2010). Such protected bacteria might not have come in contact with 
phage and moreover the V. cholerae moves actively within the intestine to colonise 
inaccessible areas (Butler and Camilli 2005) potentially escaping the passively 
moving phages.  
  
The maximum phage recovery from the treatment group was 8.77 ± 0.69 log10 
PFU/ml from caecal fluid in the experiment 3 after successful reduction in bacterial 
numbers. The dose of phage given was 1 × 109 PFU/ml but the recovery was less and 
this might be due to passive inundation as discussed in the preceding paragraph. 
During passive inundation phage numbers reduce below the inundation threshold and 
then the remaining bacteria begin multiplying (Payne and Jansen 2001). Probably, the 
passive inundation was in the proximal segments as the bacterial numbers were less 
there and active replication in the distal segments owing to more availability of 
bacteria (§ 5.2.2). Similar reduced recovery of phages was noticed by Jaiswal et al 
Chapter 5 
_____________________________________________________________________ 
174 
 
(Jaiswal, Koley et al. 2013) who recovered 6 × 106 PFU/g of phages from faeces of 
phage treated adult rabbits post V. cholerae infection after first 3 hours of oral 
administration of phage at a dose of 1 × 108 PFU/ml which further decreased steadily 
until 12th hour and disaapeared by 24th hour.  
 
The maximum of 4.7 log10 difference in the bacterial counts from 8.55 ± 0.65 log10 
CFU/ml in control group to 3.80 ± 0.82 log10 CFU/ml for phage-treated group in 
caecal fluid samples of experiment 2 was a greater reduction than noted for rabbit 
model of cholera studied by Jaiswal et al (Jaiswal, Koley et al. 2013) as they recorded 
the maximum reduction of 2 log10 through faecal samples. The reduction recorded by 
Jaiswal and colleagues was for a phage cocktail administered 6 hours after bacterial 
challenge similar to our 6-8 hours post infection phage administration. One possible 
reason for this discrepancy is the use of an adult rabbit model in which the 
colonisation is slower than the infant rabbit model (Nelson, Clements et al. 1976). 
Even, using the RITARD (Removable Intestinal Tie-Adult Rabbit Diarrhoea) model 
for phage therapy of cholera only 2 log10 reduction in the V. cholerae counts was seen 
(Bhowmick, Koley et al. 2009). While, use of oral cocktail of phages could reduce the 
V. cholerae numbers by 3 log10 in an adult mice model (Jaiswal, Koley et al. 2014). 
Apart from V. cholerae there have been reports of successful phage therapy of other 
Vibrio spp. including the mouse model of V. vulnificus which showed a 4 log 
reduction in the bacterial counts in treated animals compared to control animals 
(Cerveny, DePaola et al. 2002). A report on the phage therapy of V. parahaemolyticus 
assessing the effect of individual as well as a cocktail of phages revealed that the 
cocktail was more effective than individual phages. The individual phage VP-1 
reduced the bacterial count by 2.9 log, phage VP-2 by 3.6 log and phage VP-3 by 3.8 
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log but the cocktail of phages comprising VP-1/VP-2 could bring down the bacterial 
count by 4.0 log, while VP-1/VP-3 by 3.8 log; VP-2/VP-3 by 3.6 log and VP-1/VP-
2/VP-3 by 4.2 log indicating that cocktails were slightly more effective (Mateus, 
Costa et al. 2014). Similarly, the mono-phage therapy for a multiple antibiotic 
resistant pandemic clinical strain of V. parahaemolyticus was successful using the 
phage pVp-1 and the phage protected mice infected with lethal oral as well as 
intraperitoneal doses of bacteria (Jun, Shin et al. 2014). The success of phage therapy 
for Vibrio spp. is well documented in aquatic settings where Vibrio anguillarum 
phages have protected against experimental vibriosis in salmon (Higuera, Bastias et al. 
2013) and also in shrimp hatchery trials to protect Penaeus monodon larvae from 
Vibrio harveyi using cocktail of phages (Karunasagar, Shivu et al. 2007). 
 
Some residual bacteria were recovered and it was an indication that phage resistant 
strains of bacteria could have emerged and thus more work is required on the 
recovered V. cholerae strains to study their resistance pattern. Smith and colleagues 
showed that the phage resistant mutants paid a fitness penalty and were usually less 
virulent than the parent strain (Smith and Huggins 1983, Smith, Huggins et al. 1987). 
In those studies the cocktail of phages took care of resistant mutants as a bacterium 
resistant to one phage is often susceptible to another phage in the cocktail or to the 
mutant phage derived from the phages active on parent strains (Smith, Huggins et al. 
1987). The phages use bacterial surface receptors as their docking sites while infecting 
their hosts; while bacteria make structural changes in these surface receptors in order 
to become resistant to the phage (§ 1.6.4). During this resistance development bacteria 
pay a fitness penalty by losing the sites for the uptake of nutrients. The surface 
receptors which phages use for their adsorption are also the sites used by bacteria for 
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their nutrient uptake (Mizoguchi, Morita et al. 2003) but they have to conceal them for 
getting resistant. Thus, bacteria compromise themselves on their capacity to utilise 
nutirents and thereby loosing their virulence (Lenski 1988). 
 
Thus, owing to the effectiveness of phage therapy using single phage in the present 
study, it is possible that a cocktail of phages will be more effective, if further studies 
are carried out. The most important aspect of this study is that the phage treated 
animals were clinically normal though V. cholerae could not be totally eliminated but 
maximum 4.7 log10 reduction in their counts could be therapeutically useful. This 
success has paved a way for further studies to develop human phage therapy for 
cholera disease. 
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6 GENERAL DISCUSSION 
The work presented in this thesis describes an investigation of the potential for 
biocontrol of V. cholerae using bacteriophage. At the outset, the isolation and 
characterisation of phages specific to V. cholerae was done and then the potential 
candidate for phage therapy was used for in vivo studies in an infant rabbit cholera 
model. The isolation/collection of phages from across the globe and their 
characterisation as evidenced in chapters 3 and 4 resulted in the creation of a cholera 
phage bank. Two attempts to isolate the phages specific to O1 strains of V. cholerae in 
the UK environment were unsuccessful. This was mainly due to the absence of 
cholera disease in the UK. Similar unsuccessful attempts have been made previously 
(Atterbury and Barrow, unpublished) to isolate phages specific to O1 strains of V. 
cholerae. Non-O1 V. cholerae strains have been isolated in the UK waters in the 
eighties (West and Lee 1982) and this supports the recent isolation of phages active 
against non-O1 V. cholerae strains (Sarkar, unpublished). Owing to non availability of 
phages specific to O1 strains of V. cholerae in the UK, seven new O1 specific phages 
were isolated in cholera endemic areas of south eastern China. Success in isolating V. 
cholerae specific phages from the environment confirms the endemicity of cholera 
disease in the predicted risk areas in China (Xu, Cao et al. 2013) and again supports 
the notion that phages can be used as indicators of the presence of particular 
pathogens (Madico, Checkley et al. 1996). Other phages used in this study had been 
isolated from cholera patients or from the environmental samples in the endemic areas 
and thus it implies that the phages originated from the human intestine or were present 
in the local environment. However, the use of phage therapy in the closed 
environment where patients excreta is collected and disposed of safely, as is the case 
Chapter 6 
_____________________________________________________________________ 
179 
 
in cholera patients, the phage therapy can be effective so that the phage resistant 
bacteria are not circulated in the local environment.  
 
Not all the phages isolated would necessarily be useful for phage therapy and as 
discussed in chapter 3 and 4 only selected phages fit the criteria of broad host range, 
large burst size (which is variable for individual phage but a larger burst is considered 
good for phage therapy), strictly lytic life cycle and absence of lysogeny related and 
bacterial virulence genes in their genomes. The host ranges of the Chinese phages QH, 
H3 and J3 were broader as they could lyse 84.6%, 70.3% and 76.9% of the 91 strains 
in the current collection, respectively. Also the burst sizes of the phages X29, CJY and 
H3 were 664 ± 50, 182 ± 62 and 126 ± 18 PFU/cell, respectively. Inspite of being 
broad in their host range and having good burst sizes, the above mentioned phages 
QH, H3, J3, X29 and CJY were not selected for therapeutic purposes as they 
possessed lysogeny related genes viz. Integrase family site specific recombinase, 
Putative excisionase family protein, Cro-like protein, Antirepressor protein and 
Intergrase identified by sequencing. On the other hand, out of twelve phages which 
ZHUH IXOO\ FKDUDFWHULVHG RQO\ WKUHH SKDJHV YL] SKDJH Ɏ Ɏ DQG SKDJH  ZHUH
found to be suitable for phage therapy mainly based on their genomic features. They 
did not possess any undesirable genes associated with lysogeny/antibacterial 
UHVLVWDQFHDQGDOVRDQ\FKROHUDWR[LQJHQHV$OWKRXJKWKHKRVWUDQJHVRIɎDQGɎ
phages were not the broadest they were nevertheless able to lyse 67.0% and 62.6% of 
phages of the 91 strains used in this study. Phage 24 did not lyse any of the strains 
RWKHUWKDQLWVRZQKRVWVWUDLQ7KHEXUVWVL]HVRIWKHɎɎDQGSKDJHZHUH± 
05, 54 ± 26 and 87 ± 26 PFU, respectively. However, although phage 24 showed a 
large burst size and was free of any deleterious genes; it did not have broad spectrum 
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activity and thus was not used as a candidate for phage therapy studies. $VOLNHĭ 
ĭZDVHTXDOO\VXLWDEOHIRUSKDJHWKHUDS\ and HLWKHUĭDORQHRUin cocktail with ĭ
FRXOGKDYHEHHQHIIHFWLYHEXWLWZRQ¶WEHSRVVLEOHWRNQRZZKLFKSKDJHLQWKHFRFNWDLO
actually works. Also owing to the KXJHFRVWVLQYROYHGLQDQLPDOH[SHULPHQWVRQO\ĭ
was initially evaluated for its therapeutic potential.  
 
Chapter 4 presents the genomic characterisation of phages. The genome annotaton 
provides functions to different genes based on the existing knowledge available in the 
various databases. The coding sequences for which existing databases do not have any 
information remain hypothetical.  Therefore, sequencing of genomes do not reveal 
everything as most of the genes in all the phage genomes encode hypothetical proteins 
with no definite functions assigned to them. Even a slight difference (SNPs) in the 
genome at nucleotide level can significantly change the number of genes identified as 
it will rearrange the nucleotide sequence and thereby coding for different amino acids 
which inturn code for different functional proteins. For example phage X29 had more 
genes assigned with functions i.e. 34 out of 67 genes compared to ĭ2 i.e. 27 out of 67 
genes although they were 99 % similar to each other but had a minor difference in 
their genome sequences. Thus, some SNPs can be coding while some of them can be 
non coding ones. SNPs may also influence the latent period, burst size and host ranges 
as evidenced by differences shown for these parameters among the similar phages 
with SNP variations. 
 
3KDJHĭZDVVKRZQWREHDYLUXOHQWSKDJHZKLFKZDVVXEVHTXHQWO\XVHGWRUHGXFHV. 
cholerae numbers in the intestinal tract of infant rabbits. An interesting feature of the 
ĭJHQRPHZDVLWV*&FRQWHQW. The V. cholerae GC content is approximately 47 % 
Chapter 6 
_____________________________________________________________________ 
181 
 
(Dziejman, Balon et al. 2002) DQGĭKDGVLJQLILFDQWO\ ORZ*&FRQWHQW LH
The other N4 like family Vibrio phages also had considerably lower GC content than 
their bacterial hosts (Fouts, Klumpp et al. 2013). This deviation between the GC 
content of phage and host may be the characteristic feature of these N4 like family 
Vibrio phages and is maintained in them (Kwan, Liu et al. 2006). The virulent dsDNA 
phages have low GC content compared to their bacterial host genomes and bias 
towards AT enrichment in phages allow them to exploit the bacterial cell resources 
better during their replication (Rocha and Danchin 2002). AT rich regions aid 
replication of phage DNA as origin of replication (ori) having them adjacent to it for 
quick unwinding of DNA (Kutter, Raya et al. 2003). AT enriched phages are quick in 
transcription owing to more AT rich promoter elements (Carter, Demidenko et al. 
2003) and also they require less energy as their base pairing contains two hydrogen 
bonds to be broken as against three in GC base pairing. Thus, ĭ LV FDSDEOH RI
expoiting the bacterial cell resources and hence it might be more effective in phage 
therapy. 7KHUHPDLQLQJWZRSKDJHVLHĭDQGSKage 24 were identified as potential 
phage therapy candidates and also have a lower GC content than the host strain viz. 
42.83 and 45.40 %, respectively. It was also noted that even temperate phages are AT 
richer than their hosts but they have smaller AT deviation compared to virulent phages 
(Rocha and Danchin 2002) and it is true with all the temperate phages in this study.  
 
The statistical difference in bacterial numbers of control and treatment groups may 
have been improved if the colonisation of V. cholerae 1051 had been better. As 
discussed in the chapter 5, the colonisation of SmR 1051 was low pathogenic and may 
partly be due to antibiotic resistance as some of the antibiotic resistant mutants are less 
virulent than wild type (Bjorkman, Hughes et al. 1998). Notwithstanding the relatively 
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low pathogenicity of the intestine by SmR 1051, rabbits dosed with bacteriophage Ɏ
harboured significantly fewer V. cholerae than the control animals with difference of 
maximum 4.1 log10 CFU/g. It is conceivable that using a strain which colonised as 
well as V. cholerae C6706, the strain used in the original infant rabbit model could 
have been a better model with the availability of effective phage. Moreover, the 
original infant rabbit model had optimised the time points at which the overt clinical 
signs would be produced and also the euthanization at 24 h time point from animal 
welfare point of view. Thus, in future, alongwith the usage of a strain with better 
colonisation/pathogenicity; optimisation of the time points for wider time course 
might be necessary to see if more obvious clinical signs are noticed at later stages. 
Apart from bacterial numbers, the most significant result in this project is the fact that 
the treated animals no longer appeared to show symptoms of disease. As the distal 
portions might have had active replication (§ 5.3) further studies using lower phage 
titres for treatment may indicate whether there is an active multiplication of phages as 
evidenced by increase in phage numbers together with reduction in bacterial numbers. 
7KHUH ZDV QR µEDFWHULRSKDJH RQO\¶ FRQWURO LQ WKH Hxperiments carried out for this 
project and the kinetics of phage persistence were thus not known together with 
whether phage could be recovered in the absence of V. cholerae. Hence, it would be 
SUXGHQW WRKDYHµEDFWHULRSKDJHRQO\¶FRQWUROGXULQJDQ\ future studies based on this 
project. 
 
In this study, the treatment of infant rabbits with bacteriophage resulted in a reduction 
in V. cholerae numbers of up to 4.1 log10 CFU/g, and marked amelioration of disease 
symptoms compared with untreated control animals. This reduction in bacterial 
numbers was greater than the reduction noted for an adult rabbit model of cholera 
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(Jaiswal, Koley et al. 2013) which achieved a 2 log10 reduction recovered from faecal 
samples using a cocktail of five phages. As discussed in the preceding paragraphs and 
LQFKDSWHUDFRFNWDLORISKDJHVXVLQJĭDQGĭPD\ LPSURYH WKH UHVXOWV IRU WKH
infant rabbit cholera model used in this study and may address phage resistance in the 
target bacterium, if this becomes a major issue. Smith and colleagues (Smith and 
Huggins 1983) did not find any bacteriophage resistant bacteria after 24 h following 
phage therapy of lambs infected with E.coli S13 using a single phage. This study was 
based partly on their success of phage therapy to treat oral E. coli infections in 
neonatal animals calves, piglets and lambs (Smith and Huggins 1983, Smith, Huggins 
et al. 1987) and their suggestion for the effectiveness of phages against V. cholerae 
infection. Similar to V. cholerae, Enterotoxigenic E. coli (ETEC) causes secretary 
diarrhoea mediated by the heat labile (LT) enterotoxins which activate and produce 
high levels cAMP to alter the sodium and chloride ion channels causing massive 
efflux of chloride ions along with water in to the gut, resulting in secretary diarrhoea. 
Administering a dose of phage between 6-8 h was successful in controlling oral E. coli 
infection in calves (Smith, Huggins et al. 1987) and V. cholerae biocontrol by 
administering the phages in a similar timeframe was also successful. It is worth 
mentioning that though the phage therapy does not eliminate the pathogens but they 
are reduced to a level below which the disease does not occur and subsequently these 
low numbers of bacteria are cleared by the host immune system in an 
immunocompetent host. Moreover, it is known that cholera infection induces 
immunity to protect against subsequent infections (Nelson, Harris et al. 2009) in 
human beings.  
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In summary, this study has demonstrated that bacteriophage can be used to reduce the 
counts of V. cholerae in an established animal model of infection. This therapeutic 
trial gave promising results and suggests that further studies might improve on the 
results demonstrated here.  
 
Future work:  
The initial work of isolating and characterising the bank of phages is already done in 
this project and a monophage therapy for biocontrol of V. cholerae using 
bacteriophage in an infant rabbit model is also successful. After this initial success in 
therapeutic experiments in an infant rabbit cholera model, regulated human clinical 
experiments should be carried out to establish the safety and efficacy of phages for 
human phage therapy. The strength of this project lies in to the generation of a robust 
data and collaboration with different research groups within the UK and in cholera 
HQGHPLF UHJLRQ IRU IXOILOOLQJ WKHREMHFWLYHV7DNLQJDFOXH IURP+:LOOLDP6PLWK¶V
pioneering work on phage therapy of enterotoxigenic E. coli (ETEC), where he 
suggested that phage therapy might work for V. cholerae due to similar pathogenesis; 
this project was designed for in vivo studies post in vitro characterisation. The 
characterisation involved not only the study of traditional biological parameters but 
also the advanced phage genomics to ensure that the potential therapy candidate is 
selected appropriately. The animal studies could give very significant reductions in the 
bacterial counts and most importantly the phage treated animals were clinically 
normal without any symptoms of disease.  
 
Study had a few drawbacks pertaining to the subjective scoring for recording of 
clinical signs; involvement of variables like the bacterial dose and time of 
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inoculation/phage treatment; non-inclusion of phage only control and non-testing of 
residual bacteria for phage susceptibility. The Blinding of studies would take away the 
subjectivity of clinical scores. The variable infective bacterial dose and different days 
of dosing for the control and treatment groups might have bearing on the experimental 
outcome but two independent experiments (2 and 3) have shown significant 
reductions in bacterial colonisation across multiple GI sites and this strongly indicates 
that it is indeed the phage that is causing the effects. To be absolutely sure it is 
proposed that the further studies using this approach should have control and 
treatment groups isolated to prevent any phage cross contamination but both the 
groups be tested in parallel under identical conditions at the same time with the same 
bacterial and phage preparations. Few additional experiments with phage only control 
and resistance pattern studies would help in improving results. The following 
additional experiments would be needed to improve the results of this project:  
1. The experiments with phage only control and with reduced dose of phage to 
determine active replication.  
2. The resistance pattern study for bacterial strains isolated from the treatment 
group animals in this project.  
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APPENDIX µ$¶ 
Time 
(h) 
Trial 1         
(log10 
CFU/ml) 
Trial 2         
(log10 
CFU/ml) 
Trial 3          
(log10 
CFU/ml) 
Mean             
(log10 
CFU/ml) 
Standard 
Deviation 
0 6.23 6.31 6.18 6.24 0.11 
2 7.18 7.21 7.25 7.21 0.11 
4 9.13 9.14 9.21 9.16 0.07 
6 9.06 9.21 9.37 9.21 0.16 
8 9.64 9.30 9.33 9.42 0.18 
10 9.51 9.32 9.38 9.40 0.11 
12 9.71 9.40 9.38 9.50 0.17 
24 9.73 9.78 9.86 9.79 0.10 
 
Table 24: V. cholerae F5 counts for growth curve 
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Time 
(h) 
Trial 1         
(log10 
CFU/ml) 
Trial 2         
(log10 
CFU/ml) 
Trial 3          
(log10 
CFU/ml) 
Mean             
(log10 
CFU/ml) 
Standard 
Deviation 
0 6.34 6.68 6.83 6.62 0.24 
2 7.35 7.80 7.63 7.59 0.24 
4 8.54 8.57 8.66 8.59 0.09 
6 8.72 8.66 8.73 8.71 0.11 
8 8.84 8.75 8.79 8.79 0.07 
10 8.88 8.88 8.91 8.89 0.04 
12 8.84 8.84 8.92 8.87 0.06 
24 9.13 8.97 9.08 9.06 0.08 
 
Table 25: V. cholerae 1051 counts for growth curve 
 
Time 
(h) 
Trial 1         
(log10 
CFU/ml) 
Trial 2         
(log10 
CFU/ml) 
Trial 3          
(log10 
CFU/ml) 
Mean             
(log10 
CFU/ml) 
Standard 
Deviation 
0 7.02 6.94 7.01 6.99 0.04 
2 7.65 8.04 8.11 7.93 0.25 
4 8.84 8.91 8.74 8.83 0.08 
6 9.22 9.33 9.29 9.28 0.05 
8 9.45 9.62 9.74 9.60 0.14 
10 9.63 9.83 10.05 9.84 0.21 
 
Table 26: V. cholerae 2095 counts for growth curve 
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Time 
(h) 
Trial 1         
(log10 
CFU/ml) 
Trial 2         
(log10 
CFU/ml) 
Trial 3          
(log10 
CFU/ml) 
Mean             
(log10 
CFU/ml) 
Standard 
Deviation 
0 7.12 7.08 6.97 7.06 0.08 
2 8.15 8.14 8.07 8.12 0.05 
4 9.09 9.16 9.11 9.12 0.04 
6 9.13 9.19 9.22 9.18 0.05 
8 9.39 9.30 9.22 9.31 0.08 
10 9.33 9.31 9.26 9.30 0.04 
 
Table 27: V. cholerae C6706 counts for growth curve 
 
Time 
(h) 
Trial 1         
(log10 
CFU/ml) 
Trial 2         
(log10 
CFU/ml) 
Trial 3          
(log10 
CFU/ml) 
Mean             
(log10 
CFU/ml) 
Standard 
Deviation 
0 6.48 6.61 6.51 6.54 0.07 
2 7.87 7.42 7.68 7.66 0.22 
4 9.15 8.54 8.98 8.89 0.31 
6 9.22 8.95 9.19 9.12 0.14 
8 9.47 9.23 9.34 9.35 0.12 
10 9.55 9.37 9.24 9.39 0.15 
 
Table 28: V. cholerae 238 counts for growth curve 
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APPENDIX µ%¶ 
Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 6.79 6.76 6.85 6.80 0.04 
4 6.72 6.74 6.66 6.70 0.04 
6 6.66 6.70 6.66 6.67 0.02 
11 6.66 6.63 6.63 6.64 0.02 
16 6.73 6.69 6.66 6.69 0.04 
21 6.76 6.81 6.74 6.77 0.04 
26 6.85 6.72 7.01 6.86 0.14 
31 7.16 6.78 7.51 7.15 0.37 
36 7.68 7.38 7.45 7.51 0.16 
41 7.74 7.73 7.65 7.71 0.05 
46 7.86 7.88 7.70 7.81 0.10 
51 7.90 7.90 7.83 7.88 0.04 
56 7.89 7.80 7.87 7.85 0.05 
61 7.85 7.85 7.72 7.81 0.07 
66 7.88 7.87 7.81 7.86 0.04 
71 7.89 7.90 7.76 7.85 0.08 
76 7.88 7.88 7.90 7.89 0.01 
81 7.85 7.85 7.98 7.89 0.07 
86 7.84 7.82 7.83 7.83 0.01 
91 7.79 7.82 7.88 7.83 0.04 
 
Table 29: V. cholerae phage ĭ1 counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 6.15 6.32 6.20 6.22 0.09 
3 5.90 6.04 6.19 6.04 0.14 
5 5.85 5.98 6.10 5.97 0.13 
10 5.74 5.81 5.85 5.80 0.05 
15 5.90 5.70 5.78 5.79 0.10 
20 5.90 5.98 6.08 5.99 0.09 
25 6.26 6.40 6.28 6.31 0.08 
30 6.52 6.60 6.48 6.53 0.06 
35 6.64 6.71 6.43 6.60 0.15 
40 6.65 6.71 6.48 6.61 0.12 
45 6.54 6.69 6.53 6.59 0.09 
50 6.65 6.68 6.53 6.62 0.08 
55 6.93 6.80 6.83 6.85 0.07 
60 6.80 6.73 6.73 6.75 0.04 
65 6.65 6.73 6.72 6.70 0.04 
70 6.85 6.91 6.61 6.79 0.16 
75 6.54 6.70 6.49 6.58 0.11 
80 6.65 6.47 6.59 6.57 0.09 
85 6.85 6.62 6.59 6.68 0.14 
90 6.85 6.57 6.49 6.64 0.19 
 
Table 30: V. cholerae phage ĭ2 counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 6.56 6.76 6.73 6.68 0.11 
3 6.53 6.41 6.69 6.54 0.14 
5 6.48 6.36 6.67 6.50 0.16 
10 6.40 6.41 6.73 6.51 0.19 
15 6.48 6.43 6.85 6.59 0.23 
20 6.56 6.51 6.66 6.58 0.08 
25 6.55 6.45 6.72 6.57 0.14 
30 6.59 6.62 6.81 6.68 0.12 
35 6.61 7.06 6.83 6.83 0.23 
40 6.61 7.08 6.90 6.86 0.24 
45 6.72 7.26 7.18 7.06 0.29 
50 7.12 7.40 7.50 7.34 0.20 
55 7.59 7.38 7.77 7.58 0.19 
60 7.70 7.38 7.77 7.62 0.21 
65 7.68 7.41 7.76 7.62 0.18 
70 7.67 7.42 7.80 7.63 0.19 
75 7.70 7.46 7.87 7.68 0.20 
80 7.71 7.45 7.88 7.68 0.22 
85 7.75 7.40 7.84 7.66 0.23 
90 7.80 7.45 7.93 7.73 0.25 
 
Table 31: V. cholerae phage ĭ3 counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 5.85 5.54 5.70 5.70 0.15 
4 5.78 5.54 5.70 5.67 0.12 
6 5.74 5.74 5.60 5.69 0.08 
11 5.95 5.98 5.98 5.97 0.01 
16 6.04 5.88 5.93 5.95 0.08 
21 6.20 6.10 5.81 6.04 0.20 
26 6.56 6.56 6.51 6.54 0.03 
31 7.11 7.07 6.98 7.06 0.07 
36 7.66 7.53 7.19 7.46 0.24 
41 7.64 7.54 7.56 7.58 0.05 
46 7.67 7.65 7.57 7.63 0.05 
51 7.65 7.60 7.87 7.71 0.14 
56 7.71 7.59 7.63 7.64 0.06 
61 7.69 7.69 7.62 7.67 0.04 
66 7.83 7.57 7.63 7.68 0.14 
71 7.89 7.67 7.45 7.67 0.22 
76 7.81 7.79 7.56 7.72 0.14 
81 7.99 7.89 7.65 7.84 0.17 
86 7.88 7.83 7.74 7.81 0.07 
91 7.83 7.85 7.76 7.81 0.04 
 
Table 32: V. cholerae phage X29 counts for one step growth curve 
 
 
 
 
$SSHQGL[µ%¶ 
_____________________________________________________________________ 
195 
 
Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 6.19 6.19 6.30 6.23 0.06 
3 6.10 5.98 6.18 6.08 0.10 
5 6.32 6.11 6.34 6.26 0.13 
10 6.32 6.10 6.31 6.24 0.13 
15 6.54 6.41 6.54 6.50 0.07 
20 6.46 6.30 6.40 6.39 0.08 
25 6.37 6.27 6.36 6.33 0.06 
30 6.92 6.66 7.01 6.86 0.18 
35 7.41 7.04 7.50 7.32 0.24 
40 7.56 7.32 7.59 7.49 0.15 
45 7.61 7.45 7.59 7.55 0.08 
50 7.56 7.41 7.60 7.52 0.10 
55 7.30 7.40 7.21 7.30 0.09 
60 7.30 7.33 7.29 7.31 0.02 
65 7.32 7.21 7.31 7.28 0.06 
70 7.32 7.34 7.32 7.33 0.01 
75 7.39 7.44 7.40 7.41 0.03 
 
Table 33: V. cholerae phage 24 counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 5.88 5.93 5.78 5.86 0.08 
3 5.81 5.85 5.78 5.81 0.03 
5 5.93 5.95 5.81 5.90 0.08 
10 5.85 5.90 5.70 5.82 0.11 
15 5.90 5.85 5.65 5.80 0.13 
20 6.02 6.08 5.88 5.99 0.11 
25 6.19 6.26 5.98 6.14 0.15 
30 6.10 6.06 6.18 6.11 0.06 
35 5.98 5.98 5.98 5.98 0.00 
40 5.98 5.95 5.98 5.97 0.01 
45 6.10 6.08 6.13 6.10 0.03 
50 6.04 6.04 5.95 6.01 0.05 
55 6.00 5.90 6.13 6.01 0.11 
60 6.02 5.98 6.08 6.03 0.05 
65 6.68 6.64 6.74 6.69 0.05 
70 7.07 7.05 7.23 7.12 0.10 
75 6.65 6.78 6.99 6.81 0.17 
 
Table 34: V. cholerae phage QH counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 5.93 6.10 6.00 6.01 0.08 
3 6.27 6.20 5.90 6.12 0.19 
5 5.95 6.06 6.00 6.00 0.05 
10 5.98 6.08 5.98 6.01 0.06 
15 5.90 6.00 6.02 5.97 0.06 
20 6.02 6.10 6.00 6.04 0.05 
25 6.11 6.39 6.02 6.17 0.19 
30 6.16 6.06 6.06 6.09 0.06 
35 6.15 6.16 6.23 6.18 0.04 
40 6.04 6.04 6.27 6.12 0.13 
45 6.06 6.18 6.20 6.15 0.08 
50 6.10 6.33 5.81 6.08 0.26 
55 6.11 6.35 6.10 6.19 0.14 
60 6.26 6.22 6.20 6.23 0.03 
65 6.39 6.32 6.10 6.27 0.15 
70 7.04 6.85 6.88 6.93 0.10 
75 7.26 6.96 6.83 7.02 0.22 
80   7.26 7.10 7.18 0.11 
85   7.45 7.46 7.46 0.01 
90   7.20 7.03 7.12 0.12 
 Counts were not done 
Table 35: V. cholerae phage CJY counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 5.95 5.98 5.88 5.94 0.05 
3 5.88 6.00 5.78 5.88 0.11 
5 6.04 5.95 5.95 5.98 0.05 
10 5.90 5.85 6.06 5.94 0.11 
15 5.98 5.85 6.02 5.95 0.09 
20 6.22 6.04 6.00 6.09 0.12 
25 6.22 6.24 6.13 6.20 0.06 
30 6.16 6.24 6.20 6.20 0.04 
35 6.18 6.26 5.88 6.10 0.20 
40 5.93 6.15 6.13 6.07 0.12 
45 6.02 6.08 6.15 6.08 0.06 
50 6.10 6.13 5.98 6.07 0.08 
55 6.31 6.26 6.24 6.27 0.04 
60 6.13 6.23 6.11 6.16 0.06 
65 6.36 6.11 6.41 6.30 0.16 
70 6.31 6.11 6.67 6.36 0.28 
75 6.96 6.92 6.86 6.91 0.05 
80   7.00 6.87 6.94 0.09 
85   7.12 7.39 7.26 0.19 
90   6.92 7.13 7.02 0.15 
 Counts were not done 
Table 36: V. cholerae phage H1 counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 6.32 6.22 6.18 6.24 0.08 
3 6.20 6.00 6.11 6.11 0.10 
5 6.19 6.15 6.16 6.17 0.02 
10 5.98 6.02 6.08 6.03 0.05 
15 6.29 5.81 6.04 6.05 0.24 
20 6.27 6.00 6.28 6.18 0.16 
25 6.42 6.11 6.23 6.26 0.16 
30 6.29 6.19 6.41 6.30 0.11 
35 6.19 6.26 6.41 6.29 0.12 
40 6.35 6.24 6.31 6.30 0.06 
45 6.38 6.22 6.23 6.28 0.09 
50 6.43 5.90 6.36 6.23 0.29 
55 6.57 6.35 6.48 6.47 0.11 
60 6.49 6.13 6.30 6.31 0.18 
65 6.57 6.31 6.35 6.41 0.14 
70 6.67 6.41 6.60 6.56 0.13 
75 7.21 6.80 7.26 7.09 0.25 
80 7.18 7.53 7.22 7.31 0.19 
85 7.11 7.68 7.59 7.46 0.30 
90 7.60 7.59 7.45 7.54 0.09 
 
Table 37: V. cholerae phage H2 counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 6.04 5.95 6.13 6.04 0.09 
3 6.13 5.70 6.08 5.97 0.24 
5 6.32 5.90 6.16 6.13 0.21 
10 6.27 5.78 6.06 6.04 0.25 
15 6.27 5.98 6.16 6.14 0.15 
20 6.34 5.98 6.20 6.17 0.18 
25 6.20 6.31 6.30 6.27 0.06 
30 6.18 6.08 6.19 6.15 0.06 
35 6.26 6.08 6.23 6.19 0.10 
40 6.44 5.95 6.24 6.21 0.24 
45 6.37 6.13 6.28 6.26 0.12 
50 6.37 6.13 6.26 6.25 0.12 
55 6.43 6.42 6.40 6.42 0.02 
60 6.28 6.23 6.28 6.26 0.03 
65 6.53 6.53 6.50 6.52 0.02 
70 6.77 6.47 6.67 6.64 0.15 
75 7.11 7.33 6.95 7.13 0.19 
80 7.40 7.63 7.22 7.41 0.20 
85 7.49 7.43 7.33 7.42 0.08 
90 7.51 7.13 7.48 7.37 0.21 
 
Table 38: V. cholerae phage H3 counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 6.19 5.85 5.93 5.99 0.18 
3 5.85 5.60 5.78 5.74 0.13 
5 5.54 5.85 5.65 5.68 0.15 
10 5.98 5.81 5.74 5.84 0.12 
15 5.88 5.81 5.70 5.80 0.09 
20 5.85 5.90 5.90 5.88 0.03 
25 6.19 6.19 6.15 6.18 0.03 
30 6.08 6.08 5.93 6.03 0.09 
35 6.02 6.15 5.90 6.02 0.12 
40 6.00 6.08 5.85 5.97 0.12 
45 6.16 5.88 5.98 6.00 0.15 
50 6.00 5.98 5.93 5.97 0.04 
55 6.42 6.23 6.22 6.29 0.12 
60 6.26 6.15 6.10 6.17 0.08 
65 6.16 6.50 6.16 6.27 0.19 
70 6.44 6.46 6.39 6.43 0.04 
75 7.10 7.29 6.91 7.10 0.19 
80 7.32 7.06 7.04 7.14 0.16 
85 7.16 7.05 7.00 7.07 0.08 
90 7.14 7.10 6.96 7.07 0.10 
 
Table 39: V. cholerae phage J2 counts for one step growth curve 
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Time 
(m) 
Trial 1         
(log10 
PFU/ml) 
Trial 2         
(log10 
PFU/ml) 
Trial 3          
(log10 
PFU/ml) 
Mean             
(log10 
PFU/ml) 
Standard 
Deviation 
0 6.38 6.27 6.31 6.32 0.06 
3 6.30 6.28 6.24 6.27 0.03 
5 6.33 6.29 6.19 6.27 0.07 
10 6.28 6.33 6.18 6.26 0.08 
15 6.24 6.54 6.20 6.33 0.18 
20 6.38 6.50 6.30 6.39 0.10 
25 6.61 6.59 6.50 6.57 0.06 
30 6.54 6.35 6.38 6.42 0.10 
35 6.64 6.48 6.41 6.51 0.12 
40 6.41 6.50 6.38 6.43 0.06 
45 6.57 6.57 6.40 6.51 0.10 
50 6.41 6.56 6.40 6.46 0.09 
55 6.66 6.39 6.48 6.51 0.14 
60 6.67 6.48 6.51 6.55 0.11 
65 6.74 6.65 6.57 6.65 0.09 
70 6.91 6.80 6.68 6.80 0.12 
75 6.91 6.86 6.70 6.82 0.11 
80 7.44 7.52 7.60 7.52 0.08 
85 7.39 7.00 6.95 7.11 0.24 
90 7.43 7.33 7.13 7.30 0.15 
 
Table 40: V. cholerae phage J3 counts for one step growth curve 
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